Modified closed-end DNA (CEDNA) containing symmetrically modified inverted terminal repeats

CeDNA vectors with symmetrical modified ITRs address the limitations of AAV vectors by enabling efficient and controlled gene delivery and expression, overcoming packaging and immune response issues.

JP7590963B2Active Publication Date: 2024-11-27GENERATION BIO CO
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2021524359
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-11-09
Filing Date
2019-11-08
Publication Date
2024-11-27
Estimated Expiration
2039-11-08

AI Technical Summary

Technical Problem

Current adeno-associated virus (AAV) vectors for gene therapy face limitations such as limited viral packaging capacity, immunogenicity, and slow gene expression, which hinder their effectiveness in delivering therapeutic genes due to immune responses and size constraints.

Method used

Development of non-viral, capsid-free DNA vectors with covalently closed ends (ceDNA vectors) that utilize symmetrical modified inverted terminal repeats (ITRs) to enhance transgene capacity and enable rapid, controlled gene expression, avoiding immune responses and size limitations.

Benefits of technology

The ceDNA vectors allow for efficient delivery and expression of large genetic cargo, overcoming the limitations of AAV vectors by providing high transgene capacity and rapid onset of gene expression without immune activation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590963000047
    Figure 0007590963000047
  • Figure 0007590963000048
    Figure 0007590963000048
  • Figure 0007590963000049
    Figure 0007590963000049
Patent Text Reader

Abstract

Described herein is a ceDNA vector with a linear and continuous structure that can be produced with high yield and used for the effective transfer and expression of transgenes.According to some embodiments, the ceDNA vector comprises at least one heterologous nucleotide sequence operably arranged between two adjacent symmetric inverted terminal repeat sequences that are not wild-type AAV ITRs, and all or part of the heterologous nucleotide sequence is under the control of at least one regulatory switch.Some ceDNA vectors provided herein further comprise cis-regulatory elements, providing high gene expression efficiency.Further provided herein are methods and cell lines for the reliable and efficient production of linear, continuous, and capsid-free DNA vectors.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority to U.S. Provisional Patent Application No. 62 / 757,872, filed November 9, 2018, and U.S. Provisional Patent Application No. 62 / 757,892, filed November 9, 2018, the contents of each of which are incorporated herein by reference in their entirety.

[0002] The present invention relates to the field of gene therapy, which involves the delivery of closed-end DNA regulatory switches to target cells, tissues, organs or organisms.

[0003] Sequence Listing The Sequence Listing of the present application has been submitted electronically via EFS-Web as an ASCII Sequence Listing with the file name "05320Sequence_Listing.txt," created on November 8, 2019, and 204 KB (209,626 bytes) in size. This application contains a Sequence Listing that has been submitted electronically and is incorporated herein by reference in its entirety. [Background technology]

[0004] Gene therapy aims to improve clinical outcomes for patients suffering from either genetic mutations or acquired diseases caused by abnormalities in gene expression profiles. Gene therapy involves the treatment or prevention of conditions resulting from defective genes or dysregulation or expression, e.g., underexpression or overexpression, which can result in disorders, diseases, malignancies, etc. For example, diseases or disorders caused by defective genes can be treated, prevented, or ameliorated by delivering corrective genetic material to the patient, resulting in therapeutic expression of the genetic material in the patient's body. The basis of gene therapy is the provision of an active gene product (sometimes referred to as a transgene) in a transcription cassette, which can result in, for example, a positive gain-of-function effect, a negative loss-of-function effect, or another outcome, such as an oncolytic effect. Gene therapy can also be used to treat diseases or malignancies caused by other factors. Human single-gene disorders can be treated by the delivery and expression of a normal gene to target cells. Delivery and expression of a corrective gene in a patient's target cells can be carried out via a number of methods, including the use of engineered viruses and viral gene delivery vectors. Among the many available virus-derived vectors (e.g., recombinant retroviruses, lentiviruses, adenoviruses, etc.), recombinant adeno-associated viruses (rAAVs) have gained popularity as versatile vectors in gene therapy. However, as technology advances and highly efficient gene transfer and expression are achieved, the ability to regulate such expression at both the temporal and spatial levels becomes increasingly important.

[0005] Adeno-associated viruses (AAVs) belong to the Parvoviridae family and, more specifically, constitute the Dependoparvovirus genus. The AAV genome comprises a linear, single-stranded DNA molecule, approximately 4.7 kilobases (kb), consisting of two major open reading frames (ORFs) encoding the nonstructural Rep (replication) and structural Cap (capsid) proteins. A second ORF within the Cap gene has been identified, encoding the assembly-activating protein (AAP). Flanking the AAV coding region are two cis-acting inverted terminal repeat (ITR) sequences, approximately 145 nucleotides in length, containing an interrupted palindromic sequence that can fold into an energetically stable hairpin structure that functions as a primer for DNA replication. The wild-type sequences are typically identical but inverted relative to each other. In addition to their role in DNA replication, ITR sequences have been shown to be involved in the integration of viral DNA into the cellular genome, rescue from the host genome or plasmids, and encapsidation of viral nucleic acids in mature virions (Muzyczka, (1992) Curr. Top. Micro. Immunol. 158:97-129).

[0006] AAV-derived vectors (i.e., recombinant AAV (rAVV) or AAV vectors) are attractive for delivering genetic material because (i) they can infect (transduce) a wide variety of non-dividing and dividing cell types, including muscle cells and neurons; (ii) they lack viral structural genes, thereby reducing host cell responses to viral infection, such as interferon-mediated responses; (iii) wild-type viruses are considered non-pathogenic in humans; (iv) in contrast to wild-type AAV, which can integrate into the host cell genome, replication-deficient AAV vectors lack the rep gene and generally persist episomally, thus limiting the risk of insertional mutagenesis or genotoxicity; and (v) compared to other vector systems, AAV vectors are generally considered to be relatively poor immunogens and therefore do not elicit a significant immune response (see ii), thereby resulting in sustained vector DNA and potentially long-term expression of therapeutic transgenes. AAV vectors can also be produced and formulated at high titers and delivered via intra-arterial, intravenous, or intraperitoneal injection, enabling vector distribution and gene transfer to critical muscle regions with a single injection in rodents (Goyenvalle et al., 2004; Fougerousse et al., 2007; Koppanati et al., 2010; Wang et al., 2009) and dogs. In clinical studies to treat spinal muscular atrophy type 1, AAV vectors were delivered systemically with the intention of targeting the brain and resulting in clear clinical improvement.

[0007] However, the use of AAV particles as gene delivery vectors presents several significant drawbacks. One significant drawback associated with rAAV is the limited viral packaging capacity of approximately 4.5 kb of heterologous DNA (Dong et al., 1996; Athanasopoulos et al., 2004; Lai et al., 2010). As a result, the use of AAV vectors is limited to protein-coding capacities of less than 150,000 Da. A second drawback is the need to screen rAAV gene therapy candidates for the presence of neutralizing antibodies that eliminate the vector from patients as a result of the prevalence of wild-type AAV infection in the population. A third drawback relates to capsid immunogenicity, which prevents re-administration in patients who were not eliminated from initial treatment. In response to vectors that effectively act as a "booster" shot, the patient's immune system may stimulate the production of high-titer anti-AAV antibodies that prevent future treatment. Several recent reports have demonstrated a relationship between immunogenicity in high-dose settings. Another notable drawback is the relatively slow onset of AAV-mediated gene expression, given that single-stranded AAV DNA must be converted to double-stranded DNA before heterologous gene expression can occur. Attempts have been made to circumvent this problem by constructing double-stranded DNA vectors, but this strategy further limits the size of the transgene expression cassette that can be incorporated into the AAV vector (McCarty, 2008; Varenika et al., 2009; Foust et al., 2009).

[0008] Additionally, conventional AAV virions with capsids are produced by introducing one or more plasmids containing the AAV genome, rep gene, and cap gene (Grimm et al., 1998). Upon introduction of these helper plasmids in trans, the AAV genome is "rescued" from the host genome (i.e., released and then amplified) and further encapsidated (viral capsid), producing a biologically active AAV vector. However, such encapsidated AAV viral vectors have been found to inefficiently transduce certain cell and tissue types. The capsid also induces an immune response.

[0009] Therefore, the use of adeno-associated virus (AAV) vectors for gene therapy is limited by the single-dose requirement for immunocompetent patients (due to the patient's immune response), the limited range of transgene genetic material suitable for delivery in AAV vectors due to the minimal viral packaging capacity of the relevant AAV capsid (approximately 4.5 kb), and slow AAV-mediated gene expression. The application of rAAV for clinical gene therapy is further hindered by patient-to-patient variability that is not predicted by dose-response in syngeneic mouse models or in other model species. Recombinant capsid-free AAV vectors can be obtained as isolated linear nucleic acid molecules containing an expressible transgene and a promoter region flanked by two wild-type AAV inverted terminal repeat (ITR) sequences containing Rep binding sites and terminal resolution sites. These recombinant AAV vectors lack the sequence encoding AAV capsid proteins and can be single-stranded, double-stranded, or duplexed, with one or both ends covalently linked through two wild-type ITR palindromic sequences (e.g., WO2012 / 123430, U.S. Patent No. 9,598,703). They avoid many of the problems of AAV-mediated gene therapy in that they have a much higher transgene capacity, rapid onset of transgene expression, and lack the attributes of AAV-based vectors that usually lead to immunity and rapid clearance of these vectors. However, constant expression of a transgene is not always desirable. There remains a significant unmet need for controllable recombinant DNA vectors with improved production and / or expression characteristics. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] International Publication No. 2012 / 123430 [Patent Document 2] U.S. Patent No. 9,598,703 [Non-patent literature]

[0011] [Non-Patent Document 1] Muzyczka,(1992)Curr.Top.Micro.Immunol.158:97-129 Summary of the Invention [Means for solving the problem]

[0012] The present disclosure generally provides non-viral, capsid-free DNA vectors (herein referred to as "closed-end DNA vectors" or "ceDNA vectors") with covalently closed ends. The ceDNA vectors described herein are capsid-free, linear, duplex DNA molecules formed from consecutive strands of complementary DNA with covalently closed ends (linear, continuous, non-capsid structures), and contain identical 5' and 3' inverted terminal repeat (ITR) sequences that are reverse complements of each other (i.e., these sequences are symmetrical or substantially symmetrical). According to some embodiments, the ceDNA vectors contain at least one heterologous nucleotide sequence operably positioned between two adjacent inverted terminal repeats (ITRs), with all or part of the heterologous nucleotide sequence being under the control of at least one regulatory switch. In other embodiments, the technology described herein relates to ceDNA vectors containing two modified AAV inverted terminal repeats (ITRs), where the modified ITRs are symmetrical to each other and flank an expressible transgene. The ceDNA vectors disclosed herein can be produced in eukaryotic cells and thus lack prokaryotic DNA modifications and bacterial endotoxin contamination in insect cells.

[0013] In one aspect, a non-viral capsid-free DNA vector with covalently closed ends is preferably a linear, double-stranded molecule and is obtainable from a vector polynucleotide encoding a heterologous nucleic acid operably positioned between two symmetrically modified inverted terminal repeats (e.g., mod-ITRs) (e.g., AAV ITRs). That is, both ITRs have the same sequence but are reverse complements (inverted) of each other. In an alternative embodiment, the modified ITR pair is substantially symmetrical as defined herein, i.e., the modified ITR pair may have different sequences but have corresponding or identical symmetrical three-dimensional shapes. For example, one modified ITR may be derived from one serotype and the other modified ITR may be derived from a different serotype, but they have the same mutation (e.g., nucleotide insertion, deletion, or substitution) in the same region. In other words, for illustrative purposes only, the 5' mod-ITR may be derived from AAV2 and have a deletion in the C region, and the 3' mod-ITR may be derived from AAV5 and have a corresponding deletion in the C' region. Provided that the 5' mod-ITR and 3' mod-ITR have the same or a symmetrical three-dimensional spatial configuration, they are encompassed for use herein as a modified ITR pair.

[0014] In some embodiments, the modified ITR pair comprises at least one of deletion, insertion, or substitution, or any combination thereof, compared to the wild-type ITR sequence from the same AAV serotype. The additions, deletions, or substitutions of the symmetric ITRs are the same but are reverse complements of each other. For example, the insertion of three nucleotides into the C region of the 5'ITR is reflected by the insertion of three reverse complements of nucleotides into the corresponding section of the C' region of the 3'ITR. For illustrative purposes only, if the addition is AACG in the 5'ITR, the addition is CGTT in the 3'ITR at the corresponding site. For example, if the 5'ITR sense strand is [ka] and between G and A [ka] With the addition of the sequence [ka] The corresponding 3' ITR sense strand is [ka] (the reverse complement of ) and between T and C [ka] (i.e., the reverse complement of AACG) [ka] In some embodiments, the modified ITR does not include a terminal resolution site and / or a replication protein binding site (RPS), e.g., a Rep binding site, resulting in a 5' ITR modification (reverse complement of the 5' ITR modification), e.g., a mirror image of the 5' ITR modification. In some embodiments, the modified ITR does not include a terminal resolution site and / or a replication protein binding site (RPS), e.g., a Rep binding site.

[0015] In some embodiments, the ceDNA vector comprises: (1) an expression cassette comprising a cis-regulatory element, a promoter, and at least one transgene; (2) a promoter operably linked to at least one transgene; and (3) two self-complementary symmetric sequences, e.g., symmetrically modified ITRs, flanking the expression cassette, wherein the ceDNA vector is not associated with a capsid protein.

[0016] In one embodiment, the ceDNA vector comprises additional components for regulating the expression of the transgene, such as cis-regulatory elements and / or regulatory switches for controlling and regulating the expression of the transgene, as more fully described in the section entitled "Regulatory Switches" herein, e.g., a regulatory switch such as a kill switch that enables controlled cell death of cells containing the ceDNA vector. Cis-regulatory elements include, but are not limited to, promoters, riboswitches, insulators, mir regulatory elements, post-transcriptional regulatory elements, tissue- and cell-type-specific promoters, and enhancers. In some embodiments, the ITRs can act as promoters for the transgene.

[0017] In some embodiments, the two self-complementary sequences can be modified ITR sequences from any known parvovirus, such as a dependovirus, such as AAV (e.g., AAV1-AAV12). Any AAV serotype can be used, including, but not limited to, a modified AAV2 ITR sequence that retains a Rep binding site (RBS) and terminal resolution site (TRS), such as 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 531), in addition to a variable palindromic sequence that allows for hairpin secondary structure formation. In some embodiments, the modified ITR is a synthetic ITR sequence that can contain a functional Rep binding site (RBS) and terminal resolution site (TRS), such as 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 531), in addition to a variable palindromic sequence that allows for hairpin secondary structure formation. In some examples, the modified ITR sequence retains the structure and position of the RBS, trs sequence, and Rep binding element that forms the terminal loop portion of one ITR hairpin secondary structure from the corresponding sequence of a wild-type ITR, such as AAV1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, 11 and 12.

[0018] Exemplary modified ITR sequences for use in ceDNA vectors containing symmetrically modified ITRs are shown in Table 4 herein, showing pairs of ITRs (modified 5'ITR and symmetrically modified 3'ITR). Exemplary modified ITR sequences for use in ceDNA vectors include SEQ ID NO:484 (ITR-33, left) and SEQ ID NO:469 (ITR-18, right); SEQ ID NO:485 (ITR-34, left) and SEQ ID NO:95 (ITR-51, right); SEQ ID NO:486 (ITR-35, left) and SEQ ID NO:470 (ITR-19, right); SEQ ID NO:487 (ITR-36, left) and SEQ ID NO:471 (ITR-20, right); SEQ ID NO:488 (ITR-37, left) and SEQ ID NO:472 (ITR-21, right); SEQ ID NO:489 (ITR-38, left) and SEQ ID NO:473 (ITR-22, right); SEQ ID NO:490 (ITR-39, left) and SEQ ID NO:474 (ITR-23, right); SEQ ID NO:491 (ITR-40, left) and SEQ ID NO:475 (ITR-24, right); SEQ ID NO: 492 (ITR-41, left) and SEQ ID NO: 476 (ITR-25, right); SEQ ID NO: 493 (ITR-42, left) and SEQ ID NO: 477 (ITR-26, right); SEQ ID NO: 494 (ITR-43, left) and SEQ ID NO: 478 (ITR-27, right); SEQ ID NO: 495 (ITR-44, left) and SEQ ID NO: 479 (ITR-28, right); SEQ ID NO: 496 (ITR-45, left) and SEQ ID NO: 480 (ITR-29, right); SEQ ID NO: 497 (ITR-46, left) and SEQ ID NO: 481 (ITR-30, right); SEQ ID NO: 498 (ITR-47, left) and SEQ ID NO: 482 (ITR-31, right); SEQ ID NO: 499 (ITR-48, left) and SEQ ID NO: 483 (ITR-32, right).

[0019] In some embodiments, exemplary modified ITR sequences for use in ceDNA vectors comprise ITR subsequences selected from the pairs of sequences SEQ ID NO:101 and SEQ ID NO:102; SEQ ID NO:103 and SEQ ID NO:96; SEQ ID NO:105 and SEQ ID NO:106; SEQ ID NO:545 and SEQ ID NO:116; SEQ ID NO:111 and SEQ ID NO:112; SEQ ID NO:117 and SEQ ID NO:118; SEQ ID NO:119 and SEQ ID NO:120; SEQ ID NO:121 and SEQ ID NO:122; SEQ ID NO:107 and SEQ ID NO:108; SEQ ID NO:123 and SEQ ID NO:124; SEQ ID NO:125 and SEQ ID NO:126; SEQ ID NO:127 and SEQ ID NO:128; SEQ ID NO:129 and SEQ ID NO:130; SEQ ID NO:131 and SEQ ID NO:132; SEQ ID NO:133 and SEQ ID NO:134; SEQ ID NO:547 and SEQ ID NO:546 (which are also shown in Figures 6B-21B).

[0020] In some embodiments, a ceDNA vector can include ITRs with modifications in each ITR corresponding to any of the modifications in the ITR sequences or ITR subsequences set forth in Tables 2, 3, 4, 5, 6, 7, 8, 9, or 10A-10B of PCT / US18 / 49996, filed September 7, 2018, wherein adjacent ITR sequences are symmetrical (e.g., reverse complements) or substantially symmetrical, i.e., have a symmetrical three-dimensional spatial configuration, as defined herein.

[0021] As an illustrative example, the present disclosure provides a closed-end DNA vector comprising a promoter, with or without a regulatory switch, operably linked to a transgene, wherein the ceDNA lacks capsid protein and is (a) produced from a ceDNA-plasmid (see, e.g., Figures 1A-B) encoding symmetric ITRs, each modified ITR having the same number of intramolecularly duplexed base pairs in its hairpin secondary configuration (preferably excluding any AAA or TTT terminal loop deletions in this configuration compared to these reference sequences), and (b) identified as ceDNA using the assay for identification of ceDNA by agarose gel electrophoresis under native and denaturing conditions of Example 1.

[0022] In one embodiment, adjacent modified ITRs are substantially symmetrical to each other. In this embodiment, the modifications are identical. The additions, substitutions, or deletions are the same, but the ITRs are not identical reverse complements. In such embodiments, the modified ITR pair is substantially symmetrical in that they have a symmetrical three-dimensional spatial configuration but do not have the same reverse complementary nucleotide sequence. In other words, in some embodiments, the ITRs from a mod-ITR pair may have different reverse complementary nucleotide sequences but still have the same symmetrical three-dimensional spatial configuration. That is, both ITRs have mutations that result in the same overall three-dimensional shape. For example, one ITR (e.g., the 5' ITR) of a mod-ITR pair may be derived from one serotype, and the other ITR (e.g., the 3' ITR) may be derived from a different serotype, but both may have the same corresponding mutation (e.g., if the 5' ITR has a deletion in the C region, the cognate modified 3' ITR of the different serotype will have a deletion in the corresponding position in the C' region), thereby providing the modified ITR pair with the same symmetrical three-dimensional spatial configuration. In such an embodiment, each ITR of the modified ITR pair may be derived from a different serotype (e.g., AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12), such as a combination of AAV2 and AAV6, and the modification of one ITR is reflected in the corresponding position of the cognate ITR of the different serotype. In one embodiment, a substantially symmetrical modified ITR pair refers to a pair of modified ITRs (mod-ITRs) so long as the differences in nucleotide sequence between the ITRs do not affect their properties or overall shape and they have substantially the same shape in three-dimensional space. For example, the mod-ITRs have at least 95%, 96%, 97%, 98%, or 99% sequence identity to a canonical mod-ITR, as determined by standard means well known in the art, such as BLAST (Basic Local Alignment Search Tool) with default settings, and have a symmetrical three-dimensional spatial organization such that their three-dimensional structures have the same shape in geometric space. A substantially symmetrical mod-ITR pair has the same A, C-C', and B-B' loops in three-dimensional space.For example, if a modified ITR of a substantially symmetric mod-ITR pair has a deletion of the C-C' arm, the cognate mod-ITR has a corresponding deletion of the C-C' loop and a similar three-dimensional structure of the remaining A and B-B' loops that are identically shaped in the geometric space of the cognate mod-ITR.

[0023] In some embodiments, the structural element of an ITR can be any structural element involved in the functional interaction of an ITR with a large Rep protein (e.g., Rep78 or Rep68). In certain embodiments, the structural element provides selectivity for the interaction of an ITR with a large Rep protein, i.e., determines, at least in part, which Rep protein functionally interacts with the ITR. In other embodiments, the structural element physically interacts with a large Rep protein when the Rep protein is bound to the ITR. Each structural element can be, for example, the secondary structure of the ITR, the nucleotide sequence of the ITR, the space between two or more elements, or any combination of the above. In one embodiment, the structural element is selected from the group consisting of A and A' arms, B and B' arms, C and C' arms, D arm, Rep binding site (RBE) and RBE' (i.e., complementary RBE sequences), and terminal resolution site (trs).

[0024] More specifically, ITRs can be structurally modified. For example, the nucleotide sequence of a structural element can be modified compared to the wild-type sequence of an ITR. In one embodiment, structural elements of an ITR (e.g., A arm, A' arm, B arm, B' arm, C arm, C' arm, D arm, RBE, RBE', and trs) can be removed and replaced with wild-type structural elements from a different parvovirus. For example, the replacement structure can be from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, snake parvovirus (e.g., royal python parvovirus), bovine parvovirus, caprine parvovirus, avian parvovirus, canine parvovirus, equine parvovirus, shrimp parvovirus, porcine parvovirus, or insect AAV. For example, the ITRs can be AAV2 ITRs, with the A or A' arms or RBE replaced with structural elements from AAV5. In another example, the ITRs can be AAV5 ITRs, with the C or C' arms, RBE, and trs replaced with structural elements from AAV2. In another example, the AAV ITRs can be AAV5 ITRs, with the B and B' arms replaced with the AAV2 ITR B and B' arms.

[0025] By way of example only, Table 3 shows exemplary modifications (e.g., deletions, insertions, and / or substitutions) of at least one nucleotide in a region of a modified ITR, where X indicates the modification (e.g., deletion, insertion, and / or substitution) of at least one nucleic acid in that section relative to the corresponding wild-type ITR. In some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in any of the C and / or C' and / or B and / or B' regions retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. For example, if the modification results in either a single-arm ITR (e.g., a single C-C' arm or a single B-B' arm), or a modified C-B' arm or C'-B arm, or a two-arm ITR with at least one truncated arm (e.g., a truncated C-C' arm and / or a truncated B-B' arm), at least the single arm, or at least one of the arms of the two-arm ITR (one arm may be truncated), retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. In some embodiments, the truncated C-C' arm and / or the truncated B-B' arm has three consecutive T nucleotides (i.e., TTT) in the terminal loop.

[0026] The technology described herein further relates to ceDNA vectors capable of delivering and encoding one or more transgenes in target cells, for example, where the ceDNA vector contains a multicistronic sequence, or where a transgene and its natural genomic context (e.g., a transgene, introns, and endogenous untranslated regions) are integrated together into the ceDNA vector. A transgene can be a protein-coding transcript, a non-coding transcript, or both. A ceDNA vector can contain multiple coding sequences and non-canonical translation start sites, or multiple promoters for expressing protein-coding transcripts, non-coding transcripts, or both. A transgene can contain multiple protein-coding sequences or can be a non-coding transcript sequence. The expression cassette can contain, for example, more than 4,000 nucleotides, 5,000 nucleotides, 10,000 nucleotides, 20,000 nucleotides, 30,000 nucleotides, 40,000 nucleotides, 50,000 nucleotides, or any range between about 4,000 and 10,000 nucleotides, 10,000 and 50,000 nucleotides, or more than 50,000 nucleotides. ceDNA vectors do not have the size limitations of encapsidated AAV vectors, and therefore, delivery of large-sized expression cassettes can result in efficient expression of the transgene. In some embodiments, the ceDNA vector lacks prokaryotic cell-specific methylation.

[0027] The expression cassette may also contain an internal ribosome entry site (IRES) and / or a 2A element. Cis-regulatory elements include, but are not limited to, promoters, riboswitches, insulators, mir regulatory elements, post-transcriptional regulatory elements, tissue- and cell-type-specific promoters, and enhancers. In some embodiments, the ITRs may act as promoters for the transgene. In some embodiments, the ceDNA vector contains additional components for regulating the expression of the transgene. For example, the additional regulatory components may be the regulatory switches disclosed herein, including, but not limited to, kill switches that can kill ceDNA-infected cells, as well as other inducible and / or repressible elements as needed.

[0028] The technology described herein further provides a novel method for using ceDNA vector to deliver and efficiently and selectively express one or more transgenes.The ceDNA vector has the ability to be incorporated into host cells and transported into the nucleus in the absence of AAV capsid.In addition, the ceDNA vector described herein lacks capsid, so it can avoid the immune reaction that may occur in response to capsid-containing vectors.

[0029] Aspects of the present invention relate to methods for producing the ceDNA vectors described herein. In other embodiments, the present invention relates to ceDNA vectors produced by the methods provided herein. In one embodiment, the capsid-free, non-viral DNA vector (ceDNA vector) is obtained from a plasmid (referred to herein as a "ceDNA plasmid") containing a polynucleotide expression construct template comprising, in this order, a first 5' inverted terminal repeat (e.g., AAV ITR); an expression cassette; and a 3' ITR (e.g., AAV ITR), wherein the 5' and 3' ITRs are modified ITRs relative to the wild-type ITR, and the modifications are the same as each other, i.e., the ITRs are symmetrical (i.e., structural mirror images) relative to each other.

[0030] The ceDNA vectors disclosed herein can be obtained by several means known to those skilled in the art upon reading this disclosure. For example, the polynucleotide expression construct template used to generate the ceDNA vectors of the present disclosure can be a ceDNA-plasmid (e.g., see Table 7 or Figures 1B or 6B), a ceDNA-bacmid, and / or a ceDNA-baculovirus. In one embodiment, the ceDNA-plasmid contains a restriction cloning site (e.g., SEQ ID NO: 7) operably positioned between the ITRs, allowing insertion of, for example, an expression cassette comprising a promoter operably linked to a transgene, such as a reporter gene and / or a therapeutic gene. In some embodiments, the ceDNA vector is produced from a polynucleotide template (e.g., a ceDNA-plasmid, a ceDNA-bacmid, a ceDNA-baculovirus) containing modified symmetrical 5' and 3' ITRs flanking the expression cassette, the modification being any one or more of a deletion, insertion, and / or substitution when compared to the wild-type AAV2 or AAV3 ITR sequence.

[0031] In permissive host cells, for example, in the presence of Rep, a polynucleotide template having at least one modified ITR is combined to produce a ceDNA vector. ceDNA vector production involves two steps: first, Rep protein-mediated excision ("rescue") of the template from the template backbone (e.g., ceDNA-plasmid, ceDNA-bacmid, ceDNA-baculovirus genome, etc.), and second, Rep-mediated replication of the excised ceDNA vector. Rep proteins and Rep binding sites of various AAV serotypes are well known to those skilled in the art. Those skilled in the art will understand that Rep proteins are selected from serotypes that bind to and replicate nucleic acid sequences based on at least one functional ITR. For example, if a replicable modified ITR is derived from AAV serotype 2, the corresponding Rep will be derived from an AAV serotype that cooperates with that serotype; for example, AAV2 ITRs cooperate with AAV2 or AAV4 Rep, but not with AAV5 Rep. Upon replication, the covalently closed-end ceDNA vector continues to accumulate in permissive cells, and the ceDNA vector preferably accumulates under standard replication conditions and in the presence of Rep proteins sufficiently stably over long periods of time, for example in amounts of at least 1 pg / cell, preferably at least 2 pg / cell, preferably at least 3 pg / cell, more preferably at least 4 pg / cell, and even more preferably at least 5 pg / cell.

[0032] Thus, one aspect of the present disclosure relates to a process comprising: a) incubating a population of host cells (e.g., insect cells) harboring a polynucleotide expression construct template (e.g., ceDNA-plasmid, ceDNA-bacmid, and / or ceDNA-baculovirus) lacking a viral capsid-encoding sequence in the presence of Rep proteins under conditions effective and for a sufficient time to induce production of a ceDNA vector in the host cells, wherein the host cells do not contain a viral capsid-encoding sequence; and b) harvesting and isolating the ceDNA vector from the host cells. The presence of Rep proteins induces replication of the vector polynucleotide with modified ITRs to produce a ceDNA vector in the host cells. However, viral particles (e.g., AAV virions) are not expressed. Therefore, there is no mandatory virion size limit.

[0033] The presence of a ceDNA vector isolated from a host cell can be confirmed by digesting the DNA isolated from the host cell with a restriction enzyme that has a single recognition site on the ceDNA vector, and analyzing the digested DNA material on denaturing and native gels to confirm the presence of a characteristic linear, continuous DNA band compared to linear, discontinuous DNA.

[0034] According to one aspect, the present disclosure provides a non-viral capsid-free DNA vector (ceDNA vector) with covalently closed ends, wherein the ceDNA vector comprises at least one heterologous nucleotide sequence operably disposed between two flanking symmetric inverted terminal repeats (symmetric ITRs), wherein the symmetric ITRs are not wild-type ITRs and each flanking ITR has the same symmetric modification. According to one embodiment, the symmetric ITR sequences are synthetic. According to some embodiments, the ITRs are selected from any of those listed in Table 4. According to some embodiments, each of the symmetric ITRs is modified by deletion, insertion, and / or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D, and D'. According to some embodiments, the deletion, insertion, and / or substitution results in the deletion of all or part of the stem-loop structure normally formed by the A, A', B, B'C, or C' regions. According to some embodiments, the symmetric ITR is modified by a deletion, insertion, and / or substitution that results in the deletion of all or part of the stem-loop structure normally formed by the B and B' regions. According to some embodiments, the symmetric ITR is modified by a deletion, insertion, and / or substitution that results in the deletion of all or part of the stem-loop structure normally formed by the C and C' regions. According to some embodiments, the symmetric ITR is modified by a deletion, insertion, and / or substitution that results in the deletion of a portion of the stem-loop structure normally formed by the B and B' regions and / or a portion of the stem-loop structure normally formed by the C and C' regions. According to some embodiments, the symmetric ITR comprises a single stem-loop structure in a region that typically includes a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. According to some embodiments, the symmetric ITR comprises a single stem and two loops in a region that typically includes a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.According to some embodiments, a symmetric ITR comprises a single stem and a single loop in a region that typically comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. According to some embodiments, the symmetric ITR is a modified AAV2 ITR comprising a nucleotide sequence selected from an ITR in Figures 7A-22B or Table 4 herein, and an ITR having at least 95% sequence identity to an ITR listed in Table 4 or shown in Figures 7A-22B. According to some embodiments, all or a portion of the heterologous nucleotide sequence is under the control of at least one regulatory switch.

[0035] According to another aspect, the present disclosure provides a non-viral capsid-free DNA vector (ceDNA vector) with covalently closed ends, the ceDNA vector comprising at least one heterologous nucleotide sequence operably disposed between two flanking wild-type inverted terminal repeats (WT-ITRs), wherein all or a portion of the heterologous nucleotide sequence is under the control of at least one regulatory switch. According to some embodiments, the WT-ITR sequence is a symmetric WT-ITR sequence or a substantially symmetric WT-ITR sequence. According to some embodiments, the WT-ITR sequence is selected from any of the WT-ITR combinations shown in Table 1. According to some embodiments, the flanking WT-ITRs have at least 95% sequence identity to the ITRs listed in Table 1 or Table 2, and all substitutions are conservative nucleic acid substitutions that do not affect the structure of the WT-ITR. According to some embodiments, the at least one regulatory switch is selected from any one or combination of regulatory switches listed in Table 5 or the section entitled "Regulatory Switches" herein. According to some embodiments, the ceDNA vector, when digested with a restriction enzyme having a single recognition site on the ceDNA vector and analyzed by both native and denaturing gel electrophoresis, exhibits a characteristic linear, continuous DNA band compared to a linear, discontinuous DNA control. According to some embodiments, the ITR sequences are based on sequences derived from a virus selected from parvovirus, dependovirus, and adeno-associated virus (AAV). According to some embodiments, the ITRs are based on sequences derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. According to some embodiments, the vector is within a nanocarrier. According to some embodiments, the nanocarrier comprises a lipid nanoparticle (LNP).

[0036] According to some aspects and embodiments herein, the ceDNA vector is obtained from a process comprising: (a) incubating a population of insect cells harboring a ceDNA expression construct in the presence of at least one Rep protein under conditions effective and for a time sufficient to induce production of the ceDNA vector in the insect cells, wherein the ceDNA expression construct encodes the ceDNA vector; and (b) isolating the ceDNA vector from the insect cells. According to some embodiments, the ceDNA expression construct is selected from a ceDNA plasmid, a ceDNA bacmid, and a ceDNA baculovirus. According to some embodiments, the insect cells express at least one Rep protein. According to some embodiments, the at least one Rep protein is based on a sequence derived from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV). According to some embodiments, at least one Rep protein is derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 and AAV12.

[0037] According to some embodiments, the present disclosure provides a ceDNA expression construct encoding the ceDNA vector of any of the aspects and embodiments herein. According to some embodiments, the construct is a ceDNA plasmid, a ceDNA bacmid, or a ceDNA baculovirus.

[0038] According to some embodiments, the present disclosure provides a host cell comprising a ceDNA expression construct of any of the aspects or embodiments thereof. According to some embodiments, the host cell expresses at least one Rep protein. According to some embodiments, the at least one Rep protein is based on a sequence derived from a virus selected from parvovirus, dependovirus, and adeno-associated virus (AAV). According to some embodiments, the at least one Rep protein is derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. According to some embodiments, the host cell is an insect cell. According to some embodiments, the insect cell is an Sf9 cell.

[0039] According to some embodiments, the present disclosure provides a method of producing a ceDNA vector, the method comprising: (a) incubating a host cell of any of the aspects and embodiments herein under conditions effective and for a time sufficient to induce production of the ceDNA vector; and (b) isolating the ceDNA from the host cell.

[0040] According to some embodiments, the present disclosure provides a method for treating, preventing, ameliorating, monitoring, or diagnosing a disease or disorder in a subject, the method comprising administering to a subject in need thereof a composition comprising a ceDNA vector of any of the aspects and embodiments herein, wherein at least one heterologous nucleotide sequence is selected to treat, prevent, ameliorate, diagnose, or monitor the disease or disorder. According to some embodiments, the at least one heterologous nucleotide sequence, when transcribed or translated, corrects an abnormal amount of an endogenous protein in the subject. According to some embodiments, the at least one heterologous nucleotide sequence, when transcribed or translated, corrects an abnormal function or activity of an endogenous protein or pathway in the subject. According to some embodiments, the at least one heterologous nucleotide sequence encodes or comprises a nucleotide molecule selected from the group consisting of RNAi, siRNA, miRNA, lncRNA, and antisense oligonucleotides or polynucleotides. According to some embodiments, the at least one heterologous nucleotide sequence encodes a protein. According to some embodiments, the protein is a marker protein (e.g., a reporter protein). According to some embodiments, at least one heterologous nucleotide sequence encodes an agonist or antagonist of an endogenous protein or pathway associated with a disease or disorder. According to some embodiments, at least one heterologous nucleotide sequence encodes an antibody. According to some embodiments, the disease or disorder is selected from the group consisting of metabolic diseases or disorders, CNS diseases or disorders, eye diseases or disorders, blood diseases or disorders, liver diseases or disorders, immune diseases or disorders, infectious diseases, muscle diseases or disorders, cancer, and diseases or disorders based on abnormal levels and / or function of gene products. According to some embodiments, the metabolic disease or disorder is selected from the group consisting of diabetes, lysosomal storage disorders, mucopolysaccharide disorders, urea cycle diseases or disorders, and glycogen storage diseases or disorders.According to some embodiments, the lysosomal storage disorder is selected from the group consisting of Gaucher disease, Pompe disease, metachromatic leukodystrophy (MLD), phenylketonuria (PKU), and Fabry disease. According to some embodiments, the urea cycle disease or disorder is ornithine transcarbamylase (OTC) deficiency. According to some embodiments, the mucopolysaccharidosis is selected from the group consisting of Sly syndrome, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome, Morquio syndrome, and Marote-Lamy syndrome. According to some embodiments, the CNS disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Canavan disease, Leigh's disease, Refsum's disease, Tourette's syndrome, primary lateral sclerosis, amyotrophic lateral sclerosis, progressive muscular atrophy, Pick's disease, muscular dystrophy, multiple sclerosis, myasthenia gravis, Binswanger's disease, trauma due to spinal cord or head injury, Tay-Sachs disease, Leschnyan's disease, epilepsy, stroke, psychiatric disorders, schizophrenia, drug addiction, neurosis, psychosis, dementia, paranoia, attention deficit disorder, sleep disorder, pain disorder, eating or weight disorder, and cancers and tumors of the CNS. According to some embodiments, the ophthalmic disease or disorder is selected from the group consisting of ophthalmic disorders involving the retina, posterior thalamic tract, and / or optic nerve. According to some embodiments, the ophthalmologic disorder involving the retina, posterior thalamic tract, and / or optic nerve is selected from the group consisting of diabetic retinopathy, macular degeneration including age-related macular degeneration, geographic atrophy and vascular or "wet" macular degeneration, glaucoma, uveitis, retinitis pigmentosa, Stargardt's disease, Leber's congenital amaurosis (LCA), Usher syndrome, pseudoxanthoma elasticum (PXE), X-linked retinitis pigmentosa (XLRP), X-linked retinoschisis (XLRS), total choroidal atrophy, Leber's hereditary optic neuropathy (LHON), color blindness, cone-rod degeneration, Fuchs' endothelial corneal dystrophy, diabetic macular edema, and ocular cancers and tumors. According to some embodiments, the blood disease or disorder is selected from the group consisting of hemophilia A, hemophilia B, thalassemia, anemia, and blood cancer. According to some embodiments, the liver disease or disorder is selected from the group consisting of progressive familial intrahepatic cholestasis (PFIC) and liver cancer, and tumors.According to some embodiments, the disease or disorder is cystic fibrosis. According to some embodiments, the ceDNA vector is administered in combination with a pharmaceutically acceptable carrier.

[0041] According to some embodiments, the present disclosure provides a method for delivering a therapeutic protein to a subject, the method comprising administering to the subject a composition comprising a ceDNA vector of any of the aspects and embodiments herein, wherein at least one heterologous nucleotide sequence encodes the therapeutic protein. According to some embodiments, the therapeutic protein is a therapeutic antibody. According to some embodiments, the therapeutic protein is selected from the group consisting of an enzyme, erythropoietin, angiostatin, endostatin, superoxide dismutase, globin, leptin, catalase, tyrosine hydroxylase, cytokine, cystic fibrosis transmembrane conductance regulator (CFTR), peptide growth factor, and hormone.

[0042] According to some embodiments, the present disclosure provides a kit comprising a ceDNA vector of any of the aspects and embodiments herein and a nanocarrier packaged in a container with a packet insert.

[0043] According to some aspects, the present disclosure provides a kit for producing a ceDNA vector, the kit comprising an expression construct comprising at least one restriction site for insertion of at least one heterologous nucleotide sequence and / or regulatory switch, the at least one restriction site being operably positioned between either (i) a symmetric inverted terminal repeat (symmetric ITR) where the symmetric ITR is not a wild-type ITR, or (ii) two wild-type inverted terminal repeats (WT-ITR). According to some embodiments, the kit is suitable for producing the ceDNA vector of any one of the aspects and embodiments herein. According to some embodiments, the kit further comprises a population of insect cells lacking a viral capsid coding sequence, and is capable of inducing production of the ceDNA vector in the presence of a Rep protein. According to some embodiments, the kit further comprises a vector comprising a polynucleotide sequence encoding at least one Rep protein, the vector being suitable for expressing at least one Rep protein in insect cells.

[0044] These and other aspects of the disclosure are described in further detail below. In certain embodiments, for example, the following items are provided: (Item 1) A non-viral capsid-free DNA vector (ceDNA vector) with covalently closed ends, said ceDNA vector comprising at least one heterologous nucleotide sequence operably positioned between two adjacent symmetric inverted terminal repeats (symmetric ITRs), said symmetric ITRs being different from wild-type ITRs, and each adjacent ITR having the same symmetric modification. (Item 2) 2. The ceDNA vector of item 1, wherein the symmetric ITR sequences are synthetic. (Item 3) The ceDNA vector of any one of items 1 or 2, wherein the ITRs are selected from any of those listed in Table 4. (Item 4) 4. The ceDNA vector of any one of items 1 to 3, wherein each of the symmetric ITRs is modified by a deletion, insertion, and / or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D, and D'. (Item 5) 5. The ceDNA vector of item 4, wherein the deletion, insertion, and / or substitution results in the deletion of all or part of the stem-loop structure normally formed by the A, A', B, B'C, or C' region. (Item 6) 6. The ceDNA vector of item 4 or item 5, wherein the symmetric ITRs are modified by deletions, insertions, and / or substitutions that result in the loss of all or part of the stem-loop structure normally formed by the B and B' regions. (Item 7) 7. The ceDNA vector of any one of items 4 to 6, wherein the symmetric ITRs are modified by deletions, insertions, and / or substitutions that result in the loss of all or part of the stem-loop structure normally formed by the C and C' regions. (Item 8) 8. The ceDNA vector of item 6 or item 7, wherein the symmetric ITRs are modified by deletions, insertions, and / or substitutions that result in the deletion of part of the stem-loop structure normally formed by the B and B' regions and / or part of the stem-loop structure normally formed by the C and C' regions. (Item 9) 9. The ceDNA vector according to any one of items 1 to 8, wherein the symmetric ITR comprises a single stem-loop structure in the region that normally comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. (Item 10) 10. The ceDNA vector of item 9, wherein the symmetric ITRs comprise a single stem and two loops in a region that typically comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. (Item 11) 11. The ceDNA vector of claim 9 or 10, wherein the symmetric ITRs comprise a single stem and a single loop in the region that typically comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. (Item 12) 12. The ceDNA vector of any one of paragraphs 1 to 11, wherein the symmetric ITR is a modified AAV2 ITR comprising a nucleotide sequence selected from the ITRs in Figures 7A-22B or Table 4 herein, and ITRs having at least 95% sequence identity to the ITRs listed in Table 4 or shown in Figures 7A-22B. (Item 13) 13. The ceDNA vector of any one of items 1 to 12, wherein all or part of the heterologous nucleotide sequence is under the control of at least one regulatory switch. (Item 14) A non-viral capsid-free DNA vector (ceDNA vector) with covalently closed ends, the ceDNA vector comprising at least one heterologous nucleotide sequence operably positioned between two flanking wild-type inverted terminal repeats (WT-ITRs), wherein all or part of the heterologous nucleotide sequence is under the control of at least one regulatory switch. (Item 15) 15. The ceDNA vector of item 14, wherein the WT-ITR sequence is a symmetric WT-ITR sequence or a substantially symmetric WT-ITR sequence. (Item 16) Item 16. The ceDNA vector of item 14 or item 15, wherein the WT-ITR sequence is selected from any of the WT-ITR combinations shown in Table 1. (Item 17) 17. The ceDNA vector of any one of Items 14 to 16, wherein the flanking WT-ITRs have at least 95% sequence identity to the ITRs listed in Table 1 or Table 2, and all substitutions are conservative nucleic acid substitutions that do not affect the structure of the WT-ITRs. (Item 18) 18. The ceDNA vector of any one of items 13 to 17, wherein the at least one regulatory switch is selected from any one or combination of regulatory switches listed in Table 5 or in the section entitled "Regulatory Switches" herein. (Item 19) 19. The ceDNA vector of any one of items 1 to 18, wherein the ceDNA vector, when digested with a restriction enzyme having a single recognition site on the ceDNA vector and analyzed by both native and denaturing gel electrophoresis, exhibits a characteristic linear, continuous DNA band compared to a linear, discontinuous DNA control. (Item 20) 20. The ceDNA vector of any one of items 1 to 19, wherein the ITR sequences are based on sequences derived from a virus selected from parvovirus, dependovirus and adeno-associated virus (AAV). (Item 21) 21. The ceDNA vector of item 20, wherein the ITRs are based on sequences derived from adeno-associated virus (AAV). (Item 22) 22. The ceDNA vector of item 21, wherein the ITRs are based on a sequence derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. (Item 23) 23. The ceDNA vector of any one of items 1 to 22, wherein the vector is within a nanocarrier. (Item 24) 24. The ceDNA vector of item 23, wherein the nanocarrier comprises a lipid nanoparticle (LNP). (Item 25) 25. The ceDNA vector of any one of items 1 to 24, wherein the ceDNA vector is obtained from a process comprising the steps of: (a) incubating a population of insect cells harboring a ceDNA expression construct in the presence of at least one Rep protein under conditions effective and for a time sufficient to induce production of the ceDNA vector in the insect cells, wherein the ceDNA expression construct encodes the ceDNA vector; and (b) isolating the ceDNA vector from the insect cells. (Item 26) 26. The ceDNA vector of item 25, wherein the ceDNA expression construct is selected from a ceDNA plasmid, a ceDNA bacmid, and a ceDNA baculovirus. (Item 27) 27. The ceDNA vector of claim 25 or 26, wherein the insect cell expresses at least one Rep protein. (Item 28) 28. The ceDNA vector of item 27, wherein the at least one Rep protein is derived from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV). (Item 29) 29. The ceDNA vector of item 28, wherein the at least one Rep protein is derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. (Item 30) A ceDNA expression construct encoding the ceDNA vector of any one of items 1 to 29. (Item 31) 31. The ceDNA expression construct of item 30, which is a ceDNA plasmid, a ceDNA bacmid, or a ceDNA baculovirus. (Item 32) A host cell comprising the ceDNA expression construct of item 30 or item 31. (Item 33) 33. The host cell of item 32, which expresses at least one Rep protein. (Item 34) 34. The host cell of claim 33, wherein the at least one Rep protein is derived from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV). (Item 35) 35. The host cell of item 34, wherein the at least one Rep protein is derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. (Item 36) 36. The host cell according to any one of items 32 to 35, which is an insect cell. (Item 37) 37. The host cell of item 36, wherein the insect cell is an Sf9 cell. (Item 38) 38. A method for producing a ceDNA vector, comprising: (a) incubating the host cell of any one of items 32 to 37 under conditions effective and for a time sufficient to induce production of the ceDNA vector; and (b) isolating the ceDNA from the host cell. (Item 39) 30. A method for treating, preventing, ameliorating, monitoring or diagnosing a disease or disorder in a subject, comprising administering to a subject in need thereof a composition comprising the ceDNA vector of any one of items 1 to 29, wherein said at least one heterologous nucleotide sequence is selected to treat, prevent, ameliorate, diagnose or monitor said disease or disorder. (Item 40) 40. The method of claim 39, wherein the at least one heterologous nucleotide sequence, when transcribed or translated, corrects an abnormal amount of an endogenous protein in the subject. (Item 41) 40. The method of claim 39, wherein the at least one heterologous nucleotide sequence, when transcribed or translated, corrects an abnormal function or activity of an endogenous protein or pathway in the subject. (Item 42) 42. The method of any one of items 39 to 41, wherein the at least one heterologous nucleotide sequence encodes or comprises a nucleotide molecule selected from the group consisting of RNAi, siRNA, miRNA, lncRNA, and antisense oligonucleotides or polynucleotides. (Item 43) 42. The method of any one of items 39 to 41, wherein the at least one heterologous nucleotide sequence encodes a protein. (Item 44) 44. The method of claim 43, wherein the protein is a marker protein (e.g., a reporter protein). (Item 45) 45. The method of any one of items 39 to 44, wherein the at least one heterologous nucleotide sequence encodes an agonist or antagonist of an endogenous protein or pathway associated with the disease or disorder. (Item 46) 46. ​​The method of any one of items 39 to 45, wherein the at least one heterologous nucleotide sequence encodes an antibody. (Item 47) 47. The method of any one of items 39 to 46, wherein the disease or disorder is selected from the group consisting of a metabolic disease or disorder, a CNS disease or disorder, an eye disease or disorder, a blood disease or disorder, a liver disease or disorder, an immune disease or disorder, an infectious disease, a muscle disease or disorder, cancer, and a disease or disorder based on an abnormal level and / or function of a gene product. (Item 48) 48. The method of claim 47, wherein the metabolic disease or disorder is selected from the group consisting of diabetes, lysosomal storage disorders, mucopolysaccharidosis, urea cycle diseases or disorders, and glycogen storage diseases or disorders. (Item 49) 49. The method of item 48, wherein the lysosomal storage disorder is selected from the group consisting of Gaucher disease, Pompe disease, metachromatic leukodystrophy (MLD), phenylketonuria (PKU), and Fabry disease. (Item 50) Item 49. The method of item 48, wherein the urea cycle disease or disorder is ornithine transcarbamylase (OTC) deficiency. (Item 51) 49. The method of claim 48, wherein the mucopolysaccharidosis is selected from the group consisting of Sly syndrome, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome, Morquio syndrome, and Marote-Lamy syndrome. (Item 52) 48. The method of item 47, wherein the CNS disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Canavan disease, Leigh's disease, Refsum's disease, Tourette's syndrome, primary lateral sclerosis, amyotrophic lateral sclerosis, progressive muscular atrophy, Pick's disease, muscular dystrophy, multiple sclerosis, myasthenia gravis, Binswanger's disease, trauma due to spinal cord or head injury, Tay-Sachs disease, Leschnyan's disease, epilepsy, cerebral infarction, psychiatric disorders, schizophrenia, drug addiction, neurosis, psychosis, dementia, paranoia, attention deficit disorder, sleep disorder, pain disorder, eating or weight disorder, and cancers and tumors of the CNS. (Item 53) 48. The method of item 47, wherein the eye disease or disorder is selected from the group consisting of ophthalmic disorders involving the retina, the posterior thalamic tract, and / or the optic nerve. (Item 54) 54. The method of claim 53, wherein the ophthalmologic disorder involving the retina, posterior thalamic tract, and / or optic nerve is selected from the group consisting of diabetic retinopathy, macular degeneration including age-related macular degeneration, geographic atrophy and vascular or "wet" macular degeneration, glaucoma, uveitis, retinitis pigmentosa, Stargardt's disease, Leber's congenital amaurosis (LCA), Usher syndrome, pseudoxanthoma elasticum (PXE), X-linked retinitis pigmentosa (XLRP), X-linked retinoschisis (XLRS), total choroidal atrophy, Leber's hereditary optic neuropathy (LHON), color blindness, cone-rod degeneration, Fuchs' endothelial corneal dystrophy, diabetic macular edema, and ocular cancers and tumors. (Item 55) 48. The method of item 47, wherein the blood disease or disorder is selected from the group consisting of hemophilia A, hemophilia B, thalassemia, anemia, and blood cancer. (Item 56) 48. The method of claim 47, wherein the liver disease or liver disorder is selected from the group consisting of progressive familial intrahepatic cholestasis (PFIC) and liver cancer, and tumors. (Item 57) 40. The method of claim 39, wherein the disease or disorder is cystic fibrosis. (Item 58) 58. The method of items 39 to 57, wherein the ceDNA vector is administered in combination with a pharmaceutically acceptable carrier. (Item 59) 30. A method for delivering a therapeutic protein to a subject, comprising administering to the subject a composition comprising the ceDNA vector according to any one of items 1 to 29, wherein the at least one heterologous nucleotide sequence encodes a therapeutic protein. (Item 60) 60. The method of claim 59, wherein the therapeutic protein is a therapeutic antibody. (Item 61) 60. The method of claim 59, wherein the therapeutic protein is selected from the group consisting of an enzyme, erythropoietin, angiostatin, endostatin, superoxide dismutase, globin, leptin, catalase, tyrosine hydroxylase, cytokine, cystic fibrosis transmembrane conductance regulator (CFTR), peptide growth factor, and hormone. (Item 62) 30. A kit comprising the ceDNA vector according to any one of items 1 to 29 and a nanocarrier packaged in a container with a packet insert. (Item 63) A kit for producing a ceDNA vector, the kit comprising an expression construct comprising at least one restriction site for insertion of at least one heterologous nucleotide sequence and / or regulatory switch, the at least one restriction site being operably located between either (i) a symmetric inverted terminal repeat (symmetric ITR), where the symmetric ITR is not a wild-type ITR, or (ii) two wild-type inverted terminal repeats (WT-ITR). (Item 64) Item 64. The kit according to Item 63, which is suitable for producing the ceDNA vector according to any one of Items 1 to 21. (Item 65) 65. The kit of claim 63 or 64, further comprising a population of insect cells lacking a viral capsid coding sequence and capable of inducing production of the ceDNA vector in the presence of Rep proteins. (Item 66) 66. The kit of any one of items 63 to 65, further comprising a vector comprising a polynucleotide sequence encoding at least one Rep protein, wherein the vector is suitable for expressing the at least one Rep protein in an insect cell. [Brief explanation of the drawings]

[0045] [Figure 1A] Illustrates an exemplary structure of a ceDNA vector. In this embodiment, the exemplary ceDNA vector comprises an expression cassette containing a CAG promoter, a WPRE, and BGHpA. An open reading frame (ORF) encoding a transgene (e.g., luciferase) is inserted into the cloning site (R3 / R4) between the CAG promoter and the WPRE. The expression cassette is flanked by two symmetric inverted terminal repeats (ITRs). That is, the 5'-modified ITR and the 3'-modified ITR flanking the expression cassette are symmetric with respect to each other. [Figure 1B] 1 shows an exemplary structure of a ceDNA vector (or the corresponding sequence present in an exemplary ceDNA plasmid) with an expression cassette containing an enhancer / promoter, an open reading frame (ORF) for insertion of a transgene, a post-transcriptional element (WPRE), and a polyA signal. The open reading frame (ORF) allows for insertion of a transgene into the cloning site between the CAG promoter and the WPRE. The expression cassette is flanked by two symmetric inverted terminal repeats (ITRs): a modified ITR upstream (5' end) and a modified ITR downstream (3' end) of the expression cassette; both the 5' and 3' ITRs are modified ITRs but have the same modifications (i.e., they are structural mirror images of each other, i.e., symmetrical to each other). [Figure 2A]Illustrates an exemplary structure of a ceDNA vector. In this embodiment, the exemplary ceDNA vector comprises an expression cassette containing a CAG promoter, a WPRE, and BGHpA. An open reading frame (ORF) encoding a transgene (e.g., luciferase) is inserted into the cloning site (R3 / R4) between the CAG promoter and the WPRE. The expression cassette is flanked by two wild-type inverted terminal repeats (WT-ITR). That is, the 5'WT-ITR and the 3'WT-ITR flank the expression cassette. [Figure 2B] Figure 1 shows an exemplary structure of a ceDNA vector (or the corresponding sequence present in an exemplary ceDNA plasmid) with an expression cassette containing an enhancer / promoter, an open reading frame (ORF) for insertion of a transgene, a post-transcriptional element (WPRE), and a polyA signal. The open reading frame (ORF) allows for insertion of a transgene into the cloning site between the CAG promoter and the WPRE. The expression cassette is flanked by two WT inverted terminal repeats (WT-ITRs): one upstream (5' end) and one downstream (3' end) of the expression cassette. The 5'WT-ITR and 3'WT-ITR can be derived from the same or different serotypes. [Figure 3A] The T-shaped stem-loop structure of the wild-type left ITR of AAV2 (SEQ ID NO: 538) is shown, with the A-A' arm, B-B' arm, and C-C' arm, identifying two Rep binding sites (RBE and RBE'), and the terminal resolution site (trs) is also shown. The RBE contains a series of four double tetramers that are thought to interact with either Rep78 or Rep68. Furthermore, the RBE' is also thought to interact with the Rep complex assembled on the wild-type or variant ITR in the construct. The D and D' regions contain transcription factor binding sites and other conserved structures. [Figure 3B]1 shows the proposed Rep catalytic nicking and ligation activity in the wild-type left ITR (SEQ ID NO: 539), including the T-shaped stem-loop structure of the wild-type left ITR of AAV2 with the A-A' arm, B-B' arm, C-C' arm, identification of two Rep binding sites (RBE and RBE'), terminal resolution site (trs), and the D and D' regions, which contain several transcription factor binding sites and other conserved structures. [Figure 4A] 1 provides the primary structure (polynucleotide sequence) (left) and secondary structure (right) of the A-A' arm and the RBE-containing portions of the C-C' and B-B' arms of the wild-type left AAV2 ITR (SEQ ID NO: 540). [Figure 4B] 1 shows an exemplary mutant ITR (also referred to as a modified ITR) sequence for the left ITR. The primary structure (left) and predicted secondary structure (right) of the RBE portions of the A-A', C, and B-B' arms of an exemplary mutant left ITR (ITR-1, left) (SEQ ID NO: 113) are shown. [Figure 4C] The primary structure (left) and secondary structure (right) of the A-A' loop and the RBE-containing portions of the B-B' and C-C' arms of the wild-type right AAV2 ITR (SEQ ID NO: 541) are shown. [Figure 4D] The primary structure (left) and secondary structure (right) of the A-A' loop and the RBE-containing portions of the B-B' and C-C' arms of the wild-type right AAV2 ITR (SEQ ID NO: 541) are shown. [Figure 4E]An exemplary right-modified ITR is shown. The primary structure (left) and predicted secondary structure (right) of the A-A' arm and the RBE-containing portion of the B-B' and C arms of an exemplary mutant left ITR (ITR-1, right) (SEQ ID NO: 114) are shown. Any combination of left and right ITRs (e.g., AAV2 ITRs, or other viral serotype or synthetic ITRs) can be used, provided the left ITR is symmetric or the reverse complement of the right ITR. Each of the polynucleotide sequences in Figures 3A-3D refers to the sequence used in the plasmid or bacmid / baculovirus genome used to produce ceDNA as described herein. The corresponding ceDNA secondary structure, deduced from the ceDNA vector configuration in the plasmid or bacmid / baculovirus genome and predicted Gibb free energy values, is also included in each of Figures 4A-4E. [Figure 5A] FIG. 5C is a schematic showing the upstream process for generating baculovirus-infected insect cells (BIICs), which are useful for producing ceDNA in the process described in the schematic in FIG. 5B. [Figure 5B] FIG. 1 is a schematic diagram of an exemplary method for ceDNA production. [Figure 5C] 1 shows biochemical methods and processes for confirming ceDNA vector production. [Figure 5D]Figure 5B is a schematic diagram illustrating a process for identifying the presence of ceDNA in DNA collected from cell pellets obtained during the ceDNA production process. Figure 5E shows DNA with a discontinuous structure. ceDNA can be cleaved by a restriction endonuclease with a single recognition site on the ceDNA vector, generating two DNA fragments of different sizes (1 kb and 2 kb) under both neutral and denaturing conditions. Figure 5E also shows ceDNA with a linear, continuous structure. The ceDNA vector can be cleaved by a restriction endonuclease to generate two DNA fragments migrating as 1 kb and 2 kb under neutral but not denaturing conditions, while the strands remain connected, producing single strands migrating as 2 kb and 4 kb. Figure 5D shows the schematic expected bands of an exemplary ceDNA, either uncut or digested with a restriction endonuclease, after electrophoresis on either a native or denaturing gel. The leftmost schematic is a native gel, showing multiple bands, suggesting that in its duplex and uncleaved form, ceDNA exists in at least two monomeric and dimeric states, appearing as a faster-migrating, smaller monomer and a slower-migrating dimer that is twice the size of the monomer. The second schematic from the left shows that when ceDNA is cleaved with a restriction endonuclease, the original band disappears and a faster-migrating (e.g., smaller) band appears, corresponding to the expected fragment size remaining after cleavage. Under denaturing conditions, the original duplex DNA is single-stranded and migrates as a species twice as large as that observed on the native gel due to the covalent attachment of the complementary strand. Thus, in the second schematic from the right, the digested ceDNA shows a banding distribution similar to that observed on the native gel, but the bands migrate as fragments twice the size of their native gel counterparts. The schematic on the far right shows that uncut ceDNA under denaturing conditions migrates as a single-stranded open circle, and therefore the observed band is twice the size of that observed under native conditions where the circle is not open.In this figure, "kb" is used to indicate the relative size of a nucleotide molecule based on the length of the nucleotide chain (e.g., for single-stranded molecules observed in a denatured state) or the number of base pairs (e.g., for double-stranded molecules observed in a native state), depending on the context. [Figure 5E] Same as above. [Figure 6A] An exemplary Rep-bacmid in the pFBDLSR plasmid contains the nucleic acid sequences of the Rep proteins Rep52 and Rep78. This exemplary Rep-bacmid contains an IE1 promoter fragment (SEQ ID NO: 66), a Rep78 nucleotide sequence containing a Kozak sequence (SEQ ID NO: 67), a polyhedron promoter sequence for Rep52 (SEQ ID NO: 68), and a Kozak sequence [ka] The Rep58 nucleotide sequence (SEQ ID NO: 69) begins with: [Figure 6B] FIG. 1 is a schematic diagram of an exemplary ceDNA plasmid comprising a modified left ITR (L-modified ITR), a CAG promoter, a luciferase transgene, a WPRE and polyadenylation sequence, and a modified right ITR (R-modified ITR), where the L- and R-modified ITRs are symmetrical to each other. [Figure 6C] FIG. 1 is a schematic diagram of an exemplary ceDNA plasmid comprising a WT-left ITR (L-WT-ITR), a CAG promoter, a luciferase transgene, a WPRE and polyadenylation sequence, and a WT-right ITR (R-WT-ITR). [Figure 7A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-33 (left)" SEQ ID NO: 101). [Figure 7B]The cognate symmetric right ITR (ITR-18, right) is shown, along with the predicted lowest energy structure of an RBE containing a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-18 (right)," SEQ ID NO: 102). Both ITR-33 (left) and ITR-18 (right) are predicted to form structures with a single arm (i.e., a single C-C' arm). [Figure 8A] 1 shows the predicted lowest energy structure of an RBE including portions of the A-A' arm and portions C-C' and B-B' of an exemplary modified left ITR ("ITR-34 (left)" SEQ ID NO: 103). [Figure 8B] The cognate symmetric right ITR (ITR-51, right) is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-51 (right)," SEQ ID NO: 96). Both ITR-34 (left) and ITR-51 (right) are predicted to form structures with a single arm (i.e., a single B-B' arm). [Figure 9A] 1 shows the predicted lowest energy structure of an RBE including portions of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-35 (left)" SEQ ID NO: 105). [Figure 9B] The cognate symmetric right ITR (ITR-19, right) is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-35 (right)" SEQ ID NO: 105). Both ITR-35 (left) and ITR-19 (right) are predicted to form structures with a single arm (i.e., a single C-C' arm). [Figure 10A] 1 shows the predicted lowest energy structure of an RBE including portions of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-36 (left)" SEQ ID NO: 454). [Figure 10B]The cognate symmetric right ITR ("ITR-20(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-18(right)" SEQ ID NO: 116). Both ITR-36(left) and ITR-20(right) are predicted to form structures with two arms, one of which is truncated (e.g., the C-C' arm is truncated). [Figure 11A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-37 (left)" SEQ ID NO: 111). [Figure 11B] The cognate symmetric right ITR ("ITR-21(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-21(right)" SEQ ID NO: 112). Both ITR-37 (left) and ITR-21 (right) are predicted to form structures with a single stem (e.g., a single stem-loop structure in the region containing the first stem-loop structure, usually formed by the B and B' regions, and the second stem-loop structure, usually formed by the C and C' regions). [Figure 12A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-38 (left)" SEQ ID NO: 117). [Figure 12B] The cognate symmetric right ITR ("ITR-22(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-22(right)" SEQ ID NO: 118). Both ITR-38 (left) and ITR-22 (right) are predicted to form structures with two arms, one of which is truncated (e.g., the B-B' arm is truncated). [Figure 13A]1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-39 (left)" SEQ ID NO: 119). [Figure 13B] The cognate symmetric right ITR ("ITR-23(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-23(right)" SEQ ID NO: 120). Both ITR-39 (left) and ITR-23 (right) are predicted to form structures with two arms, one of which is truncated (e.g., the B-B' arm is truncated). [Figure 14A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-40 (left)" SEQ ID NO: 121). [Figure 14B] The cognate symmetric right ITR ("ITR-24(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-24(right)" SEQ ID NO: 122). Both ITR-40(left) and ITR-24(right) are predicted to form structures with two arms, one of which is truncated (e.g., the B-B' arm is truncated). [Figure 15A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-41 (left)," SEQ ID NO: 107). [Figure 15B] The cognate symmetric right ITR ("ITR-25(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-25(right)" SEQ ID NO: 108). Both ITR-41 (left) and ITR-25 (right) are predicted to form structures with two arms, one of which is truncated (e.g., the B-B' arm is truncated). [Figure 16A]1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-42 (left)" SEQ ID NO: 123). [Figure 16B] The cognate symmetric right ITR ("ITR-26(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-26(right)" SEQ ID NO: 124). Both ITR-42 (left) and ITR-26 (right) are predicted to form structures with two arms, one of which is elongated (e.g., the C-C' arm is truncated). [Figure 17A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-43 (left)" SEQ ID NO: 125). [Figure 17B] The cognate symmetric right ITR ("ITR-27(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-27(right)" SEQ ID NO: 126). Both ITR-43 (left) and ITR-27 (right) are predicted to form structures with two arms, one of which is elongated (e.g., the C-C' arm is truncated). [Figure 18A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-44 (left)" SEQ ID NO: 127). [Figure 18B] The cognate symmetric right ITR ("ITR-28(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-28(right)" SEQ ID NO: 128). Both ITR-44(left) and ITR-28(right) are predicted to form structures with two arms, one of which is truncated (e.g., the C-C' arm is truncated). [Figure 19A]1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-45 (left)" SEQ ID NO: 129). [Figure 19B] The cognate symmetric right ITR ("ITR-29(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-29(right)" SEQ ID NO: 130). Both ITR-45(left) and ITR-29(right) are predicted to form structures with two arms, one of which is truncated (e.g., the C-C' arm is truncated). [Figure 20A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-46 (left)" SEQ ID NO: 131). [Figure 20B] The cognate symmetric right ITR ("ITR-30(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-30(right)" SEQ ID NO: 132). Both ITR-46(left) and ITR-30(right) are predicted to form structures with two arms, one of which is truncated (e.g., the C-C' arm is truncated). [Figure 21A] 1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-47 (left)" SEQ ID NO: 133). [Figure 21B] The cognate symmetric right ITR ("ITR-31(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the AA' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-31(right)" SEQ ID NO: 134). Both ITR-47(left) and ITR-31(right) are predicted to form structures with two arms, one of which is truncated (e.g., the C-C' arm is truncated). [Figure 22A]1 shows the predicted lowest energy structure of an RBE including a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified left ITR ("ITR-48 (left)" SEQ ID NO: 547). [Figure 22B] The cognate symmetric right ITR ("ITR-32(right)") is shown, along with the predicted lowest energy structure of an RBE containing a portion of the A-A' arm and the C-C' and B-B' portions of an exemplary modified right ITR ("ITR-32(right)" SEQ ID NO: 546). Both ITR-48(left) and ITR-32(right) are predicted to form structures with two arms, one of which is truncated (e.g., the C-C' arm is truncated). [Figure 23] Luciferase activity of Sf9 GlycoBac insect cells transfected with 16 ceDNAs containing symmetric mutant ITR mutants from Table 4 is shown (see also Table 7 for complete constructs). The ceDNA vectors carried a luciferase gene flanked by symmetric mutant ITRs selected from Table 4. The "mock" condition was transfection reagent only, without donor DNA. [Figure 24A] Figure 24 shows GFP activity in Sf9 GlycoBac insect cells transfected with the WT / WT ITR construct described in Example 4. The ceDNA vector carried the GFP gene flanked by WT ITRs. Figure 24A provides an image using a fluorescent microscope at 40x magnification of Sf9 cells transfected with the WT / WT ITR GFP ceDNA vector and subsequently infected with Rep virus. Figure 24B provides a bright-field image at 40x magnification of the same cells shown in image "A." [Figure 24B] Same as above. [Figure 24C] Brightfield images at 40x magnification of control cells transfected with WT / WT ITR but not infected with Rep virus are provided. These cells failed to produce a fluorescent signal. [Figure 25]A native agarose gel (1% agarose) of putative ceDNA containing wild-type ITRs is shown. Lane 1 shows the 1 kb Plus DNA ladder, and lane 2 shows ceDNA produced using a plasmid containing the wild-type ITR cassette. Both are from the same gel. A GFP ceDNA monomer species is expected at approximately 4 kb, and a dimer is expected at approximately 8 kb. [Figure 26] Denaturing gel of ceDNA containing wild-type ITRs. Lane 1 shows the 1 kb Plus DNA Ladder, lane 2 shows wild-type ceDNA that has not been cleaved with an endonuclease, and lane 3 shows the same wild-type ceDNA but cleaved with the restriction endonuclease enzyme ClaI. All samples are from the same gel. [Figure 27] Potential secondary structures of the symmetric ITRs of construct-388 (mutant) and construct-393 (wild-type AAV2) are shown. [Figure 28] Figure 1 shows the weight changes in CD-1 mice treated with LNP + polyC (control); LNP + Sf9 produced asymmetric ceDNA with WT AAV2 ITRs on the left and truncated ITRs on the right; LNP + synthetic ceDNA with WT AAV2 ITRs symmetrically on both the left and right sides; LNP + synthetic ceDNA with asymmetric ITRs, i.e., WT AAV2 ITRs on the left and truncated ITRs on the right; Sf9 produced ceDNA with mutant ITRs symmetrically on both the left and right sides (construct -388); and ceDNA containing wild-type AAV2 ITRs symmetrically on both the left and right sides of the construct (construct -393; produced by Sf9). [Figure 29A] Images of luciferase in vivo expression at day 14 in CD-1 mice treated with: (1) LNP+polyC (control; top left); (2) LNP+ceDNA (top right) with symmetric mutant ITRs on both the left and right sides of a construct produced in Sf9 (construct-388); and Sf9-produced ceDNA containing symmetric wild-type AAV2 ITRs (construct-393; bottom center panel). [Figure 29B] Same as above. DETAILED DESCRIPTION OF THE INVENTION

[0046] One of the biggest hurdles in developing treatments, especially for rare diseases, is the large number of individual conditions. Approximately 350 million people on the planet live with a rare disorder, and the National Institutes of Health defines a rare disorder as a disorder or condition diagnosed in fewer than 200,000 people. Approximately 80% of these rare disorders are genetic in origin, and approximately 95% of them have no FDA-approved treatment.

[0047] Among the advantages of the ceDNA vectors described herein are that they provide an approach that can be rapidly adapted to multiple diseases, particularly rare single-gene diseases, which can meaningfully alter the current state of treatment for many genetic disorders or diseases. Furthermore, the ceDNA vectors described herein contain regulatory switches, thus allowing for controllable gene expression after delivery.

[0048] I. Definition Unless otherwise defined herein, scientific and technical terms used in connection with this application shall have the meanings commonly understood by one of ordinary skill in the art to which this disclosure pertains. It is understood that the present invention is not limited to the specific methodology, protocols, and reagents, etc., described herein, and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims. Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 19th Edition, published by Merck Sharp & Dohme Corp., 2011 (ISBN 978-0-911910-19-3), Robert S. Porter et al. (eds.), Fields Virology, 6 thEdition,published by Lippincott Williams&Wilkins,Philadelphia,PA,USA(2013),Knipe,D.M.and Howley,P.M.(ed.),The Encyclopedia of Molecular Cell Biology and Molecular Medicine,published by Blackwell Science Ltd.,1999-2012(ISBN 9783527600908)、およびRobert A.Meyers(ed.),Molecular Biology and Biotechnology:a Comprehensive Desk Reference,published by VCH Publishers,Inc.,1995(ISBN 1-56081-569-8)、Immunology by Werner Luttmann,published by Elsevier,2006、Janeway’s Immunobiology,Kenneth Murphy,Allan Mowat,Casey Weaver(eds.),Taylor&Francis Limited,2014(ISBN 0815345305,9780815345305)、Lewin’s Genes XI,published by Jones&Bartlett Publishers,2014(ISBN-1449659055)、Michael Richard Green and Joseph Sambrook,Molecular Cloning:A Laboratory Manual,4 thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2012) (ISBN 1936113414), Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X), Laboratory Methods in Enzymology: DNA, Jon Lorsch(ed.)Elsevier,2013(ISBN 0124199542), Current Protocols in Molecular Biology(CPMB),Frederick M.Ausubel(ed.),John Wiley and Sons,2014(ISBN047150338X,9780471503385),Current Protocols in Protein Science(CPPS),John E.Coligan(ed.), John Wiley and Sons, Inc., 2005, and Current Protocols in Immunology (CPI) (John E. Coligan, A.D.A. M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of all of which are incorporated herein by reference in their entireties.

[0049] As used herein, the terms "administration," "administering," and variations thereof refer to the introduction of a composition or agent (e.g., a nucleic acid, particularly ceDNA) into a subject, including simultaneous and sequential introduction of one or more compositions or agents. "Administration" can refer to, for example, therapeutic, pharmacokinetic, diagnostic, research, placebo, and experimental methods. "Administration" also includes in vitro and ex vivo treatments. Introduction of a composition or agent into a subject can be by any suitable route, including oral, pulmonary, intranasal, parenteral (intravenous, intramuscular, intraperitoneal, or subcutaneous), rectal, intralymphatic, intratumoral, or topical. Administration includes self-administration and administration by another. Administration can be carried out by any suitable route. A suitable administration route allows the composition or agent to perform its intended function. For example, if the suitable route is intravenous, the composition is administered by introducing the composition or agent into the subject's vein.

[0050] As used herein, the term "antibody" is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity. An "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the same antigen as the intact antibody. In one embodiment, an antibody or antibody fragment comprises an immunoglobulin chain or antibody fragment and at least one immunoglobulin variable domain sequence. Examples of antibodies include, but are not limited to, Fv, scFv, Fab fragment, Fab', F(ab')2, Fab'-SH, single-domain antibodies (dAbs), heavy chain, light chain, heavy and light chain, complete antibodies (e.g., including each of Fc, Fab, heavy chain, light chain, variable region, etc.), bispecific antibodies, diabodies, linear antibodies, single-chain antibodies, intrabodies, monoclonal antibodies, chimeric antibodies, multispecific antibodies, or multimeric antibodies. The antibody or fragment thereof can be of any class, including but not limited to IgA, IgD, IgE, IgG, and IgM, and any subclass thereof, including but not limited to IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. Furthermore, the antibody can be derived from any mammal, such as a primate, human, rat, mouse, horse, goat, etc. In one embodiment, the antibody is human or humanized. In some embodiments, the antibody is a modified antibody. In some embodiments, components of the antibody can be expressed separately such that the antibody self-assembles after expression of the protein components. In some embodiments, the antibody is "humanized" to reduce immunogenic responses in humans. In some embodiments, the antibody has a desired function, e.g., desired protein interaction and inhibition, for purposes of treating a disease or disease symptoms. In one embodiment, the antibody or antibody fragment comprises a framework region or F domain. c Includes the area.

[0051] As used herein, the term "antigen-binding domain" of an antibody molecule refers to the portion of an antibody molecule, e.g., an immunoglobulin (Ig) molecule, that is involved in antigen binding. In embodiments, the antigen-binding site is formed by amino acid residues from the variable (V) regions of the heavy (H) and light (L) chains. Three highly divergent stretches within the variable regions of the heavy and light chains are called hypervariable regions and are located between more conserved adjacent stretches called "framework regions" (FRs). FRs are amino acid sequences naturally found between and adjacent to the hypervariable regions of immunoglobulins. In embodiments, in an antibody molecule, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are positioned relative to each other in three-dimensional space to form an antigen-binding surface that is complementary to the three-dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions" or "CDRs." Framework regions and CDRs are defined and described, for example, in Kabat, E. A. et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917. Each variable chain (e.g., variable heavy chain and variable light chain) typically consists of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following amino acid order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0052] As used herein, phrases such as "anti-therapeutic nucleic acid immune response," "anti-transfer vector immune response," "immune response to a therapeutic nucleic acid," "immune response to a transfer vector," and the like refer to any unwanted immune response to a therapeutic nucleic acid, whether viral or non-viral in origin. In some embodiments, the unwanted immune response is an antigen-specific immune response against the viral transfer vector itself. In some embodiments, the immune response is specific to the transfer vector, which may be double-stranded DNA, single-stranded RNA, or double-stranded RNA. In other embodiments, the immune response is specific to the sequence of the transfer vector. In other embodiments, the immune response is specific to the CpG content of the transfer vector.

[0053] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, etc. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the composition. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce toxic, allergic, or similar adverse reactions when administered to a host.

[0054] As used herein, the term "ceDNA" refers to capsid-free, closed-ended, linear, double-stranded (ds) duplex DNA for synthetic or other non-viral gene transfer. A detailed description of ceDNA is provided in International Application No. PCT / US2017 / 020828, filed March 3, 2017, the entire contents of which are expressly incorporated herein by reference. Certain methods for producing ceDNA vectors containing various inverted terminal repeat (ITR) sequences and configurations using cell-based methods are described in Example 1 of International Application Nos. PCT / US18 / 49996, filed September 7, 2018, and PCT / US2018 / 064242, filed December 6, 2018, each of which is incorporated herein by reference in its entirety. Certain methods for producing synthetic ceDNA vectors containing various ITR sequences and configurations are described, for example, in International Application No. PCT / US2019 / 14122, filed January 18, 2019, the entire contents of which are incorporated herein by reference. As used herein, the terms "ceDNA vector" and "ceDNA" are used interchangeably. According to some embodiments, the ceDNA is a closed-end linear double-stranded (CELiD) CELiD DNA. According to some embodiments, the ceDNA is a DNA-based minicircle. According to some embodiments, the ceDNA is a minimal immunologically defined gene expression (MIDGE) vector. According to some embodiments, the ceDNA is ministering DNA. According to some embodiments, the ceDNA is a dumbbell-shaped linear double-stranded closed-end DNA containing two hairpin structures of ITRs at the 5' and 3' ends of the expression cassette. According to some embodiments, the ceDNA is doggybone™ DNA.

[0055] As used herein, the term "ceDNA-bacmid" refers to an infectious baculovirus genome that contains a ceDNA genome as an intermolecular duplex that can be propagated as a plasmid in E. coli, thereby manipulating it as a baculovirus shuttle vector.

[0056] As used herein, the term "ceDNA-baculovirus" refers to a baculovirus that contains a ceDNA genome as an intermolecular duplex within the baculovirus genome.

[0057] As used herein, the terms "ceDNA-baculovirus-infected insect cells" and "ceDNA-BIIC" are used interchangeably and refer to invertebrate host cells (including but not limited to insect cells (e.g., Sf9 cells)) infected with a ceDNA-baculovirus.

[0058] As used herein, the term "ceDNA genome" refers to an expression cassette that further incorporates at least one inverted terminal repeat region. The ceDNA genome may further comprise one or more spacer regions. In some embodiments, the ceDNA genome is incorporated into a plasmid or viral genome as an intermolecular double-stranded polynucleotide of DNA.

[0059] As used herein, the term "ceDNA-plasmid" refers to a plasmid that contains a ceDNA genome as an intermolecular duplex.

[0060] As used herein, "closed-end DNA vector," "ceDNA vector," and "ceDNA" are used interchangeably and refer to a non-viral capsid-free DNA vector (i.e., an intermolecular duplex) having at least one covalently closed end. In some embodiments, the ceDNA comprises two covalently closed ends.

[0061] As used herein, the term "ceDNA spacer region" refers to an intervening sequence that separates functional elements in a ceDNA vector or ceDNA genome. In some embodiments, a ceDNA spacer region maintains two functional elements in a desired arrangement for optimal functionality. In some embodiments, a ceDNA spacer region provides or increases the genetic stability of a ceDNA genome, for example, within a plasmid or baculovirus. In some embodiments, a ceDNA spacer region facilitates easy genetic manipulation of a ceDNA genome by providing a convenient location for a cloning site or the like. For example, in certain aspects, an oligonucleotide "polylinker" containing several restriction endonuclease sites, or a non-open reading frame sequence designed to lack known protein (e.g., transcription factor) binding sites, can be positioned in a ceDNA genome to separate cis-acting elements, e.g., inserting a 6-mer, 12-mer, 18-mer, 24-mer, 48-mer, 86-mer, 176-mer, etc., between the terminal resolution site and the upstream transcriptional regulatory element. Similarly, a spacer can be incorporated between a polyadenylation signal sequence and a 3' terminal resolution site.

[0062] As used herein, the phrase "effective amount" or "therapeutically effective amount" of a therapeutic agent, such as an active agent or therapeutic nucleic acid, is an amount sufficient to produce a desired effect, e.g., inhibition of expression of a target sequence, compared to the expression level detected in the absence of the therapeutic nucleic acid. Suitable assays for measuring the expression of a target gene or target sequence include, for example, examination of protein or RNA levels using techniques known to those skilled in the art, such as dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzymatic function, and phenotypic assays known to those skilled in the art.

[0063] As used herein, the term "exogenous" refers to a substance present in a cell other than its natural source. As used herein, the term "exogenous" can refer to a nucleic acid (e.g., a nucleic acid encoding a polypeptide) or polypeptide that is not normally found and that has been introduced into a biological system, such as a cell or organism, by a process involving the hand of man, where it is desired to introduce the nucleic acid or polypeptide into such a cell or organism. Alternatively, "exogenous" can refer to a nucleic acid or polypeptide that is found in relatively low amounts and that has been introduced into a biological system, such as a cell or organism, by a process involving the hand of man, where it is desired to increase the amount of the nucleic acid or polypeptide in the cell or organism, e.g., to cause ectopic expression or levels. In contrast, as used herein, the term "endogenous" refers to a substance that is native to a biological system or cell.

[0064] As used herein, the term "effector protein" refers to a polypeptide that provides a detectable readout, for example, as a reporter polypeptide, or more appropriately, as a cell-killing polypeptide, such as a toxin or a drug that renders cells susceptible to killing by a selected agent or its deletion. Effector proteins include any protein or peptide that directly targets or damages host cell DNA and / or RNA. For example, effector proteins include, but are not limited to, restriction endonucleases (whether genomic or extrachromosomal) that target host cell DNA sequences, proteases that target polypeptides required for cell survival, DNA gyrase inhibitors, and ribonuclease-type toxins. In some embodiments, the expression of an effector protein controlled by a synthetic biological circuit described herein can participate as a factor in another synthetic biological circuit, thereby expanding the scope and complexity of the reactivity of the biological circuit system.

[0065] As used herein, the terms "expression cassette" and "transcription cassette" are used interchangeably and refer to a linear stretch of nucleic acid that includes a transgene operably linked to one or more promoters or other regulatory sequences sufficient to direct transcription of the transgene, but does not include capsid-encoding sequences, other vector sequences, or inverted terminal repeat regions. An expression cassette may additionally include one or more cis-acting sequences (e.g., promoters, enhancers, or repressors), one or more introns, and one or more post-transcriptional regulatory elements.

[0066] As used herein, the term "adjacent" refers to the relative position of a nucleic acid sequence relative to another nucleic acid sequence. Generally, in the sequence ABC, A and C are adjacent to B on both sides. The same applies to the arrangement AxBxC. Thus, an adjacent sequence precedes or follows the adjacent sequence, but does not necessarily have to be contiguous or immediately adjacent to the adjacent sequence. In one embodiment, the term adjacent refers to the terminal repeats at each end of a linear single-stranded synthetic AAV vector.

[0067] As used herein, the term "full length antibody" refers to an immunoglobulin (Ig) molecule (e.g., an IgG antibody), e.g., that occurs in nature and is formed by recombinant processes of conventional immunoglobulin gene fragments.

[0068] As used herein, the term "functional antibody fragment" refers to a fragment that binds to the same antigen recognized by an intact (e.g., full-length) antibody. The term "antibody fragment" or "functional fragment" also includes isolated fragments consisting of the variable regions, such as an "Fv" fragment consisting of the variable regions of the heavy and light chains, or a recombinant single-chain polypeptide molecule in which the light and heavy chain variable regions are connected by a peptide linker ("scFv protein"). In some embodiments, an antibody fragment does not include a portion of an antibody without antigen-binding activity, such as an Fc fragment or a single amino acid residue.

[0069] As used herein, the terms "gap" and "nick" are used interchangeably and are meant to refer to an interrupted portion of the synthetic DNA vector of the present disclosure, creating a stretch of single-stranded DNA in the otherwise double-stranded cDNA. The gap can be from 1 base pair to 100 base pairs in length for one strand of the double-stranded DNA. Exemplary gaps designed and created by the methods described herein, and synthetic vectors generated thereby, can be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 bp in length. Exemplary gaps in the present disclosure can be 1 bp to 10 bp in length, 1 to 20 bp in length, or 1 to 30 bp in length.

[0070] As used herein, the term "gene" is used broadly to refer to any segment of nucleic acid involved in the expression of a given RNA or protein in vitro or in vivo. Thus, a gene includes a region that encodes the expressed RNA (usually including a polypeptide-coding sequence) and often the regulatory sequences required for their expression. Genes can be obtained from a variety of sources, including cloning from a source of interest or synthesis from known or predicted sequence information, and may include sequences specifically designed to have desired parameters.

[0071] As used herein, the phrase "genetic disease" or "genetic disorder" refers to a disease that is caused, in part or in whole, directly or indirectly, by one or more abnormalities in the genome, particularly conditions present from birth. The abnormality may be a mutation, insertion, or deletion in a gene. The abnormality may affect the coding sequence of the gene or its regulatory sequence.

[0072] As used herein, the term "heterologous" is meant to refer to a nucleotide or polypeptide sequence that is not found in the native nucleic acid or protein, respectively.

[0073] As used herein, the terms "heterologous nucleotide sequence" and "transgene" are used interchangeably and refer to a nucleic acid of interest (other than a nucleic acid encoding a capsid polypeptide) that can be incorporated into, delivered, and expressed by, the ceDNA vectors disclosed herein. A heterologous nucleic acid sequence can be linked (e.g., by genetic engineering) to a naturally occurring nucleic acid sequence (or a variant thereof) to generate a chimeric nucleotide sequence encoding a chimeric polypeptide. A heterologous nucleic acid sequence can be linked (e.g., by genetic engineering) to a variant polypeptide to generate a nucleotide sequence encoding a fusion variant polypeptide. Transgenes of interest include, but are not limited to, nucleic acids encoding polypeptides, preferably therapeutic (e.g., for medical, diagnostic, or veterinary uses) or immunogenic polypeptides (e.g., for vaccines). In some embodiments, the nucleic acid of interest comprises a nucleic acid that is transcribed into a therapeutic RNA. Transgenes included for use in the ceDNA vectors of the present disclosure include, but are not limited to, those that express or encode one or more polypeptides, peptides, ribozymes, aptamers, peptide nucleic acids, siRNAs, RNAi, miRNAs, IncRNAs, antisense oligo- or polynucleotides, antibodies, antigen-binding fragments, or any combination thereof.

[0074] As used herein, the term "homology" or "homology" refers to the percentage of nucleotide residues in the homology arm that are identical to the nucleotide residues of the corresponding sequence on the target chromosome, after aligning the sequences as necessary and introducing gaps to achieve the maximum sequence identity percentage. Alignment for the purpose of determining the nucleotide sequence homology percentage can be achieved in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ClustalW2, or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment across the entire length of the sequences being compared. In some embodiments, for example, a nucleic acid sequence (e.g., a DNA sequence) of a homology arm of a repair template is considered "homologous" if the sequence is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to the corresponding native or unedited nucleic acid sequence (e.g., genomic sequence) of the host cell.

[0075] As used herein, the term "host cell" refers to any cell type that is susceptible to transformation, transfection, transduction, etc. with a nucleic acid therapeutic agent of the present disclosure. By way of non-limiting example, host cells can include isolated primary cells, pluripotent stem cells, CD34 + The host cell may be a cell, an induced pluripotent stem cell, or some immortalized cell line (e.g., HepG2 cell). Alternatively, the host cell may be a cell in situ or in vivo in a tissue, organ, or organism. Furthermore, the host cell may be, for example, a target cell in a mammalian subject (e.g., a human patient requiring gene therapy).

[0076] As used herein, "immunoglobulin variable domain sequence" refers to an amino acid sequence capable of forming the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally occurring variable domain. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations compatible with forming a protein structure.

[0077] As described herein, an "inducible promoter" is characterized by initiating or enhancing transcriptional activity when in the presence of, affected by, or contacted by an inducer or inducer agent. As defined herein, an "inducer" or "inducer agent" can be endogenous or can be a compound or protein, usually exogenous, administered in such a manner that it is active in inducing transcriptional activity from an inducible promoter. In some embodiments, the inducer or inducer agent, i.e., a chemical, compound, or protein, can itself be the result of transcription or expression of a nucleic acid sequence (i.e., the inducer can be an inducer protein expressed by another component or module) and can itself be under the control of an inducible promoter. In some embodiments, an inducible promoter is induced in the absence of certain agents, such as repressors. Examples of inducible promoters include, but are not limited to, tetracycline, metallothionine, ecdysone, mammalian viruses (e.g., adenovirus late promoter and mouse mammary tumor virus long terminal repeat (MMTV-LTR)), as well as other steroid-responsive promoters, rapamycin-responsive promoters, and the like.

[0078] As used herein, an "input agent-responsive domain" is a domain of a transcription factor that responds to a condition or input agent such that it binds to or otherwise renders the linked DNA-binding fusion domain responsive to the presence of that condition or input. In one embodiment, the presence of the condition or input results in a conformational change in the input agent-responsive domain or the protein to which it is fused, which modifies the transcriptional regulatory activity of the transcription factor.

[0079] The term "in vivo" refers to an assay or process that occurs in or within an organism, such as a multicellular animal. In some of the embodiments described herein, the method or use may be said to occur "in vivo" when a unicellular organism, such as a bacterium, is used. The term "ex vivo" refers to methods and uses carried out using living cells with intact membranes outside the body of a multicellular animal or plant, for example, explants, cultured cells (including primary cells and cell lines), transformed cell lines, and extracted tissues or cells (including blood cells), among others.

[0080] The term "in vitro" refers to assays and methods that do not require the presence of cells with intact membranes, such as cell extracts, and can refer to introducing programmable synthetic biological circuits into a non-cellular system, e.g., a medium that does not contain cells or cell systems, such as a cell extract.

[0081] As used herein, the term "local delivery" refers to the direct delivery of an active agent, such as interfering RNA (e.g., siRNA), to a target site within an organism.For example, the agent can be locally delivered by direct injection into disease site (e.g., tumor) or other target site (e.g., inflammation site), or target organ (e.g., liver, heart, pancreas, kidney).

[0082] As used herein, the phrases "modified ITR" or "mod-ITR" or "mutant ITR" are used interchangeably herein and refer to an ITR that has a mutation in at least one or more nucleotides compared to a WT-ITR from the same serotype. The mutation may result in a change in one or more of the A, C, C', B, and B' regions of the ITR, resulting in a change in its three-dimensional spatial configuration (i.e., its three-dimensional structure in geometric space) compared to the three-dimensional spatial configuration of a WT-ITR from the same serotype.

[0083] As used herein, the term "neDNA" or "nicked ceDNA" is meant to refer to closed-end DNA that has a nick or gap of 1 to 100 base pairs in the stem or spacer region 5' upstream of the open reading frame (e.g., the promoter and transgene to be expressed).

[0084] As used herein, the term "nucleic acid" refers to a polymer containing at least two nucleotides (i.e., deoxyribonucleotides or ribonucleotides) in either single-stranded or double-stranded form, including DNA, RNA, and hybrids thereof. DNA may be in the form of, for example, antisense molecules, plasmid DNA, DNA-DNA duplexes, pre-condensed DNA, PCR products, vectors (P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations of these groups. DNA may be in the form of minicircles, plasmids, bacmids, minigenes, ministring DNA (linear covalently closed DNA vectors), closed-end linear double-stranded DNA (CELiD or ceDNA), doggybone™ DNA, dumbbell-shaped DNA, minimal immunologically defined gene expression (MIDGE) vectors, viral vectors, or non-viral vectors. RNA can be in the form of small interfering RNA (siRNA), Dicer substrate dsRNA, short hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), mRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and have similar binding properties to the reference nucleic acid. Examples of such analogs and / or modified residues include phosphorothioates, phosphorodiamidate morpholino oligomers (morpholinos), phosphoramidates, methyl phosphonates, chiral methyl phosphonates, 2'-O-methyl ribonucleotides, locked nucleic acids (LNA™), and peptide nucleic acids (PNAs). Unless otherwise specified, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties to the reference nucleic acid. Unless otherwise specified, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated.

[0085] As used herein, a "nucleotide" comprises the sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate group.

[0086] As used herein, the phrases "nucleic acid therapy," "therapeutic nucleic acid," and "TNA" are used interchangeably and refer to any modality of treatment that uses nucleic acids as the active ingredient of a therapeutic agent to treat a disease or disorder. As used herein, these phrases refer to RNA-based therapeutic agents and DNA-based therapeutic agents. Non-limiting examples of RNA-based therapeutic agents include mRNA, antisense RNA and oligonucleotides, ribozymes, aptamers, interfering RNA (RNAi), dicer substrate dsRNA, short hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), and microRNA (miRNA). Non-limiting examples of DNA-based therapeutics include minicircle DNA, minigenes, viral DNA (e.g., lentivirus or AAV genome) or nonviral synthetic DNA vectors, closed-end linear double-stranded DNA (ceDNA / CELiD), plasmids, bacmids, doggybone™ DNA vectors, minimal immunologically defined gene expression (MIDGE)-vectors, nonviral ministring DNA vectors (linear covalently closed DNA vectors), or dumbbell-shaped DNA minimal vectors ("dumbbell DNA").

[0087] As used herein, the term "promoter" refers to any nucleic acid sequence that regulates the expression of another nucleic acid sequence by driving the transcription of that nucleic acid sequence, which may be a heterologous target gene encoding a protein or RNA. A promoter can be constitutive, inducible, repressible, tissue-specific, or any combination thereof. A promoter is a control region of a nucleic acid sequence where the initiation and rate of transcription of the remainder of the nucleic acid sequence are controlled. A promoter can also contain genetic elements to which regulatory proteins and molecules, such as RNA polymerase and other transcription factors, can bind. In some embodiments of the aspects described herein, a promoter can drive the expression of a transcription factor that regulates its own expression or of another promoter used in another modular component of the synthetic biological circuit described herein. Within the promoter sequence, one will find a transcription initiation site, as well as protein binding domains involved in the binding of RNA polymerase. Eukaryotic promoters often, but not necessarily, contain "TATA" and "CAT" boxes. A variety of promoters, including inducible promoters, can be used to drive the expression of transgenes in the ceDNA vectors disclosed herein.

[0088] As used herein, the term "enhancer" refers to a cis-acting regulatory sequence (e.g., 50 to 1,500 base pairs) that binds to one or more proteins (e.g., activator proteins or transcription factors) to increase transcriptional activation of a nucleic acid sequence. Enhancers can be located up to 1,000,000 base pairs upstream of the start site of the gene they regulate or downstream of the start site of the gene. Enhancers can be located within intronic or exon regions of unrelated genes.

[0089] A promoter can be said to drive expression or drive transcription of the nucleic acid sequence it regulates. "Operably linked" refers to the juxtaposition of the components so described, in a relationship that allows them to function in their intended manner. For example, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression. The phrases "operably linked," "operably positioned," "operably linked," "under control," and "under transcriptional control" indicate that the promoter is in the correct functional location and / or orientation with respect to a nucleic acid sequence and regulates to control transcription initiation and / or expression of that sequence. As used herein, an "inverted promoter" refers to a promoter in which a nucleic acid sequence is in the reverse orientation, such that what was the coding strand is now the non-coding strand, and vice versa. Inverted promoter sequences are used in various embodiments to regulate the state of a switch. Additionally, in various embodiments, a promoter can be used in conjunction with an enhancer.

[0090] A promoter can be one that is naturally associated with a gene or sequence, which can be obtained by isolating the 5' non-coding sequence located upstream of the coding segment and / or exon of a given gene or sequence. Such a promoter can be referred to as "endogenous." Similarly, in some embodiments, an enhancer can be one that is naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence.

[0091] In some embodiments, a coding nucleic acid segment is placed under the control of a "recombinant promoter" or "heterologous promoter," both of which refer to a promoter that is not normally associated with an operably linked encoded nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers to an enhancer that is not normally associated with a given nucleic acid sequence in its natural environment. Such promoters or enhancers can include promoters or enhancers of other genes, promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell, and synthetic promoters or enhancers that are not "naturally occurring," i.e., may contain different elements of different transcriptional regulatory regions and / or mutations that alter expression through methods of genetic engineering known in the art. In addition to synthetically producing promoter and enhancer nucleic acid sequences, promoter sequences can be produced using recombinant cloning and / or nucleic acid amplification techniques, including PCR, for the synthetic biological circuits and modules disclosed herein (see, e.g., U.S. Pat. Nos. 4,683,202 and 5,928,906, each of which is incorporated herein by reference). Furthermore, it is contemplated that regulatory sequences that direct transcription and / or expression of sequences within non-nuclear organelles, such as mitochondria, chloroplasts, etc., can be similarly employed.

[0092] As used herein, "Rep binding site," "Rep binding element," "RBE," and "RBS" are used interchangeably and refer to the binding site of a Rep protein (e.g., AAV Rep78 or AAV Rep68), which, upon binding by the Rep protein, allows the Rep protein to perform its site-specific endonuclease activity on the sequence incorporating the RBS. An RBS sequence and its reverse complement together form a single RBS. RBS sequences are known in the art and include, for example, the RBS sequence specified in AAV2, 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 531). Any known RBS sequence may be used in embodiments of the present invention, including other known AAV RBS sequences and other naturally occurring or synthetic RBS sequences. Without being bound by theory, it is believed that the nuclease domain of the Rep protein binds to the double-stranded nucleotide sequence GCTC, and thus two known AAV Rep proteins directly bind and stably assemble to the double-stranded oligonucleotide 5'-(GCGC)(GCTC)(GCTC)(GCTC)-3' (SEQ ID NO: 531). In addition, soluble aggregated conformers (i.e., an indefinite number of interrelated Rep proteins) dissociate and bind to oligonucleotides containing the Rep binding site. Each Rep protein interacts with both the nitrogenous bases and the phosphodiester backbone on each strand. The interactions with the nitrogenous bases provide sequence specificity, while the interactions with the phosphodiester backbone are non- or low-sequence specific, stabilizing the protein-DNA complex.

[0093] As used herein, the term "reporter" refers to a protein that can be used to provide a detectable readout. Reporters generally produce a measurable signal, such as fluorescence, color, or luminescence. A reporter protein coding sequence encodes a protein whose presence in a cell or organism is easily observed. For example, fluorescent proteins cause cells to fluoresce when excited with a particular wavelength of light, luciferase causes cells to catalyze a light-producing reaction, and enzymes such as β-galactosidase convert a substrate into a colored product. Exemplary reporter polypeptides useful for experimental or diagnostic purposes include, but are not limited to, β-lactamase, β-galactosidase (LacZ), alkaline phosphatase (AP), thymidine kinase (TK), green fluorescent protein (GFP) and other fluorescent proteins, chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art.

[0094] As used herein, a "repressor protein" or an "inducer protein" is a protein that binds to a regulatory sequence element and represses or activates, respectively, the transcription of a sequence operably linked to the regulatory sequence element. Preferred repressor and inducer proteins described herein are sensitive to the presence or absence of at least one input agent or environmental input. Preferred proteins described herein are modular in form, for example, containing separable DNA binding and input agent binding or reactive elements or domains.

[0095] As used herein, the term "sequence identity" refers to the relationship between two nucleotide sequences. For purposes of this disclosure, the degree of sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra), preferably version 3.0.0 or later. Optional parameters used are a gap opening penalty of 10, a gap extension penalty of 0.5, and an EDNAFULL (the EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows: (identical deoxyribonucleotides × 100) / alignment length - total number of gaps in the alignment). The length of the alignment is preferably at least 10 nucleotides, preferably at least 25 nucleotides, more preferably at least 50 nucleotides, and most preferably at least 100 nucleotides.

[0096] As used herein, the terms "sense" and "antisense" refer to the orientation of a structural element on a polynucleotide. The sense and antisense versions of an element are the reverse complements of each other.

[0097] As used herein, the term "spacer region" refers to an intervening sequence that separates functional elements within a vector or genome. In some embodiments, an AAV spacer region maintains two functional elements in a desired arrangement for optimal functionality. In some embodiments, the spacer region provides or increases the genetic stability of the vector or genome. In some embodiments, the spacer region facilitates easy genetic manipulation of the genome by providing a convenient location for cloning sites and gaps of a designed number of base pairs. For example, in certain aspects, an oligonucleotide "polylinker" or "polycloning site" containing several restriction endonuclease sites, or a non-open reading frame sequence designed to lack known protein (e.g., transcription factor) binding sites, can be positioned in the vector or genome to separate cis-acting elements, e.g., inserting a 6mer, 12mer, 18mer, 24mer, 48mer, 86mer, 176mer, etc.

[0098] As used herein, the term "subject" refers to a human or animal to which treatment, including preventive treatment, with the ceDNA vector of the present invention is provided. Typically, the animal is a vertebrate, such as, but not limited to, a primate, a rodent, a domestic animal, or a game animal. Primates include, but are not limited to, chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, such as rhesus monkeys. Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Domestic and game animals include, but are not limited to, cattle, horses, pigs, deer, bison, buffalo, feline species, such as domestic cats, canine species, such as dogs, foxes, wolves, avian species, such as chickens, emus, ostriches, and fish, such as trout, catfish, and salmon. In certain embodiments of the aspects described herein, the subject is a mammal, such as a primate or human. The subject may be male or female. Additionally, the subject may be an infant or child. In some embodiments, the subject may be a neonatal or fetal subject, e.g., the subject is present in utero. Preferably, the subject is a mammal. The mammal may be, but is not limited to, a human, non-human primate, mouse, rat, dog, cat, horse, or cow. Non-human mammals may be advantageously used as subjects representing animal models of diseases and disorders. Additionally, the methods and compositions described herein may be used with domestic animals and / or pets. Human subjects may be of any age, sex, race, or ethnic group, e.g., Caucasian (white), Asian, African, Black, African-American, African-European, Latino, Middle Eastern, etc. In some embodiments, the subject may be a patient or other subject in a clinical setting. In some embodiments, the subject is already undergoing treatment.

[0099] As used herein, the term "substantially symmetric modified ITR" or "substantially symmetric mod-ITR pair" refers to a pair of modified ITRs within a single ceDNA genome or ceDNA vector, both of which have reverse-complementary sequences throughout their entire length. For example, modified ITRs can be considered substantially symmetric even if there are some nucleotide sequence deviations from the reverse-complementary sequence, as long as the changes do not affect the properties and overall shape. As a non-limiting example, the sequences have at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity (measured using BLAST with default settings) to the canonical sequence and have a symmetric three-dimensional spatial organization relative to their cognate modified ITR, such that their three-dimensional structures have the same shape in geometric space. In other words, a substantially symmetric modified ITR pair has the same A, C-C', and B-B' loops organized in three-dimensional space. In some embodiments, the ITRs from a mod-ITR pair may have different reverse-complementary nucleotide sequences but still have the same symmetrical three-dimensional spatial organization. That is, both ITRs have mutations that result in the same overall three-dimensional shape. For example, one ITR (e.g., the 5' ITR) of a mod-ITR pair may be derived from one serotype, and the other ITR (e.g., the 3' ITR) may be derived from a different serotype, but both may have the same corresponding mutation (e.g., if the 5' ITR has a deletion in the C region, the cognate modified 3' ITR of the different serotype will have a deletion in the corresponding position in the C' region), thereby resulting in the modified ITR pair having the same symmetrical three-dimensional spatial organization. In such embodiments, each ITR of a modified ITR pair can be derived from a different serotype (e.g., AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12), such as a combination of AAV2 and AAV6, and modifications in one ITR are reflected in the corresponding position of the cognate ITR of a different serotype. In one embodiment, a substantially symmetric modified ITR pair refers to a pair of modified ITRs (mod-ITRs), so long as the nucleotide sequence differences between the ITRs do not affect their properties or overall shape and they have substantially the same shape in three-dimensional space.As a non-limiting example, a mod-ITR has at least 95%, 96%, 97%, 98%, or 99% sequence identity to a canonical mod-ITR, as determined by standard means well known in the art, such as BLAST (Basic Local Alignment Search Tool) or BLASTN with default settings, and has a symmetrical three-dimensional spatial organization such that their three-dimensional structures have the same shape in geometric space. A substantially symmetric mod-ITR pair will have the same A, C-C', and B-B' loops in three-dimensional space. For example, if the modified ITR of a substantially symmetric mod-ITR pair has a deletion of the C-C' arm, the cognate mod-ITR will have a corresponding deletion of the C-C' loop and a similar three-dimensional structure of the remaining A and B-B' loops that are the same shape in geometric space as its cognate mod-ITR.

[0100] As used herein, the term "substantially symmetric WT-ITR" or "substantially symmetric WT-ITR pair" refers to a pair of WT-ITRs within a single ceDNA genome or ceDNA vector, both of which are wild-type ITRs with reverse-complementary sequences throughout their entire length. For example, an ITR can be considered to have a wild-type sequence even if it has one or more nucleotides that deviate from the naturally occurring canonical sequence, as long as the changes do not affect the sequence's characteristics and overall three-dimensional structure. In some embodiments, the deviating nucleotides represent conservative sequence changes. As a non-limiting example, a sequence has at least 95%, 96%, 97%, 98%, or 99% sequence identity (e.g., as measured using BLAST with default settings) to the canonical sequence and has a symmetric three-dimensional spatial organization relative to the other WT-ITR, such that their three-dimensional structures have the same shape in geometric space. A substantially symmetric WT-ITR has the same A, C-C', and B-B' loops in three-dimensional space. Substantially symmetric WT ITRs can be functionally confirmed as WT by determining that they have an operable Rep binding site (RBE or RBE') and terminal resolution site (trs) that pairs with the appropriate Rep protein. Optionally, other functions can be tested, including transgene expression under permissive conditions.

[0101] As used herein, the terms "suppress," "reduce," "interfere," "inhibit," and / or "reduce" (and similar terms) generally refer to the act of directly or indirectly decreasing a concentration, level, function, activity, or behavior relative to natural, expected, or average, or relative to a control condition.

[0102] As used herein, the term "symmetric ITRs" refers to a pair of ITRs within a single ceDNA genome or ceDNA vector that are mutated or modified relative to the wild-type Dependvirus ITR sequence and are reverse-complementary across their entire length. Neither ITR is the wild-type ITR AAV2 sequence (i.e., they are modified ITRs, also referred to as mutant ITRs), and their sequence may differ from the wild-type ITR due to nucleotide additions, deletions, substitutions, truncations, or point mutations. For convenience, the ITR located 5' (upstream) of the expression cassette in the ceDNA vector is referred to as the "5' ITR" or "left ITR," and the ITR located 3' (downstream) of the expression cassette in the ceDNA vector is referred to as the "3' ITR" or "right ITR."

[0103] As used herein, the terms "synthetic AAV vector" and "synthetic production of AAV vector" are meant to refer to AAV vectors and methods for their synthetic production in an entirely cell-free environment.

[0104] As used herein, the term "terminal repeat" or "TR" includes any viral or synthetic terminal sequence that contains at least one minimally necessary origin of replication and a region containing a palindromic hairpin structure. The Rep binding sequence ("RBS") (also referred to as an RBE (Rep binding element)) and terminal resolution site ("TRS") together constitute the "minimally necessary origin of replication," and thus a TR contains at least one RBS and at least one TRS. TRs that are reverse complements of each other within a given stretch of polynucleotide sequence are typically referred to as "inverted terminal repeats" or "ITRs," respectively. In the viral context, ITRs mediate replication, viral packaging, integration, and proviral rescue. As unexpectedly found in the present invention, ITRs that are not wild-type depend viral ITRs can still perform the traditional functions of wild-type ITRs, and therefore the term ITR is used herein to refer to TRs in a ceDNA genome or ceDNA vector that are capable of mediating replication of the ceDNA vector. It will be understood by those skilled in the art that there may be more than two ITRs or symmetric ITR pairs in a composite ceDNA vector construct. The ITRs may be AAV or non-AAV ITRs, or AAV ITRs or non-AAV ITRs. ITRs can be derived from ITRs. For example, ITRs can be derived from the Parvoviridae family, including parvoviruses and dependoviruses (e.g., canine parvovirus, bovine parvovirus, mouse parvovirus, porcine parvovirus, human parvovirus B-19), or the SV40 hairpin that serves as the origin of SV40 replication can be used as an ITR, which can be further modified by truncation, substitution, deletion, insertion, and / or addition. Parvoviridae family viruses are composed of two subfamilies: Parvovirinae, which infect vertebrates, and Densovirinae, which infect invertebrates. Usually, these ITRs are about 145 nucleotides long and are essentially inverted relative to other ITRs.Dependoparvoviruses include the adeno-associated virus (AAV) family of viruses that are capable of replication in vertebrate hosts, including but not limited to humans, primates, bovine, canine, equine, and ovine species.

[0105] As used herein, the terms "terminal resolution site" and "TRS" are used interchangeably herein and refer to the region where Rep forms a tyrosine-phosphodiester bond with the 5'-thymidine, generating a 3'-OH that serves as a substrate for DNA elongation via a cellular DNA polymerase, such as DNA pol δ or DNA pol ε. Alternatively, the Rep-thymidine complex can participate in a coordinate ligation reaction. In some embodiments, the TRS minimally includes a non-base-paired thymidine. In some embodiments, the nicking efficiency of the TRS can be controlled, at least in part, by its distance from the RBS within the same molecule. When the acceptor substrate is a complementary ITR, the resulting product is an intermolecular duplex. TRS sequences are known in the art and include, for example, the hexanucleotide sequence 5'-GGTTGA-3' (SEQ ID NO: 45) identified in AAV2. Any known TRS sequence can be used in embodiments of the invention, including other known AAV TRS sequences, other naturally known or synthetic TRS sequences such as AGTT (SEQ ID NO:46), GGTTGG (SEQ ID NO:47), AGTTGG (SEQ ID NO:48), AGTTGA (SEQ ID NO:49), and other motifs such as RRTTRR (SEQ ID NO:50).

[0106] As used herein, the term "transcriptional regulator" refers to transcriptional activators and repressors that activate or repress the transcription of a gene of interest. A promoter is a region of nucleic acid that initiates transcription of a specific gene. A transcriptional activator typically binds near the transcriptional promoter and recruits RNA polymerase to directly initiate transcription. A repressor binds to the transcriptional promoter and sterically blocks transcription initiation by RNA polymerase. Other transcriptional regulators can serve as either activators or repressors depending on where they bind and the cellular and environmental conditions. Non-limiting examples of transcriptional regulator classes include, but are not limited to, homeodomain proteins, zinc finger proteins, winged helix (forkhead) proteins, and leucine-zipper proteins.

[0107] As used herein, the terms "treat," "treating," and / or "treatment" include suppressing, substantially inhibiting, slowing, or reversing the progression of a condition, substantially ameliorating clinical symptoms of a condition, or substantially preventing the appearance of clinical symptoms, to obtain beneficial or desired clinical results. Furthermore, treating refers to achieving one or more of the following: (a) reducing the severity of the disorder; (b) limiting the onset of symptoms characteristic of one or more disorders being treated; (c) limiting the worsening of symptoms characteristic of one or more disorders being treated; (d) limiting the recurrence of one or more disorders in patients who previously had one or more disorders; and (e) limiting the recurrence of symptoms in patients who were previously asymptomatic for the disorder(s).

[0108] Beneficial or desired clinical results, such as pharmacological and / or physiological effects, include, but are not limited to, preventing a disease, disorder or condition from occurring in a subject who may be predisposed to the disease, disorder or condition but who has not yet experienced or is not exhibiting symptoms of the disorder (prophylactic treatment), alleviating the symptoms of the disease, disorder or condition, reducing the severity of the disease, disorder or condition, stabilizing (i.e., not worsening) the disease, disorder or condition, preventing the spread of the disease, disorder or condition, slowing or retarding the progression of the disease, disorder or condition, ameliorating or alleviating the disease, disorder or condition, and combinations thereof, as well as prolonging survival as compared to expected survival if not receiving treatment.

[0109] As used herein, the terms "therapeutic amount," "therapeutically effective amount," "effective amount," or "pharmaceutical effective amount" of an active agent (e.g., the ceDNA lipid particles described herein) are used interchangeably and refer to an amount sufficient to provide the intended therapeutic benefit. However, dosage levels are based on various factors, such as the type of injury, age, weight, sex, patient's condition, severity of the condition, route of administration, and the specific active agent used. Thus, dosage regimens may vary widely, but can be routinely determined by a physician using standard methods. Furthermore, the terms "therapeutic amount," "therapeutically effective amount," and "pharmaceutical effective amount" include the preventive or preventive amount of the described compositions of the present invention. In the prophylactic or preventative applications of the described invention, pharmaceutical compositions or medicaments are administered to a patient susceptible to or otherwise at risk of a disease, disorder, or condition in an amount sufficient to eliminate or reduce the risk, reduce the severity, or delay the onset of the disease, disorder, or condition, including the biochemical, histological, and / or behavioral symptoms of the disease, disorder, or condition, its complications, and intermediate pathological phenotypes manifesting during the development of the disease, disorder, or condition. It is generally preferred to use the maximum dose, i.e., the highest safe dose, according to some medical judgment. The terms "dose" and "administration" are used interchangeably herein.

[0110] As used herein, the term "therapeutic effect" refers to a result of treatment, which result is determined to be desirable and beneficial. A therapeutic effect can include, directly or indirectly, the prevention, reduction, or elimination of disease symptoms. A therapeutic effect can also include, directly or indirectly, the prevention, reduction, or elimination of the progression of disease symptoms.

[0111] For any therapeutic agent described herein, the therapeutically effective amount can be initially determined from preliminary in vitro studies and / or animal models.The therapeutically effective dose can also be determined from human data.The applied dose can be adjusted based on the relative bioavailability and efficacy of the administered compound.It is within the ability of a person skilled in the art to adjust the dose to achieve maximum efficacy based on the above methods and other well-known methods.The general principles for determining therapeutic efficacy are summarized below, which can be found in Chapter 1 of Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill (New York) (2001), which is incorporated herein by reference.

[0112] Pharmacokinetic principles provide the basis for modifying dosing regimens to achieve the desired degree of therapeutic effect while minimizing unacceptable side effects. In situations where the plasma concentration of a drug can be measured and is related to the therapeutic window, additional guidance regarding dosage modifications is available.

[0113] The term "vector" or "expression vector" is intended to refer to a replicon, such as a plasmid, bacmid, phage, virus, virion, or cosmid, to which another DNA segment, i.e., an "insert," "transgene," or "expression cassette," can be attached to bring about the expression or replication of the attached segment ("expression cassette") in a cell. A vector can be a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be of viral or non-viral origin in its final form. However, for the purposes of this disclosure, "vector" generally refers to a synthetic AAV vector or a nicked ceDNA vector. Thus, the term "vector" encompasses any genetic element that, when associated with the appropriate control elements, is capable of replication and of transferring gene sequences into a cell. In some embodiments, a vector can be a recombinant vector or an expression vector.

[0114] As used herein, the phrase "recombinant vector" refers to a vector that contains a heterologous nucleic acid sequence or a "transgene" that can be expressed in vivo. It should be understood that in some embodiments, the vectors described herein can be combined with other suitable compositions and therapeutic methods. In some embodiments, the vector is episomal. The use of a suitable episomal vector provides a means for maintaining the nucleotide of interest in a subject in high copy number extrachromosomal DNA, thereby eliminating the potential effects of chromosomal integration.

[0115] "Wild-type ITR" or "WT-ITR" refers to the sequence of a naturally occurring ITR sequence in an AAV or other dependant virus, e.g., that retains Rep binding activity and Rep nicking ability. The nucleotide sequence of a WT-ITR from any AAV serotype may differ slightly from the naturally occurring canonical sequence due to degeneracy of the genetic code or drift; therefore, WT-ITR sequences encompassed for use herein include WT-ITR sequences that result from naturally occurring variations (e.g., replication errors) that occur during the production process.

[0116] As used herein, the terms "comprising" or "comprises" are used in reference to compositions, methods, and their respective component(s) that are essential to the method or composition, but are open to the inclusion of unspecified elements, whether essential or not.

[0117] As used herein, the term "consisting essentially of" refers to elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment.

[0118] The term "consisting of" refers to the compositions, methods, and their respective components described herein, excluding any element not recited in the description of the embodiment.

[0119] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a "method" includes one or more methods, and / or steps of the type described herein and / or that will become apparent to those of ordinary skill in the art upon reading this disclosure, etc. Similarly, the word "or" is intended to include "and" unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The abbreviation "eg" is derived from the Latin "exempli gratia" and is used herein to indicate a non-limiting example. Thus, the abbreviation "eg" is synonymous with "for example."

[0120] As used herein, the terms "such as," "for example," and the like are intended to refer to example embodiments and do not limit the scope of the present disclosure.

[0121] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, suitable materials and methods are described herein.

[0122] Except in working examples or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood to be modified in all instances by the term "about." The term "about," when used in connection with percentages, may mean ±1%. The present invention is further illustrated by the following examples, but the scope of the present invention should not be limited thereto.

[0123] It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[0124] II. Closed-end DNA (ceDNA) vectors Provided herein is a novel non-viral capsid-free ceDNA molecule (ceDNA) with covalently closed ends.The ceDNA vector disclosed herein does not have the packaging constraints imposed by the limited space within the viral capsid.In contrast to the enclosed AAV genome, the ceDNA vector represents a practical and eukaryotic alternative to the prokaryotically produced plasmid DNA vector.This allows the insertion of control elements, such as the regulatory switches disclosed herein, large transgenes, multiple transgenes, etc., and, if necessary, the integration of the native gene regulatory elements of the transgene.

[0125] There are many structural features of ceDNA vectors that distinguish them from plasmid-based expression vectors. ceDNA vectors may have one or more of the following characteristics: lack of original (i.e., uninserted) bacterial DNA, lack of a prokaryotic replication origin, be self-contained (i.e., do not require any sequences other than the two ITRs containing Rep binding and terminal resolution sites (RBS and TRS), and do not require any exogenous sequences between the ITRs), have hairpin-forming ITR sequences of eukaryotic origin (i.e., are produced in eukaryotic cells), and lack bacterial-type DNA methylation, or indeed any other methylation that would be considered abnormal by a mammalian host. Generally, it is preferred that the vector does not contain any prokaryotic DNA, although it is contemplated that some prokaryotic DNA may be inserted as exogenous sequences, such as, for example, promoter or enhancer regions. Another important feature that distinguishes ceDNA vectors from plasmid expression vectors is that ceDNA vectors are single-stranded linear DNA with closed ends, whereas plasmids are always double-stranded DNA.

[0126] Compared to plasmid-based expression vectors, the use of ceDNA vectors as described herein offers several advantages. These advantages include, but are not limited to: 1) Plasmids contain bacterial DNA sequences and are subject to prokaryotic cell-specific methylation, such as 6-methyladenosine and 5-methylcytosine methylation, whereas capsid-free AAV vector sequences are of eukaryotic origin and are not subject to prokaryotic cell-specific methylation. As a result, capsid-free AAV vectors are less likely to induce inflammation and immune responses compared to plasmids. 2) Plasmids require the presence of resistance genes during the production process, whereas ceDNA vectors do not. 3) Circular plasmids are not delivered to the nucleus upon introduction into cells and require overloading to bypass degradation by cellular nucleases, whereas ceDNA vectors contain viral cis elements, i.e., modified ITRs, that confer resistance to nucleases and can be designed to be targeted and delivered to the nucleus. The minimal defining elements essential for ITR function are hypothesized to be a Rep binding site (RBS, 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO:531) for AAV2) and a terminal resolution site (TRS, 5'-AGTTGG-3' (SEQ ID NO:48) for AAV2), plus a variable palindromic sequence that allows hairpin formation. In contrast, transduction with the capsid-free AAV vectors disclosed herein can use a variety of delivery reagents and efficiently target cell and tissue types that are difficult to transduce with conventional AAV virions.

[0127] The ceDNA vector preferably has a linear, continuous structure rather than a discontinuous structure, as determined by restriction enzyme digestion assays and electrophoretic analysis (Figure 5D). A linear, continuous structure is believed to be more stable against attack by cellular endonucleases and less likely to recombine and cause mutagenesis. Therefore, a ceDNA vector with a linear, continuous structure is a preferred embodiment. Continuous, linear, single-stranded, intramolecularly duplexed ceDNA vectors may have covalently linked termini without sequences encoding AAV capsid proteins. These ceDNA vectors are structurally distinct from plasmids (including the ceDNA plasmids described herein), which are circular, double-stranded nucleic acid molecules of bacterial origin. While the complementary strands of a plasmid can be separated following denaturation to produce two nucleic acid molecules, a ceDNA vector, although having complementary strands, is a single DNA molecule and therefore remains a single molecule even when denatured. In some embodiments, the ceDNA vectors described herein, unlike plasmids, can be produced without prokaryotic cell-type DNA base methylation. Thus, ceDNA vectors and ceDNA-plasmids differ both in terms of their structure (in particular, linear vs. circular) and the methods used to produce and purify these different entities (see below), as well as in terms of their DNA methylation, which is of prokaryotic cell type in the case of ceDNA-plasmids and eukaryotic cell type in the case of ceDNA-vectors.

[0128] Provided herein are non-viral capsid-free ceDNA molecules (ceDNA) with covalently closed ends. These non-viral capsid-free ceDNA molecules can be produced in permissive host cells from expression constructs (e.g., ceDNA-plasmids, ceDNA-baculoviruses, or integrative cell lines) containing a heterologous gene (transgene) positioned between two symmetric inverted terminal repeat (ITR) sequences, where the ITRs are symmetrical to each other rather than to the wild-type ITRs. That is, the ITRs are modified ITRs, where the sequence of the 3' ITR is the reverse complement of the sequence of the 5' ITR, and vice versa. In some embodiments, the ITRs are modified by deletion, insertion, and / or substitution compared to the wild-type ITR sequence (e.g., AAV ITR). In some embodiments, the modified ITRs contain functional terminal resolution sites and Rep binding sites. The ceDNA vector is preferably double-stranded, e.g., self-complementary, over at least a portion of the molecule, such as an expression cassette (e.g., the ceDNA is not a double-stranded circular molecule like a plasmid). The ceDNA vector has covalently closed ends and is therefore resistant to exonuclease digestion (e.g., exonuclease I or exonuclease III), e.g., for greater than 1 hour at 37°C.

[0129] In one aspect, the ceDNA vector comprises, from 5' to 3', a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest (e.g., an expression cassette described herein), and a second AAV ITR. In some embodiments, the first ITR (5'ITR) and the second ITR (3'ITR) are asymmetric with respect to each other. That is, they have different three-dimensional spatial configurations. As an exemplary embodiment, the first ITR may be a wild-type ITR, and the second ITR may be a mutant or modified ITR, or vice versa, where the first ITR may be a mutant or modified ITR, and the second ITR may be a wild-type ITR. In one embodiment, the first ITR and the second ITR are both mutated or modified, but have different sequences, or have different modifications, or are not the same mutant or modified ITR, and have different three-dimensional spatial configurations. In other words, ceDNA vectors using asymmetric ITRs may have ITRs in which any changes in one ITR relative to the WT-ITR are not reflected in the other ITR, or, if the asymmetric ITRs have a mutated or modified asymmetric ITR pair, they may have different sequences and different three-dimensional shapes relative to each other.

[0130] According to some embodiments, a ceDNA vector comprises, from 5' to 3', a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest (e.g., an expression cassette described herein), and a second AAV ITR, wherein the first and second ITRs are asymmetric with respect to each other. That is, they have different three-dimensional spatial configurations. In some embodiments, a ceDNA vector may comprise ITR sequences with symmetric three-dimensional spatial configurations, such that their structures have the same shape in geometric space or the same A, C-C', and B-B' loops in three-dimensional space. In such embodiments, a symmetric or substantially symmetric ITR pair may be a mutant or modified ITR that is not a wild-type ITR. As an exemplary embodiment, the first ITR may be a wild-type ITR and the second ITR may be a mutant or modified ITR, or vice versa, where the first ITR may be a mutant or modified ITR and the second ITR may be a wild-type ITR. In one embodiment, the first ITR and the second ITR are both modified, but have different sequences, or have different modifications, or are not identical modified ITRs, but have different three-dimensional spatial configurations. In another exemplary embodiment, the first ITR (or 5'ITR) can be a modified ITR, for example, SEQ ID NO: 484 (i.e., ITR-33, left), and the second ITR (or 3'ITR) can be a mutant or modified ITR, for example, SEQ ID NO: 469 (i.e., ITR-18, right). In other words, a ceDNA vector using asymmetric ITRs may contain ITRs in which any changes in one ITR relative to the WT-ITR are not reflected in the other ITR, or, if the asymmetric ITR has a modified asymmetric ITR pair, they may have different sequences and different three-dimensional shapes relative to each other. The mutant or modified ITR pair may have one or more modifications from the wild-type ITR and have the same sequence that is the reverse complement (inverse) of each other. In one embodiment, the modified ITR pair is substantially symmetric as defined herein, i.e., the modified ITR pair may have different sequences but may have corresponding or the same symmetrical three-dimensional shapes.In some embodiments, the symmetric or substantially symmetric ITRs are wild-type (WT-ITR) as described herein. That is, both ITRs have wild-type sequences, but are not necessarily WT-ITRs of the same AAV serotype. In one embodiment, one WT-ITR may be derived from one AAV serotype, and the other WT-ITR may be derived from a different AAV serotype. In such embodiments, the WT-ITR pair is substantially symmetric as defined herein, that is, they may have one or more conservative nucleotide modifications while maintaining a symmetrical three-dimensional spatial configuration.

[0131] According to some embodiments, the ceDNA vector comprises, from 5' to 3', a first wild-type adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest (e.g., an expression cassette as described herein), and a second WT-ITR, wherein the first WT-ITR and the second WT-ITR are derived from the same or different AAV serotypes. In an exemplary embodiment, the first WT-ITR (or 5'WT-ITR) may be derived from AAV2, and the second WT-ITR (or 3'WT-ITR) may be derived from AAV6. Exemplary WT-ITRs in ceDNA vectors are discussed below in the section entitled "ITRs" and in Table 1.

[0132] The wild-type ITR sequences provided herein represent DNA sequences included in expression constructs (e.g., ceDNA-plasmid, ceDNA-bacmid, ceDNA-baculovirus) for the production of ceDNA vectors.

[0133] In some embodiments, the ceDNA vectors described herein comprising an expression cassette carrying a transgene may be, for example, a regulatory sequence, a sequence encoding a nucleic acid (e.g., an miR or antisense sequence), or a sequence encoding a polypeptide (e.g., a transgene). In one embodiment, the transgene may be operably linked to one or more regulatory sequences that enable or control expression of the transgene. In one embodiment, the polynucleotide comprises a first WT-ITR sequence and a second WT-ITR sequence, and the nucleotide sequence of interest is flanked on either side by the first and second WT-ITR sequences.

[0134] Exemplary ITRs are discussed below in the section entitled "ITRs" and in Tables 2 and 5 herein, or in Tables 2, 3, 4, 5, 6, 7, 8, 9, or 10A-10B of PCT / US18 / 49996, filed September 7, 2018, to which the adjacent ITR sequence is symmetric (e.g., reverse complement) or substantially symmetric.

[0135] The ITR sequences provided herein represent DNA sequences included in an expression construct (e.g., ceDNA-plasmid, ceDNA-bacmid, ceDNA-baculovirus) for the production of a ceDNA vector. Thus, the ITR sequences actually contained in a ceDNA vector produced from a ceDNA-plasmid or other expression construct may or may not be identical to the ITR sequences provided herein as a result of naturally occurring variations (including conservative and non-conservative modifications) that occur during the production process (e.g., replication errors).

[0136] In some embodiments, the ceDNA vector described herein, which comprises an expression cassette having a transgene that is a therapeutic nucleic acid sequence, can be operably linked to one or more regulatory sequences that allow or control the expression of the transgene. In one embodiment, the polynucleotide comprises a first ITR sequence and a second ITR sequence, and the nucleotide sequence of interest is flanked on both sides by the first and second ITR sequences, and the first and second ITR sequences are asymmetric or symmetric relative to each other.

[0137] In one embodiment, the expression cassette is located between two ITRs and includes, in that order, a promoter operably linked to a transgene, a post-transcriptional regulatory element, and one or more polyadenylation and termination signals. In one embodiment, the promoter is regulatable—inducible or repressible. The promoter can be any sequence that promotes transcription of the transgene. In one embodiment, the promoter is a CAG promoter (e.g., SEQ ID NO: 03) or a variant thereof. The post-transcriptional regulatory element is a sequence that regulates the expression of the transgene, and, as a non-limiting example, is any sequence that creates a tertiary structure that enhances the expression of the transgene, which is a therapeutic nucleic acid sequence.

[0138] In one embodiment, the post-transcriptional regulatory element comprises WPRE (e.g., SEQ ID NO: 8). In one embodiment, the polyadenylation and termination signal comprises BGH polyA (e.g., SEQ ID NO: 9). Any cis-regulatory element known in the art, or combinations thereof, can additionally be used, such as the SV40 late polyA signal upstream enhancer sequence (USE) or other post-transcriptional processing elements (including, but not limited to, the thymidine kinase gene of herpes simplex virus or hepatitis B virus (HBV)). In one embodiment, the length of the expression cassette in the 5' to 3' orientation exceeds the maximum length known to be encapsidated in AAV virions. In one embodiment, the length is greater than 4.6 kb, or greater than 5 kb, or greater than 6 kb, or greater than 7 kb. Various expression cassettes are exemplified herein.

[0139] An expression cassette can comprise more than 4000 nucleotides, 5000 nucleotides, 10,000 nucleotides, 20,000 nucleotides, 30,000 nucleotides, 40,000 nucleotides, or 50,000 nucleotides, or any range between about 4000 and 10,000 nucleotides, or 10,000 and 50,000 nucleotides, or greater than 50,000 nucleotides. In some embodiments, an expression cassette can comprise a transgene (e.g., a therapeutic nucleic acid sequence) in the length range of 500 to 50,000 nucleotides. In some embodiments, an expression cassette can comprise a transgene (e.g., a therapeutic nucleic acid sequence) in the length range of 500 to 75,000 nucleotides. In some embodiments, an expression cassette can comprise a transgene (e.g., a therapeutic nucleic acid sequence) in the length range of 500 to 10,000 nucleotides. In some embodiments, an expression cassette can comprise a transgene (e.g., a therapeutic nucleic acid sequence) in the length range of 1000 to 10,000 nucleotides. In some embodiments, the expression cassette can contain a transgene (e.g., a therapeutic nucleic acid sequence) ranging in length from 500 to 5,000 nucleotides. ceDNA vectors do not have the size limitations of encapsidated AAV vectors, thus allowing delivery of large expression cassettes resulting in efficient expression of the transgene. In some embodiments, the ceDNA vector lacks prokaryotic cell-specific methylation.

[0140] According to some embodiments, the expression cassette may also contain an internal ribosome entry site (IRES) and / or a 2A element. Cis-regulatory elements include, but are not limited to, promoters, riboswitches, insulators, mir regulatory elements, post-transcriptional regulatory elements, tissue- and cell-type-specific promoters, and enhancers. In some embodiments, the ITRs may act as promoters for the transgene. In some embodiments, the ceDNA vector contains additional components for regulating the expression of the transgene, such as a regulatory switch for controlling and regulating the expression of the transgene, as described in the section entitled "Regulatory Switches" herein, and, if desired, a kill switch that enables controlled cell death of cells containing the ceDNA vector.

[0141] 1A-1B show schematic diagrams of non-limiting exemplary ceDNA vectors, or the corresponding sequences of ceDNA plasmids. The ceDNA vector is capsid-free and can be obtained from a plasmid encoding a first ITR, an expressible transgene cassette, and a second ITR, in that order, where the first and second ITR sequences are mutated relative to the corresponding wild-type AAV2 ITR sequences, and the mutations are the same (i.e., the modified ITRs are symmetrical). The expressible transgene cassette preferably includes one or more of an enhancer / promoter, an ORF reporter (transgene), a post-transcriptional regulatory element (e.g., WPRE), and a polyadenylation and termination signal (e.g., BGH polyA), in that order.

[0142] 2A-2B show schematic diagrams of non-limiting exemplary ceDNA vectors or corresponding sequences of ceDNA plasmids. The ceDNA vector is capsid-free and can be obtained from a plasmid encoding a first WT-ITR, an expressible transgene cassette, and a second WT-ITR, in that order. In some embodiments, the first and second ITR sequences are wild-type AAV2 ITR sequences. In some embodiments, the first and second ITR sequences are selected from any of the WT-ITR combinations shown in Table 1. The expressible transgene cassette preferably includes one or more of an enhancer / promoter or regulatory switch, an ORF reporter (transgene), a post-transcriptional regulatory element (e.g., WPRE), and a polyadenylation and termination signal (e.g., BGH polyA), in that order.

[0143] Figures 1A-1C of International Application No. PCT / US2018 / 050042, filed September 7, 2018, and incorporated herein by reference in its entirety, show schematic diagrams of non-limiting exemplary ceDNA vectors, or corresponding sequences of ceDNA plasmids. The ceDNA vectors are capsid-free and are derived from plasmids encoding, in that order, a first ITR, an expressible transgene cassette, and a second ITR, with at least one of the first and / or second ITR sequences being mutated relative to the corresponding wild-type AAV2 ITR sequence. The expressible transgene cassette preferably includes, in that order, one or more of an enhancer / promoter, an ORF reporter (transgene), a post-transcriptional regulatory element (e.g., WPRE), and a polyadenylation and termination signal (e.g., BGH polyA).

[0144] therapeutic nucleic acids The expression cassette can contain any transgene of interest.The transgene of interest includes, but is not limited to, a nucleic acid encoding a polypeptide or a non-coding nucleic acid (such as RNAi, miR, etc.), preferably a therapeutic (for example, medical, diagnostic, or veterinary use) or immunogenic polypeptide (for example, for vaccine).In certain embodiments, the transgene in the expression cassette encodes one or more polypeptides, peptides, ribozymes, peptide nucleic acids, siRNA, RNAis, antisense oligonucleotides, antisense polynucleotides, antibodies, antigen-binding fragments, or any combination thereof.

[0145] Exemplary therapeutic nucleic acids of the present disclosure can include, but are not limited to, minigenes, plasmids, minicircles, small interfering RNAs (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), ribozymes, closed-ended double-stranded DNA (e.g., ceDNA, CELiDs, linear covalently closed DNA ("ministring"), doggybone™ DNA, protelomeric closed-ended DNA, or dumbbell linear DNA), Dicer substrate dsRNA, small hairpin RNAs (shRNAs), asymmetric interfering RNAs (aiRNAs), microRNAs (miRNAs), mRNAs, tRNAs, rRNAs, and DNA viral vectors, viral RNA vectors, and any combination thereof.

[0146] siRNA or miRNA, which can downregulate the intracellular level of specific proteins through a process called RNA interference (RNAi), are also contemplated by the present invention as nucleic acid therapeutic agents.After siRNA or miRNA is introduced into the cytoplasm of host cells, these double-stranded RNA constructs can bind to a protein called RISC.The sense strand of siRNA or miRNA is removed by the RISC complex.When the RISC complex binds to complementary mRNA, it cleaves the mRNA and releases the cleaved strand.RNAi is caused by specifically destroying mRNA, which leads to the downregulation of corresponding proteins.

[0147] Antisense oligonucleotides (ASOs) and ribozymes that inhibit mRNA translation into proteins can be used as nucleic acid therapeutic agents. In the case of antisense constructs, these single-stranded deoxyribonucleotides have sequences complementary to the target protein mRNA sequence, and can bind to the mRNA through Watson-Crick base pairing. This binding prevents the translation of the target mRNA and / or causes RNase H degradation of the mRNA transcript. As a result, antisense oligonucleotides have enhanced specificity of action (i.e., downregulation of specific disease-related proteins).

[0148] In any of the methods provided herein, the therapeutic nucleic acid can be a therapeutic RNA. The therapeutic RNA can be an inhibitor of mRNA translation, an RNA interference (RNAi) agent, a catalytically active RNA molecule (ribozyme), a transfer RNA (tRNA), or an mRNA transcript (ASO), an RNA that binds to a protein or other molecular ligand (aptamer). In any of the methods provided herein, the RNAi agent can be a double-stranded RNA, a single-stranded RNA, a microRNA, a short interfering RNA, a short hairpin RNA, or a triple-helix-forming oligonucleotide.

[0149] In some embodiments, the transgene is a therapeutic gene or a marker protein. In some embodiments, the transgene is an agonist or antagonist. In some embodiments, the antagonist is a targeting mimetic or an antibody or antibody fragment, or an antigen-binding fragment thereof, such as a neutralizing antibody or antibody fragment. In some embodiments, the transgene encodes an antibody, including a full-length antibody or antibody fragment, as defined herein. In some embodiments, the antibody is an antigen-binding domain or immunoglobulin variable domain sequence, as defined herein. In particular, the transgene is one or more therapeutic agents, including, but not limited to, protein(s), polypeptide(s), peptide(s), enzyme(s), antibodies, antigen-binding fragments, and variants and / or active fragments thereof, for use in the treatment, prevention, and / or amelioration of, for example, one or more symptoms of a disease, dysfunction, injury, and / or disorder. Exemplary therapeutic genes are described herein in the section entitled "Methods of Treatment."

[0150] III. Inverted Terminal Repeats (ITRs) As described herein, according to one embodiment, a ceDNA vector is a non-encapsid-containing linear duplex DNA molecule formed from continuous strands of complementary DNA with covalently linked ends (linear, continuous, non-encapsid structure), and includes 5' inverted terminal repeat (ITR) sequences and 3' ITR sequences that are different or asymmetric with respect to each other. According to some embodiments, the ITR sequences are wild-type ITR sequences. According to some embodiments, the ITR sequences are not wild-type ITR sequences. According to some embodiments, the ITR sequences are modified ITR sequences.

[0151] According to some embodiments, the ceDNA vector comprises a heterologous nucleic acid sequence located between two adjacent wild-type inverted terminal repeat (WT-ITR) sequences, which are either reverse complements (inverted) of each other or, alternatively, are substantially symmetrical to each other. That is, the WT-ITR pair has a symmetrical three-dimensional spatial configuration. In some embodiments, the wild-type ITR sequence (e.g., AAV WT-ITR) comprises a functional Rep binding site (RBS, e.g., 5'-GCGCGCTCGCTCGCTC-3' for AAV2, SEQ ID NO: 531) and a functional terminal resolution site (TRS, e.g., 5'-AGTT-3', SEQ ID NO: 46).

[0152] According to some embodiments, the ceDNA vector comprises a heterologous gene located between two adjacent modified inverted terminal repeat (mod-ITR) sequences, which are reverse complements (inverted) of each other or are substantially symmetrical (i.e., have corresponding modifications) as defined herein, and are not wild-type ITRs. These reverse-complementary ITRs are referred to as symmetric ITRs. The ITRs are modified from an existing, naturally occurring parvovirus wild-type ITR (e.g., AAV ITR) by deletion, insertion, and / or substitution, and may contain a functional Rep binding site (RBS, e.g., 5'-GCGCGCTCGCTCGCTC-3' for AAV2, SEQ ID NO: 531) and a functional terminal resolution site (TRS, e.g., 5'-AGTT-3', SEQ ID NO: 46).

[0153] In some embodiments, the ITR sequences can be derived from viruses of the Parvoviridae family, which includes two subfamilies: Parvovirinae, which infect vertebrates, and Densovirinae, which infect insects. Parvovirinae (also called parvoviruses) includes the Dependovirus genus, whose members, under most conditions, require co-infection with a helper virus, such as an adenovirus or herpesvirus, for productive infection. The Dependovirus family includes adeno-associated viruses (AAVs), which typically infect humans (e.g., serotypes 2, 3A, 3B, 5, and 6) or primates (e.g., serotypes 1 and 4), as well as related viruses that infect other warm-blooded animals (e.g., bovine, canine, equine, and ovine adeno-associated viruses). Parvoviruses and other members of the Parvoviridae family are generally described in Kenneth I. Berns, "Parvoviridae: The Viruses and Their Replication," Chapter 69 in FIELDS VIROLOGY (3d Ed. 1996). One of skill in the art will recognize that ITRs from any known parvovirus can be used in the compositions and methods described herein. According to some embodiments, the ITRs are derived from a dependovirus, such as AAV (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV5, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genomes). For example, NCBI:NC002077;NC001401;NC001729;NC001829;NC006152;NC006260;NC006261), chimeric ITRs, or ITRs from any synthetic AAV. In some embodiments, the AAV can infect warm-blooded animals, such as avian (AAAV), bovine (BAAV), canine, equine, and ovine adeno-associated viruses.In some embodiments, the ITRs are derived from B19 parvovirus (GenBank accession number NC000883), minute virus of mice (MVM) (GenBank accession number NC001510), goose parvovirus (GenBank accession number NC001701), or snake parvovirus 1 (GenBank accession number NC006148).

[0154] According to some embodiments, the serotype selected may be based on the tissue tropism of the serotype. AAV2 has broad tissue tropism, AAV1 preferentially targets neurons and skeletal muscle, and AAV5 targets neurons, retinal pigment epithelium, and photoreceptors. AAV6 preferentially targets skeletal muscle and lung. AAV8 preferentially targets liver, skeletal muscle, heart, and pancreatic tissue. AAV9 preferentially targets liver, skeletal, and lung tissue. According to some embodiments, the serotype is AAV2.

[0155] Those skilled in the art know that ITR sequences have the general structure of a double-stranded Holliday junction, typically a T- or Y-shaped hairpin structure (see, e.g., Figures 3A and 4A), with each ITR formed by two palindromic arms or loops (B-B' and C-C') embedded in a larger palindromic arm (A-A') and a single-stranded D sequence (the order of these palindromic sequences defines the flip or flop orientation of the ITR). Therefore, based on the exemplary AAV2 ITR sequences provided herein, modified ITR sequences from any AAV serotype can be engineered for use in ceDNA vectors or ceDNA plasmids. See, for example, structural analysis and sequence comparison of ITRs from different AAV serotypes (AAV1-AAV6). Grimm et al., J. Virology, 2006;80(1);426-439, Yan et al., J. Virology, 2005;364-379, Duan et al., Virology 1999;261;8-14.

[0156] Thus, although AAV2 ITRs are used as exemplary ITRs (e.g., wild-type (WT) or modified ITRs) in the ceDNA vectors disclosed herein, the ceDNA vectors disclosed herein can be prepared using or based on ITRs from any known AAV serotype, including AAV serotype 1 (AAV1), AAV serotype 2 (AAV2), AAV serotype 4 (AAV4), AAV serotype 5 (AAV5), AAV serotype 6 (AAV6), AAV serotype 7 (AAV7), AAV serotype 8 (AAV8), AAV serotype 9 (AAV9), AAV serotype 10 (AAV10), AAV serotype 11 (AAV11), or AAV serotype 12 (AAV12). Those skilled in the art can determine corresponding sequences in other serotypes by known means. The present invention further provides populations and multiple ceDNA vectors comprising ITRs from combinations of different AAV serotypes. That is, one ITR (e.g., wild-type (WT) or modified ITR) can be derived from one AAV serotype, and the other ITR (e.g., wild-type (WT) or modified ITR) can be derived from a different serotype. Without being bound by theory, in one embodiment, one ITR (e.g., a wild-type (WT) or modified ITR) may be derived from or based on an AAV2 ITR sequence, and the other ITR (e.g., a wild-type (WT) or modified ITR) of the ceDNA vector may be derived from or based on any one or more ITR sequences of AAV serotype 1 (AAV1), AAV serotype 4 (AAV4), AAV serotype 5 (AAV5), AAV serotype 6 (AAV6), AAV serotype 7 (AAV7), AAV serotype 8 (AAV8), AAV serotype 9 (AAV9), AAV serotype 10 (AAV10), AAV serotype 11 (AAV11), or AAV serotype 12 (AAV12).

[0157] Certain modifications and mutations of WT-ITR are described herein so that ceDNA can incorporate substantially symmetrical WT-ITR, i.e., have a symmetrical three-dimensional spatial configuration so that their structures have the same shape in geometric space. This can occur, for example, when GC pairs are modified to CG pairs or vice versa, or when AT pairs are modified to TA pairs or vice versa. Thus, [ka] and 5'WT-ITR containing the sequence [ka] Using the above illustrative example of a 3'WT-ITR containing (i.e., the reverse complement of ATCGATCG), e.g., [ka] (T is changed to A), and a substantially symmetric 3'WT-ITR [ka] (A is not changed to T), these WT-ITR pairs are still substantially symmetric. In some embodiments, such WT-ITR pairs are substantially symmetric because they have a symmetric three-dimensional spatial organization.

[0158] Specific alterations and mutations in ITRs are described in detail herein, but in the context of ITRs, "altered," "mutated," or "modified" refers to nucleotide insertions, deletions, and / or substitutions compared to the wild-type or naturally occurring ITR sequence. Two ITRs flanking a transgene or heterologous nucleic acid have the same modifications, as defined herein, or are substantially symmetrical, i.e., have the same three-dimensional spatial organization, such that their structures have the same geometric spatial shape. An altered or mutated ITR may be an engineered ITR. As used herein, "engineered" refers to an aspect that has been manipulated by human hands. For example, a polypeptide is considered "engineered" when at least one aspect of the polypeptide, e.g., its sequence, has been manipulated by human hands and is different from its naturally occurring aspect.

[0159] In some embodiments, the ITRs (e.g., wild-type (WT) or modified ITRs) can be synthetic. In one embodiment, the synthetic ITRs are based on ITR sequences from two or more AAV serotypes. In another embodiment, the synthetic ITRs do not contain AAV-based sequences. In yet another embodiment, the synthetic ITRs preserve the ITR structure described above but have little or no AAV-origin sequences. In some embodiments, the synthetic ITRs may preferentially interact with wild-type Rep or Rep of a particular serotype, or in some cases, be not recognized by wild-type Rep but only by mutant Rep. In some embodiments, the ITRs are synthetic ITR sequences that retain a functional Rep binding site (RBS) and terminal resolution site (TRS), such as 5'-GCGCGCTCGCTCGCTC-3', in addition to a variable palindromic sequence that allows hairpin secondary structure formation. In some examples, the modified ITR sequence retains the RBS, trs sequences, and the structure and position of the Rep binding element that forms the terminal loop portion of one ITR hairpin secondary structure from the corresponding sequence of the wild-type AAV2 ITR. Exemplary ITR sequences for use in ceDNA vectors are disclosed in Tables 2-9, 10A, and 10B, SEQ ID NOs: 2, 52, 101-449, and 545-547, and the partial ITR sequences shown in Figures 26A-26B of PCT Application No. PCT / US18 / 49996, filed September 7, 2018. In some embodiments, a ceDNA vector may include an ITR with modifications in the ITR corresponding to any of the modifications in the ITR sequences or ITR partial sequences shown in any one or more of Tables 2, 3, 4, 5, 6, 7, 8, 9, 10A, and 10B of PCT Application No. PCT / US18 / 49996, filed September 7, 2018.

[0160] In one embodiment, adjacent ITRs (e.g., wild-type (WT) or modified ITRs) are substantially symmetrical to each other. When an ITR is a modified ITR, the modifications are identical. The additions, substitutions, or deletions are the same, but the ITRs are not identical reverse complements. For example, the ITRs (e.g., wild-type (WT) or modified ITRs) can be derived from different serotypes (e.g., AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12), such as a combination of AAV2 and AAV6, with modifications at corresponding positions.

[0161] In one embodiment, a substantially symmetric ITR is at least 80% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical, and all points in between, when one ITR is inverted relative to the other ITR. Homology can be determined by standard means well known in the art, such as BLAST (Basic Local Alignment Search Tool) or BLASTN with default settings. ITRs are considered substantially symmetrical if the overall shapes of the A, B, and C loops are similar. In some embodiments, a WT-ITR pair is substantially symmetrical because they have a symmetrical three-dimensional spatial configuration, for example, the same three-dimensional configuration of the A, C-C', B-B', and D arms. In one embodiment, a substantially symmetric WT-ITR pair is inverted relative to the other and is at least 95% identical to each other, at least 96%...97%...98%...99%...99.5%, and all points in between, where one WT-ITR retains the Rep binding site (RBS) and terminal resolution site (trs) of 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 531). In some embodiments, a substantially symmetric WT-ITR pair is inverted relative to the other and is at least 95% identical to each other, at least 96%...97%...98%...99%...99.5%, and all points in between, where one WT-ITR retains the Rep binding site (RBS) and terminal resolution site (trs) of 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 531), in addition to a variable palindromic sequence that allows for hairpin secondary structure formation.

[0162] In one embodiment, a substantially symmetrical modified ITR pair refers to a pair of modified ITRs (mod-ITRs) so long as the differences in nucleotide sequence between the ITRs do not affect their properties or overall shape and they have substantially the same shape in three-dimensional space. For example, the mod-ITRs have at least 95%, 96%, 97%, 98%, or 99% sequence identity to a canonical mod-ITR, as determined by standard means well known in the art, such as BLAST (Basic Local Alignment Search Tool) with default settings, and have a symmetrical three-dimensional spatial organization such that their three-dimensional structures have the same shape in geometric space. A substantially symmetrical mod-ITR pair has the same A, C-C', and B-B' loops in three-dimensional space. For example, if the modified ITR of a substantially symmetric mod-ITR pair has a deletion of the C-C' arm, the cognate mod-ITR will have a corresponding deletion of the C-C' loop and a similar three-dimensional structure of the remaining A and B-B' loops that are the same shape in geometric space as the cognate mod-ITR. By way of example only, substantially symmetric ITRs can have symmetric stereochemistry such that their structures are the same shape in geometric space. This can occur, for example, when a GC pair is modified to, for example, a CG pair, or vice versa, or when an AT pair is modified to a TA pair, or vice versa. Thus, [ka] Modified 5'ITR as [ka] A modified 3'ITR as (i.e., [ka] Using the illustrative example above, which includes a 5' ITR (the reverse complement of [ka] (wherein the G in the addition is changed to C), and a substantially symmetrical 3'-ITR [ka] (the T in the addition is not changed to A), these modified ITRs are still symmetric. In some embodiments, such modified ITR pairs are substantially symmetric, since the modified ITR pair has symmetric stereochemistry.

[0163] In some embodiments, the ITRs from a mod-ITR pair can have different reverse-complementary nucleotide sequences but still have the same symmetrical three-dimensional spatial organization. That is, both ITRs have mutations that result in the same overall three-dimensional shape. For example, one ITR (e.g., the 5' ITR) of a mod-ITR pair can be from one serotype, and the other ITR (e.g., the 3' ITR) can be from a different serotype, but both can have the same corresponding mutation (e.g., if the 5' ITR has a deletion in the C region, the cognate modified 3' ITR of the different serotype will have a deletion in the corresponding position in the C' region), thereby resulting in the modified ITR pair having the same symmetrical three-dimensional spatial organization. Substantially symmetric mod-ITRs have the same A, C-C', and B-B' loops in three-dimensional space. As a non-limiting example, if a modified ITR in a substantially symmetric mod-ITR pair has a deletion in the C-C' arm, the cognate mod-ITR will have a corresponding deletion in the C-C' loop and a similar three-dimensional structure with the remaining A and B-B' loops of the same shape in the geometric space of the cognate mod-ITR. In another example, if a 5' mod-ITR has a deletion of one or more nucleic acids in the B region, the cognate modified 3'-ITR will have a deletion at the corresponding nucleotide position in the B' arm.

[0164] When a 5'mod-ITR has a modification in the A region, the cognate 3'ITR has a modification in the corresponding position in the A' region; when a 5'mod-ITR has a modification in the C region, the cognate 3'ITR has a modification in the corresponding position in the C' region, or vice versa; when a 5'mod-ITR has a modification in the C' region, the cognate 3'ITR has a modification in the corresponding position in the C' region; when a 5'mod-ITR has a modification in the B region, the cognate 3'ITR has a modification in the corresponding position in the B' region, or vice versa; when a 5'mod-ITR has a modification in the B' region, the cognate 3'ITR has a modification in the corresponding position in the B' region; and when a 5'mod-ITR has a modification in the A' region, the cognate 3'mod-ITR has a modification in the corresponding position in the A' region, such that it is well known to those skilled in the art that modified ITR pairs are symmetrical, or substantially symmetrical, as defined herein, and have the same symmetrical three-dimensional spatial configuration.

[0165] In some embodiments where the symmetrically modified ITR is substantially symmetrical, the difference in the nucleotide sequence of an adjacent symmetrically modified ITR compared to another ITR is that the change is the substitution of one nucleic acid in a conserved nucleic acid. In some embodiments where the symmetrically modified ITR is substantially symmetrical, the difference in the nucleotide sequence of an adjacent symmetrically modified ITR compared to another ITR is that the change is the substitution of one, two, or three nucleic acids in their complementary nucleic acids. These changes can be sequential, dispersed, or non-sequential across the ITR. In some embodiments where the symmetrically modified ITR pair is substantially symmetrical as defined herein, the ITR can have any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleic acid substitutions in their complementary nucleic acids compared to the adjacent substantially symmetrically modified ITR. provided that the differences in nucleotide sequence between the two substantially symmetrical modified ITRs do not affect the properties or overall shape, and that they have substantially the same shape in 3D space.

[0166] Any parvovirus ITR can be used for modification as an ITR (e.g., wild-type (WT) or modified ITR) or as a basic ITR. Preferably, the parvovirus is a dependovirus. More preferably, it is an AAV. The serotype selected can be based on the tissue tropism of the serotype. AAV2 has broad tissue tropism, AAV1 preferentially targets neurons and skeletal muscle, and AAV5 targets neurons, retinal pigment epithelium, and photoreceptors. AAV6 preferentially targets skeletal muscle and lung. AAV8 preferentially targets liver, skeletal muscle, heart, and pancreatic tissue. AAV9 preferentially targets liver, skeletal, and lung tissue. In one embodiment, the modified ITR is based on the AAV2 ITR.

[0167] According to some embodiments, the vector polynucleotide comprises a pair of WT-ITRs selected from the group shown in Table 1. Table 1 shows exemplary combinations of WT-ITRs derived from the same or different serotypes, or different parvoviruses. The order shown does not indicate the ITR position; for example, "AAV1, AAV2" specifies that the ceDNA may comprise a WT-AAV1 ITR at the 5' position and a WT-AAV2 ITR at the 3' position, or vice versa, a WT-AAV2 ITR at the 5' position and a WT-AAV1 ITR at the 3' position. Abbreviations: AAV serotype 1 (AAV1), AAV serotype 2 (AAV2), AAV serotype 3 (AAV3), AAV serotype 4 (AAV4), AAV serotype 5 (AAV5), AAV serotype 6 (AAV6), AAV serotype 7 (AAV7), AAV serotype 8 (AAV8), AAV serotype 9 (AAV9), AAV serotype 10 (AAV10), AAV serotype 11 (AAV11), or AAV serotype 12 (AAV12); AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genomes (e.g., NCBI: NC002077; NC001401; NC0017 29; NC001829; NC006152; NC006260; NC006261), ITRs derived from warm-blooded animals (avian AAV (AAAV), bovine AAV (BAAV), canine, equine, and ovine AAV), ITRs derived from B19 parvovirus (GenBank accession number: NC000883), minute virus of mice (MVM) (GenBank accession number: NC001510); goose: goose parvovirus (GenBank accession number: NC001701); snake: snake parvovirus 1 (GenBank accession number NC006148). [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0168] According to some embodiments, the vector polynucleotide or the non-viral capsid-free DNA vector with covalently closed ends comprises a pair of WT-ITRs selected from the WT-ITRs shown in Table 2. By way of example only, Table 2 shows the sequences of exemplary WT-ITRs from different AAV serotypes. [Table 2-1] [Table 2-2]

[0169] In certain embodiments of the invention, the ceDNA vector does not have a WT-ITR consisting of a nucleotide sequence selected from any of the sequences in Table 2. According to some embodiments, the ceDNA vector does not have a WT-ITR consisting of a nucleotide sequence selected from any of SEQ ID NOs: 558-567, SEQ ID NO: 51, or SEQ ID NO: 1.

[0170] In alternative embodiments of the invention, when a ceDNA vector has a WT-ITR comprising a nucleotide sequence selected from any of SEQ ID NOs: 558-567, SEQ ID NO: 51, or SEQ ID NO: 1, the adjacent ITR is also WT and the cDNA comprises a regulatory switch, e.g., as disclosed herein. In some embodiments, the ceDNA vector comprises a regulatory switch as disclosed herein and the selected WT-ITR having a nucleotide sequence selected from any of SEQ ID NOs: 558-567, SEQ ID NO: 51, or SEQ ID NO: 1.

[0171] The ceDNA vectors described herein may contain a WT-ITR structure that retains operable RBE, trs, and RBE' portions. Figures 3A and 3B, using wild-type ITRs for illustrative purposes, show one possible mechanism for engineering the trs site within the wild-type ITR structure portion of a ceDNA vector. In some embodiments, the ceDNA vector contains one or more functional WT-ITR polynucleotide sequences that include a Rep-binding site (RBS, 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 531) for AAV2) and a terminal resolution site (TRS, 5'-AGTT (SEQ ID NO: 46)). In some embodiments, at least one WT-ITR is functional. In alternative embodiments, where the ceDNA vector contains two WT-ITRs that are substantially symmetrical to each other, at least one WT-ITR is functional and at least one WT-ITR is non-functional. In alternative embodiments, where the ceDNA vector comprises two modified ITRs that are substantially symmetrical to one another, at least one modified ITR is functional and at least one modified ITR is non-functional, these ceDNAs may include a regulatory switch, for example, as disclosed herein and described in further detail in Section V, below.

[0172] In some embodiments, the ceDNA vector does not have modified ITRs selected from any sequence consisting of or consisting essentially of SEQ ID NOs: 500-529, as provided herein. In some embodiments, the ceDNA vector does not have ITRs selected from any sequence selected from SEQ ID NOs: 500-529.

[0173] According to some embodiments, the ceDNA vector comprises SEQ ID NO:484 (ITR-33, left) and SEQ ID NO:469 (ITR-18, right); SEQ ID NO:485 (ITR-34, left) and SEQ ID NO:95 (ITR-51, right); SEQ ID NO:486 (ITR-35, left) and SEQ ID NO:470 (ITR-19, right); SEQ ID NO:487 (ITR-36, left) and SEQ ID NO:471 (ITR-20, right); SEQ ID NO:488 (ITR-37, left) and SEQ ID NO:472 (ITR-21, right); SEQ ID NO:489 (ITR-38, left) and SEQ ID NO:473 (ITR-22, right); SEQ ID NO:490 (ITR-39, left) and SEQ ID NO:474 (ITR-23, right); SEQ ID NO:491 (ITR-40, left) and SEQ ID NO:475 (ITR-24, right) ; SEQ ID NO: 492 (ITR-41, left) and SEQ ID NO: 476 (ITR-25, right); SEQ ID NO: 493 (ITR-42, left) and SEQ ID NO: 477 (ITR-26, right); SEQ ID NO: 494 (ITR-43, left) and SEQ ID NO: 478 (ITR-27, right); SEQ ID NO: 495 (ITR-44, left) and SEQ ID NO: 479 (ITR-28, right); SEQ ID NO: 496 (ITR-45, left) and SEQ ID NO: 480 (ITR-29, right); SEQ ID NO: 497 (ITR-46, left) and SEQ ID NO: 481 (ITR-30, right); SEQ ID NO: 498 (ITR-47, left) and SEQ ID NO: 482 (ITR-31, right); SEQ ID NO: 499 (ITR-48, left) and SEQ ID NO: 483 (ITR-32, right).

[0174] In one embodiment of each of these aspects, the ceDNA vector or non-viral capsid-free DNA vector with covalently closed ends comprises a pair of symmetric ITRs selected from ITRs comprising the partial ITR sequences shown in Figures 6B-21B, or selected from combinations of SEQ ID NO:101 and SEQ ID NO:102; SEQ ID NO:103 and SEQ ID NO:96; SEQ ID NO:105 and SEQ ID NO:106; SEQ ID NO:545 and SEQ ID NO:116; SEQ ID NO:111 and SEQ ID NO:112; SEQ ID NO:117 and SEQ ID NO:118; SEQ ID NO:119 and SEQ ID NO:120; SEQ ID NO:121 and SEQ ID NO:122; SEQ ID NO:107 and SEQ ID NO:108; SEQ ID NO:123 and SEQ ID NO:124; SEQ ID NO:125 and SEQ ID NO:126; SEQ ID NO:127 and SEQ ID NO:128; SEQ ID NO:129 and SEQ ID NO:130; SEQ ID NO:131 and SEQ ID NO:132; SEQ ID NO:133 and SEQ ID NO:134; SEQ ID NO:547 and SEQ ID NO:546.

[0175] In some embodiments, a ceDNA vector can include an ITR with a modification in the ITR corresponding to any of the modifications in the ITR sequences or ITR subsequences shown in Table 5 herein, or the sequences shown in Figures 7A-22B herein or in Tables 2, 3, 4, 5, 6, 7, 8, 9, or 10A-10B of PCT / US18 / 49996, filed September 7, 2018, and the adjacent ITR sequence is a mirror image (e.g., a reverse complement) or substantially a mirror image thereof.

[0176] In some embodiments, ceDNA can form intramolecular duplex secondary structures. By way of example only, the secondary structures of a first ITR and a symmetric second ITR are illustrated in the context of wild-type ITRs (see, e.g., Figures 2A, 2B, and 4C) and / or modified ITR structures (see, e.g., Figures 7A-22B). The secondary structures are inferred or predicted based on the ITR sequences of the plasmids used to produce the ceDNA vectors. Exemplary secondary structures of modified symmetric ITR pairs in which a portion of the stem-loop structure has been deleted are shown in Figures 7A-22B. Exemplary secondary structures of modified ITRs comprising a single stem and two loops are shown in Figures 10A-10B, 12A-12B, 13A-13B, and 13A-22B. Exemplary secondary structures of modified ITRs with a single stem and a single loop are shown in Figures 7A-7B (e.g., a single C-C' loop) and Figures 8A-8B (e.g., a single B-B' loop). Exemplary secondary structures of modified ITRs with a single stem instead of two loops are shown in Figures 11A-11B. In some embodiments, secondary structures can be predicted using nearest-neighbor thermodynamic methods, as shown herein, which predict structural stability as quantified by the folding free energy change. For example, structures can be predicted by finding the lowest free energy structure. In some embodiments, ITR structures can be predicted using the algorithm disclosed in Reuter, JS, & Mathews, DH (2010) RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics. 11, 129, and implemented in the RNAstructure software (available at the World Wide Web address "rna.urmc.rochester.edu / RNAstructureWeb / index.html"). This algorithm can also include both free energy change parameters at 37°C and enthalpy change parameters derived from experimental literature, allowing for the prediction of conformational stability at any temperature.Using RNAstructure software, several modified ITR structures can be predicted as modified T-shaped stem-loop structures with estimated Gibbs unfolding free energies (ΔG) under physiological conditions shown in Figures 7A-22B. Using RNAstructure software, three types of modified ITRs are predicted to have higher Gibbs unfolding free energies than the wild-type AAV2 ITR (-92.9 kcal / mol), and the single-arm / single-unpaired loop structure provided herein is predicted to have a Gibbs unfolding free energy in the range of -85 to -70 kcal / mol. (b) Modified ITRs with single hairpin structures provided herein are predicted to have a Gibbs unfolding free energy in the range of -70 to -40 kcal / mol. (c) Modified ITRs with two-arm structures provided herein are predicted to have a Gibbs unfolding free energy in the range of -90 to -70 kcal / mol. Without wishing to be bound by theory, structures with high Gibbs free energy are easier to unfold for replication by Rep68 or Rep78 replication proteins. Therefore, modified ITRs with high Gibbs unfolding free energy (e.g., single-arm / single-unpaired loop structure, single-hairpin structure, truncated structure) tend to be replicated more efficiently than wild-type ITRs.

[0177] In one embodiment, the left ITR of the ceDNA vector is modified or mutated relative to the wild-type AAV ITR structure, and the right ITR is a symmetrical (reverse complement) ITR with the same mutation. In one embodiment, the right ITR of the ceDNA vector is modified relative to the wild-type AAV ITR structure, and the left ITR is a symmetrical (reverse complement) ITR with the same mutation. In such an embodiment, the modification of the ITR (e.g., the left or right ITR) can be generated by deleting, inserting, or substituting one or more nucleotides from the wild-type ITR derived from the AAV genome.

[0178] The ITRs used herein can be degradable or non-degradable, and those selected for use in ceDNA vectors are preferably AAV sequences, with serotypes 1, 2, 3, 4, 5, 6, 7, 8, and 9 being preferred. Degradable AAV ITRs do not require wild-type ITR sequences (e.g., endogenous or wild-type AAV ITR sequences may be altered by insertion, deletion, truncation, and / or missense mutation), so long as the terminal repeats mediate the function of interest (e.g., replication, viral packaging, integration, and / or proviral rescue, etc.). Typically, although not necessarily, the ITRs are derived from the same AAV serotype. For example, both ITR sequences in a ceDNA vector are derived from AAV2. As discussed above, in some embodiments, the modified ITR pairs are substantially symmetrical in that they have a symmetrical three-dimensional spatial organization but do not have identical reverse-complementary nucleotide sequences. In such embodiments, each ITR of a modified ITR pair can be derived from a different serotype (e.g., AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12), such as a combination of AAV2 and AAV6, with modifications of one ITR mirrored in the corresponding position of the cognate ITR of a different serotype. In some embodiments, the modified ITR can be a synthetic sequence that functions as an AAV inverted terminal repeat, such as the "double D sequence" described in U.S. Patent No. 5,478,745 to Samulski et al.

[0179] In one embodiment, the ceDNA may comprise an ITR structure that is mutated with respect to one of the wild-type ITRs disclosed herein, but where the mutant or modified ITR still retains an operable Rep binding site (RBE or RBE') and terminal resolution site (trs). In one embodiment, the mutant ceDNA ITR comprises a functional replication protein site (RPS-1), and a replicative protein that binds to the RPS-1 site is used for production.

[0180] In one embodiment, at least one of the ITRs is defective with respect to Rep binding and / or Rep nicking. In one embodiment, the defect is at least 30% relative to the wild-type ITR, and in other embodiments, it is at least 35%, 50%, 65%, 75%, 85%, 90%, 95%, 98%, or completely lacking function, or any point in between. The host cell does not express viral capsid proteins, and the polynucleotide vector template lacks viral capsid-coding sequences. In one embodiment, the polynucleotide vector template and host cell lacking AAV capsid genes, and the resulting proteins, also do not encode or express capsid genes of other viruses. Additionally, in certain embodiments, the nucleic acid molecule also lacks AAV Rep protein-coding sequences.

[0181] In some embodiments, the structural element of an ITR can be any structural element involved in the functional interaction of an ITR with a large Rep protein (e.g., Rep78 or Rep68). In certain embodiments, the structural element provides selectivity for the interaction of an ITR with a large Rep protein, i.e., determines, at least in part, which Rep protein functionally interacts with the ITR. In other embodiments, the structural element physically interacts with a large Rep protein when the Rep protein is bound to the ITR. Each structural element can be, for example, the secondary structure of the ITR, the nucleotide sequence of the ITR, the space between two or more elements, or any combination of the above. In one embodiment, the structural element is selected from the group consisting of A and A' arms, B and B' arms, C and C' arms, D arm, Rep binding site (RBE) and RBE' (i.e., complementary RBE sequences), and terminal resolution site (trs).

[0182] More specifically, ITRs can be structurally modified. For example, the nucleotide sequence of a structural element can be modified compared to the wild-type sequence of an ITR. In one embodiment, structural elements of an ITR (e.g., A arm, A' arm, B arm, B' arm, C arm, C' arm, D arm, RBE, RBE', and trs) can be removed and replaced with wild-type structural elements from a different parvovirus. For example, the replacement structure can be from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, snake parvovirus (e.g., royal python parvovirus), bovine parvovirus, caprine parvovirus, avian parvovirus, canine parvovirus, equine parvovirus, shrimp parvovirus, porcine parvovirus, or insect AAV. For example, the ITRs can be AAV2 ITRs, with the A or A' arms or RBE replaced with structural elements from AAV5. In another example, the ITRs can be AAV5 ITRs, with the C or C' arms, RBE, and trs replaced with structural elements from AAV2. In another example, the AAV ITRs can be AAV5 ITRs, with the B and B' arms replaced with the AAV2 ITR B and B' arms.

[0183] By way of example only, Table 3 shows exemplary modifications (e.g., deletions, insertions, and / or substitutions) of at least one nucleotide in a region of a modified ITR, where X indicates the modification (e.g., deletion, insertion, and / or substitution) of at least one nucleic acid in that section relative to the corresponding wild-type ITR. In some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in any of the C and / or C' and / or B and / or B' regions retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. For example, if the modification results in either a single-arm ITR (e.g., a single C-C' arm or a single B-B' arm), or a modified C-B' arm or C'-B arm, or a two-arm ITR with at least one truncated arm (e.g., a truncated C-C' arm and / or a truncated B-B' arm), at least the single arm, or at least one of the arms of the two-arm ITR (one arm may be truncated), retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. In some embodiments, the truncated C-C' arm and / or the truncated B-B' arm has three consecutive T nucleotides (i.e., TTT) in the terminal loop.

[0184] Table 3 shows exemplary combinations of modifications (e.g., deletions, insertions, and / or substitutions) of at least one nucleotide for different B-B' and C-C' regions or arms of the ITR (X indicates a nucleotide modification, e.g., an addition, deletion, or substitution of at least one nucleotide in the region). [Table 3]

[0185] In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 3, as well as a modification of at least one nucleotide in any one or more of the regions selected from between A' and C, between C and C', between C' and B, between B and B', and between B' and A. In some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in the C or C' or B or B' region still preserves the terminal loop of the stem-loop. In some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide between C and C' and / or B and B' preserves three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. In alternative embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide between C and C' and / or B and B' preserves three consecutive A nucleotides (i.e., AAA) in at least one terminal loop. In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 3 and a modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in any one or more of the regions selected from the A', A, and / or D. For example, in some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 3 and also at least one modification (e.g., deletion, insertion, and / or substitution) in the A region. In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 3 and also at least one nucleotide modification (e.g., deletion, insertion, and / or substitution) in the A' region. In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 3 and also at least one nucleotide modification (e.g., deletion, insertion, and / or substitution) in the A and / or A' regions.In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 3, as well as a modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in the D region.

[0186] In one embodiment, the nucleotide sequence of a structural element can be modified (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides, or any range therein) to produce a modified structural element. In one embodiment, specific modifications to symmetric ITRs are exemplified herein (e.g., the pairs of symmetrically modified ITRs identified in Table 4).

[0187] In some embodiments, an ITR can be modified (e.g., by modifying 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides, or any range therein). In other embodiments, the ITR is a modified ITR of Table 4 (or SEQ ID NO:101 and SEQ ID NO:102; SEQ ID NO:103 and SEQ ID NO:96; SEQ ID NO:105 and SEQ ID NO:106; SEQ ID NO:545 and SEQ ID NO:116; SEQ ID NO:111 and SEQ ID NO:112; SEQ ID NO:117 and SEQ ID NO:118; SEQ ID NO:119 and SEQ ID NO:120; SEQ ID NO:121 and SEQ ID NO:122; SEQ ID NO:107 and SEQ ID NO:108; SEQ ID NO:123 and SEQ ID NO:124; SEQ ID NO:125 and SEQ ID NO:126; SEQ ID NO:127 and and the RBE-containing sections of the A-A' arms and the C-C' and B-B' arms of the symmetrically modified pair selected from the group consisting of SEQ ID NO:128; SEQ ID NO:129 and SEQ ID NO:130; SEQ ID NO:131 and SEQ ID NO:132; SEQ ID NO:133 and SEQ ID NO:134; SEQ ID NO:547 and SEQ ID NO:546, etc.

[0188] In some embodiments, modified ITRs can include, for example, removal or deletion of all of a particular arm, e.g., all or part of the A-A' arm, or all or part of the B-B' arm, or all or part of the C-C' arm, or removal of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs forming the stem of a loop (e.g., see ITR-6), so long as a final loop capping the stem (e.g., a single arm) is still present. In some embodiments, modified ITRs can include removal of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs from the B-B' arm. In some embodiments, modified ITRs can include removal of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs from the C-C' arm. In some embodiments, the modified ITR can include the deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs from the C-C' arm and the deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs from the B-B' arm. Any combination of base pair deletions is contemplated, for example, 6 base pairs in the C-C' arm and 2 base pairs in the B-B' arm can be deleted. An illustrative example is a modified ITR having at least 7 base pairs deleted from each of the C and C' portions, a substitution of a nucleotide in the loop between the C and C' regions, and the deletion of at least one base pair from each of the B and B' regions, such that the modified ITR comprises two arms in which at least one arm (e.g., C-C') is truncated. Note that in some instances, because the modified ITR includes the deletion of at least one base pair from each of the B and B' regions, the B-B' arm is also truncated relative to the WT ITR.

[0189] In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or more complementary base pairs are removed from each of the C and C' portions of the C-C' arm, thereby cleaving the C-C' arm. That is, when a base in the C portion of the C-C' arm is removed, a complementary base pair in the C' portion is removed, thereby cleaving the C-C' arm. In such embodiments, 2, 4, 6, 8, or more base pairs are removed from the C-C' arm, thereby cleaving the C-C' arm. In alternative embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs are removed from the C portion of the C-C' arm, thereby leaving only the C' portion of the arm. In alternative embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs are removed from the C' portion of the C-C' arm, thereby leaving only the C portion of the arm.

[0190] In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or more complementary base pairs are removed from each of the B and B' portions of the B-B' arm, thereby cleaving the B-B' arm. That is, when a base is removed from the B portion of the B-B' arm, a complementary base pair is removed from the B' portion, thereby cleaving the B-B' arm. In such embodiments, 2, 4, 6, 8, or more base pairs are removed from the B-B' arm, thereby cleaving the B-B' arm. In alternative embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs are removed from the B portion of the B-B' arm, thereby leaving only the B' portion of the arm. In alternative embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs are removed from the B' portion of the B-B' arm, thereby leaving only the B portion of the arm.

[0191] In some embodiments, the modified ITRs may have a 1-50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotide deletion relative to the full-length wild-type ITR sequence. In some embodiments, the modified ITRs may have a 1-30 nucleotide deletion relative to the full-length WT ITR sequence. In some embodiments, the modified ITRs have a 2-20 nucleotide deletion relative to the full-length wild-type ITR sequence.

[0192] In some embodiments, the modified ITR forms two opposing, symmetric stem-loops. For example, the C-C' loop is a different length from the B-B' loop. In some embodiments, one of the opposing, symmetric stem-loops of the modified ITR has a C-C' and / or B-B' stem portion ranging from 8 to 10 base pairs in length and a loop portion having 2 to 5 unpaired deoxyribonucleotides (e.g., between C-C' or B-B'). In some embodiments, one symmetric stem-loop of the modified ITR has a C-C' and / or B-B' stem portion less than 8, or less than 7, 6, 5, 4, 3, 2, or 1 base pairs in length, and a loop portion having 0 to 5 nucleotides (e.g., between C-C' or B-B'). In some embodiments, a modified ITR with an asymmetric stem-loop has a C-C' and / or B-B' stem portion less than 3 base pairs in length.

[0193] In some embodiments, the modified ITRs do not contain any nucleotide deletions in the RBE-containing portions of the A or A' regions so as not to interfere with DNA replication (e.g., binding to the RBE by Rep proteins or nicking at the terminal resolution site). In some embodiments, modified ITRs encompassed for use herein have one or more deletions in the B, B', C, and / or C regions described herein. Some non-limiting examples of modified ITRSs are shown in Figures 6B-21B.

[0194] In some embodiments, modified ITRs can include a deletion of the B-B' arm, leaving a C-C' arm. See, for example, exemplary ITR-33 (left) and ITR-18 (right) shown in Figures 7A-7B, or ITR-35 (left) and ITR-19 (right) (Figures 9A-9B). In some embodiments, modified ITRs can include a deletion of the C-C' arm, leaving a B-B' arm. See, for example, exemplary ITR-34 (left) and ITR-51 (right) shown in Figures 8A-8B. In some embodiments, modified ITRs can include a deletion of the B-B' arm and the C-C' arm, leaving a single stem-loop. See, for example, exemplary ITR-37 (left) and ITR-21 (right) shown in Figures 11A-11B. In some embodiments, the modified ITRs may include a deletion of the C' region, leaving a truncated C loop and B-B' arm. See, for example, ITR-36 (left) and ITR-20 (right) shown in Figures 10A-10B, ITR-42 (left) and ITR-26 (right) (Figures 16A-16B), ITR-43 (left) and ITR-27 (right) (Figures 17A-17B), ITR-44 (left) and ITR-28 (right) (Figures 18A-18B), ITR-45 (left) and ITR-29 (right) (Figures 19A-19B), ITR-46 (left) and ITR-23 (right) (Figures 20A-20B), ITR-47 (left) and ITR-31 (right) (Figures 21A-21B), and ITR-48 (left) and ITR-32 (right) (Figures 22A-22B). Similarly, in some embodiments, modified ITRs can include deletions of the B region, leaving a truncated B loop and C-C' arm. See, e.g., ITR-38 (left) and ITR-22 (right) shown in Figures 12A-12B, ITR-39 (left) and ITR-23 (right) (Figures 13A-13B), ITR-40 (left) and ITR-24 (right) (Figures 14A-14B), and ITR-41 (left) and ITR-25 (right) (Figures 15A-15B).

[0195] In some embodiments, modified ITRs can include deletion of base pairs in any one or more of the C, C', B, or B' portions, such that complementary base pairs occur between the C-B' and C'-B portions to generate a single arm. See, e.g., ITR-10 (right) and ITR-10 (left).

[0196] In some embodiments, in addition to modification of one or more nucleotides in the C, C', B, and / or B' regions, modified ITRs for use herein may include modification (e.g., deletion, substitution, or addition) of at least 1, 2, 3, 4, 5, or 6 nucleotides in one or more regions selected from between A' and C, between C and C', between C' and B, between B and B', and between B' and A. For example, the nucleotides between B' and C in the modified right ITR can be substituted from A to G, C, or A, deleted, or one or more nucleotides can be added. The nucleotides between C' and B in the modified left ITR can be changed from T to G, C, or A, deleted, or one or more nucleotides can be added.

[0197] In certain embodiments of the invention, the ceDNA vector does not have a modified ITR consisting of a nucleotide sequence selected from any of SEQ ID NOs: 550 to 557. In certain embodiments of the invention, the ceDNA vector does not have a modified ITR consisting of a nucleotide sequence selected from any of SEQ ID NOs: 550 to 557.

[0198] In some embodiments, the ceDNA vector comprises a regulatory switch as disclosed herein and a selected modified ITR having a nucleotide sequence selected from the group consisting of any of SEQ ID NOs: 550-557.

[0199] In another embodiment, the structure of the structural element may be modified. For example, the structural element may have a change in stem height and / or the number of nucleotides in the loop. For example, the stem height may be about 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or more, or any range therein. In one embodiment, the stem height may be about 5 nucleotides to about 9 nucleotides and may functionally interact with Rep. In another embodiment, the stem height may be about 7 nucleotides and may functionally interact with Rep. In another example, the loop may have a length of 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or more, or any range therein.

[0200] In another embodiment, the number of GAGY-binding sites or GAGY-related binding sites in an RBE or extended RBE can be increased or decreased. In one example, an RBE or extended RBE can contain 1, 2, 3, 4, 5, 6, or more GAGY-binding sites, or any range therein. Each GAGY-binding site can independently be the exact GAGY sequence or a sequence similar to GAGY, so long as the sequence is sufficient to bind to the Rep protein.

[0201] In another embodiment, the spacing between two elements (such as, but not limited to, an RBE and a hairpin) can be altered (e.g., increased or decreased) to alter functional interactions with a large Rep protein. For example, the spacing can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides or more, or any range therein.

[0202] Table 4 shows exemplary symmetrically modified ITR pairs (i.e., left-modified ITRs and symmetrically right-modified ITRs). The bold (red) portions of the sequences identify the partial ITR sequences (i.e., the sequences of the A-A', C-C', and B-B' loops) that are also shown in Figures 7A-22B. These exemplary modified ITRs can include an RBE GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 531), a spacer ACTGAGGC (SEQ ID NO: 532), a spacer complement GCCTCAGT (SEQ ID NO: 535), and an RBE' (i.e., a complement to the RBE) GAGCGAGCGAGCGCGC (SEQ ID NO: 536). [Table 4-1] [Table 4-2] [Table 4-3]

[0203] In an embodiment of the present invention, the ceDNA vector disclosed herein does not have a modified ITR having a nucleotide sequence selected from any of the group of SEQ ID NOs: 550, 551, 552, 553, 553, 554, 555, 556, and 557.

[0204] IV. Regulatory Elements ceDNA vectors can be produced from expression constructs that further contain a specific combination of cis-regulatory elements. Cis-regulatory elements include, but are not limited to, promoters, riboswitches, insulators, mir regulatory elements, post-transcriptional regulatory elements, tissue- and cell-type-specific promoters, and enhancers. In some embodiments, ITRs can act as promoters for transgenes. In some embodiments, ceDNA vectors contain additional components for regulating the expression of transgenes, such as regulatory switches described herein, which regulate the expression of transgenes or kill switches that can kill cells containing ceDNA vectors.

[0205] ceDNA vectors can be produced from expression constructs that further include specific combinations of cis-regulatory elements, such as the WHP posttranscriptional regulatory element (WPRE) (e.g., SEQ ID NO: 8) and BGH polyA (SEQ ID NO: 9). Suitable expression cassettes for use in expression constructs are not limited by packaging constraints imposed by viral capsids.

[0206] Promoter: The expression cassettes of the present invention contain promoters that can affect cell specificity as well as overall expression levels. In the case of transgene expression, they can include highly active viral-derived immediate early promoters. The expression cassettes can contain tissue-specific eukaryotic promoters to restrict transgene expression to specific cell types and reduce toxic effects and immune responses resulting from unregulated ectopic expression.

[0207] Suitable promoters, including those described above, can be derived from viruses and therefore can be referred to as viral promoters, or they can be derived from any organism, including prokaryotes or eukaryotes. Suitable promoters can be used to drive expression by any RNA polymerase (e.g., pol I, pol II, pol III). Exemplary promoters include, but are not limited to, the SV40 early promoter, the mouse mammary tumor virus long terminal sequence (LTR) promoter, the adenovirus major late promoter (Ad MLP); the herpes simplex virus (HSV) promoter, the cytomegalovirus (CMV) promoter, such as the CMV immediate early promoter region (CMVIE), the Rous sarcoma virus (RSV) promoter, the human U6 micronucleus promoter (U6, e.g., SEQ ID NO: 18) (Miyagishi et al., Nature Biotechnology 20, 497-500 (2002)), the enhanced U6 promoter (e.g., Xia et al., Nucleic Acids Res. 2003 Sep. 1; 31 (17)), the human H1 promoter (H1) (e.g., SEQ ID NO: 19), the CAG promoter, the human alpha 1-antitypsin (hAAT) promoter (e.g., SEQ ID NO: 21), and the like. In embodiments, these promoters are modified at their downstream intron-containing ends to include one or more nuclease cleavage sites. In embodiments, the DNA containing the nuclease cleavage site(s) is exogenous to the promoter DNA.

[0208] According to some embodiments, promoters can further enhance expression and / or alter their spatial and / or temporal expression by including one or more specific transcriptional regulatory sequences. Promoters can also include distal enhancer or repressor elements, which can be located thousands of base pairs away from the start site of transcription. Promoters can be derived from sources including viruses, bacteria, fungi, plants, insects, and animals. Promoters can regulate the expression of genetic components constitutively or differentially with respect to the cell, tissue, or organ in which expression occurs, with respect to the developmental stage in which expression occurs, or in response to external stimuli such as physiological stress, pathogens, metal ions, or inducers. Representative examples of promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV40 late promoter and CMV IE promoter, as well as the promoters listed below. Such promoters and / or enhancers can be used to express any gene of interest, such as a gene editing molecule, a donor sequence, a therapeutic protein, etc. For example, the vector can include a promoter operably linked to a nucleic acid sequence encoding a therapeutic protein. The promoter operably linked to the therapeutic protein coding sequence can be a promoter derived from Simian Virus 40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter, such as a bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter, such as a CMV immediate early promoter, an Epstein-Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter.The promoter may also be a promoter from a human gene, such as human ubiquitin C (hUbC), human actin, human myosin, human hemoglobin, human muscle creatine, or human metallothionein. The promoter may also be a natural or synthetic tissue-specific promoter, for example, a liver-specific promoter, for example, human alpha 1-antithymidine (hAAT). In one embodiment, delivery to the liver may be achieved using endogenous ApoE-specific targeting of a composition comprising a ceDNA vector to hepatocytes via the low-density lipoprotein (LDL) receptor present on the surface of hepatocytes.

[0209] In one embodiment, the promoter used is the native promoter of the gene encoding the therapeutic protein.The promoter and other regulatory sequences of each gene encoding the therapeutic protein are known and characterized.The promoter region used may further comprise one or more additional regulatory sequences (e.g., native), such as enhancers (e.g., SEQ ID NO: 22 and SEQ ID NO: 23).

[0210] Non-limiting examples of suitable promoters for use in accordance with the present invention include, for example, the CAG promoter (SEQ ID NO: 3), the hAAT promoter (SEQ ID NO: 21), the human EF1-α promoter (SEQ ID NO: 6), or a fragment of the EF1a promoter (SEQ ID NO: 15), the IE2 promoter (e.g., SEQ ID NO: 20), and the rat EF1-α promoter (SEQ ID NO: 24).

[0211] According to some embodiments, the expression cassette may contain a synthetic regulatory element such as the CAG promoter (SEQ ID NO: 3). The CAG promoter includes (i) a cytomegalovirus (CMV) early enhancer element, (ii) the promoter, the first exon and first intron of the chicken β-actin gene, and (iii) the splice acceptor of the rabbit β-globin gene. Alternatively, the expression cassette may contain the hAAT promoter (SEQ ID NO: 21), the alpha-1-antitrypsin (AAT) promoter (SEQ ID NO: 4 or SEQ ID NO: 74), the liver-specific (LP1) promoter (SEQ ID NO: 5 or SEQ ID NO: 16), the human elongation factor-1 alpha (EF1a) promoter or a fragment thereof (e.g., SEQ ID NO: 6 or SEQ ID NO: 15), the rat EF1a promoter (SEQ ID NO: 24), or the IE2 promoter (SEQ ID NO: 20). In some embodiments, the expression cassette comprises one or more constitutive promoters, such as the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with an RSV enhancer), or the cytomegalovirus (CMV) immediate early promoter (optionally with a CMV enhancer, e.g., SEQ ID NO: 22). Alternatively, an inducible promoter, the transgene's native promoter, a tissue-specific promoter, or various promoters known in the art can be used.

[0212] Polyadenylation sequence: A sequence encoding a polyadenylation sequence can be included in a ceDNA vector to stabilize mRNA expressed from the ceDNA vector and to aid in nuclear transport and translation. In one embodiment, the ceDNA vector does not contain a polyadenylation sequence. In other embodiments, the vector contains at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 45, at least 50 or more adenine dinucleotides. In some embodiments, the polyadenylation sequence contains about 43 nucleotides, about 40-50 nucleotides, about 40-55 nucleotides, about 45-50 nucleotides, about 35-50 nucleotides, or any range therebetween.

[0213] Expression cassettes can include polyadenylation sequences known in the art or variations thereof, such as naturally occurring sequences isolated from bovine BGHpA (e.g., SEQ ID NO: 74) or viral SV40pA (e.g., SEQ ID NO: 10), or synthetic sequences (e.g., SEQ ID NO: 27). Some expression cassettes can also include an SV40 late polyA signal upstream enhancer (USE) sequence. In some embodiments, a USE can be used in combination with SV40pA or a heterologous polyA signal.

[0214] The expression cassette may also contain post-transcriptional elements to increase transgene expression. In some embodiments, the woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE) (e.g., SEQ ID NO: 8) is used to increase transgene expression. Other post-transcriptional processing elements, such as those from the thymidine kinase gene of herpes simplex virus or hepatitis B virus (HBV), can be used. A secretory sequence can be linked to the transgene, for example, the VH-02 and VK-A26 sequences, e.g., SEQ ID NO: 25 and SEQ ID NO: 26.

[0215] In one embodiment, the host cell does not express viral capsid proteins, and the polynucleotide vector template lacks any viral capsid-encoding sequence. In one embodiment, the polynucleotide vector template lacks the AAV capsid gene, but also the capsid genes of other viruses). In one embodiment, the nucleic acid molecule also lacks the AAV Rep protein-encoding sequence. Thus, in some embodiments, the nucleic acid molecule of the present invention lacks both functional AAV cap and AAV rep genes.

[0216] V. Adjustment switch A molecular regulatory switch is one that generates a measurable change in state in response to a signal. Such regulatory switches can be usefully combined with the ceDNA vectors described herein to control the output of the ceDNA vector. In some embodiments, the ceDNA vector includes a regulatory switch that serves to fine-tune the expression of a transgene. For example, it can serve as a biological containment function for the ceDNA vector. In some embodiments, the switch is an "on / off" switch designed to start or stop (i.e., shut down) the controllable and regulatable expression of a gene of interest in the ceDNA vector. In some embodiments, the switch can include a "kill switch" that, once activated, can instruct cells containing the ceDNA vector to undergo programmed cell death.

[0217] A. Binary adjustment switch In some embodiments, the ceDNA vector comprises a regulatory switch that can controllably adjust the expression of the transgene.In such embodiments, the expression cassette located between the ITRs of the ceDNA vector can additionally comprise a regulatory region, such as a promoter, a cis-element, a repressor, an enhancer, etc., operably linked to the gene of interest, and this regulatory region is regulated by one or more cofactors or exogenous agents.Therefore, in one embodiment, the transcription and expression of the gene of interest from the ceDNA vector only occurs when one or more cofactors or exogenous agents are present in the cell.In another embodiment, the transcription and expression of the gene of interest can be derepressed using one or more cofactors or exogenous agents.

[0218] Any nucleic acid regulatory region known by those skilled in the art can be used in a ceDNA vector designed to contain a regulatory switch. By way of example only, the regulatory region can be regulated by a small molecule switch or an inducible or repressible promoter. Non-limiting examples of inducible promoters include hormone-inducible or metal-inducible promoters. Other exemplary inducible promoter / enhancer elements include, but are not limited to, RU486-inducible promoters, ecdysone-inducible promoters, rapamycin-inducible promoters, and metallothionein promoters. Exemplary tetracycline-based or other antibiotic-based switches are encompassed for use, including those disclosed in (Fussenegger et al., Nature Biotechnol. 18:1203-1208 (2000)).

[0219] B. Small Molecule Regulatory Switches Various small molecule-based regulatory switches known in the art can be combined with the ceDNA vectors known in the art and disclosed herein to form a ceDNA vector controlled by the regulatory switch. In some embodiments, the regulatory switch is an orthogonal ligand / nuclear receptor pair, such as retinoid receptor mutants / LG335 and GRQCIMFI (with an artificial promoter controlling the expression of an operably linked transgene, such as that disclosed in Taylor, et al., BMC Biotechnology 10 (2010): 15); an engineered steroid receptor, such as a modified progesterone receptor with a C-terminal truncation that cannot bind progesterone but binds RU486 (mifepristone) (U.S. Patent No. 5,364,791); the ecdysone receptor from Drosophila and its ecdysteroid ligands (Saez, et al., PNAS, 97 (26) (2000), 14512-14517), or Sando R 3 rd ; Nat Methods. 2013, 10(11):1085-8; and any one or combination of switches controlled by the antibiotic trimethoprim (TMP) disclosed therein.

[0220] Other small molecule-based regulatory switches known by those skilled in the art are also contemplated for use in controlling transgene expression in ceDNA, including those disclosed in Buskirk et al., Cell; Chem and Biol., 2005; 12(2); 151-161; abscisic acid-sensitive ON switches, such as those disclosed in Liang, F.-S., et al., (2011) Science Signaling, 4(164); exogenous L-arginine-sensitive ON switches, such as those disclosed in Hartenbach, et al. Nucleic Acids Research, 35(20), 2007; synthetic bile acid-sensitive ON switches, such as those disclosed in Rossger et al., Metab Eng. 2014, 21:81-90; and biotin-sensitive ON switches, such as those disclosed in Weber et al., Metab. Eng. 2009. Mar;11(2):117-124; dual-input food additive benzoate / vanillin-sensitive regulatory switches, such as those disclosed in Xie et al., Nucleic Acids Research, 2014;42(14);e116; 4-hydroxytamoxifen-sensitive switches, such as those disclosed in Giuseppe et al., Molecular Therapy, 6(5),653-663; and flavinoid (phloretin)-sensitive regulatory switches, such as those disclosed in Gitzinger et al., Proc. Natl. Acad. Sci. US A. 2009 Jun 30;106(26):10638-10643.

[0221] In some embodiments, the regulatory switch for controlling the transgene expressed by the ceDNA vector is a prodrug activation switch, such as those disclosed in U.S. Pat. Nos. 8,771,679 and 6,339,070.

[0222] Exemplary regulatory switches for use in ceDNA vectors include, but are not limited to, those in Table 5.

[0223] C. "Passcode" adjustment switch In some embodiments, the regulatory switch may be a "passcode switch" or "passcode circuit." Passcode switches allow for fine-tuning of the control of transgene expression from a ceDNA vector when specific conditions occur. That is, a combination of conditions must be present for transgene expression and / or repression to occur. For example, at least conditions A and B must occur for transgene expression to occur. A passcode regulatory switch may be any number of conditions, e.g., at least two, or at least three, or at least four, or at least five, or at least six, or at least seven or more conditions must be present for transgene expression to occur. In some embodiments, at least two conditions (e.g., conditions A and B) must occur, and in some embodiments, at least three conditions (e.g., conditions A, B, and C or A, B, and D) must occur. By way of example only, conditions A, B, and C must be present for gene expression from a ceDNA having a passcode "ABC" regulatory switch to occur. Conditions A, B, and C may be as follows: Condition A is the presence of a pathology or disease, Condition B is a hormonal response, and Condition C is a response to transgene expression. As merely illustrative examples, if the transgene is insulin, condition A occurs when the subject has diabetes, condition B occurs when blood sugar levels are high, and condition C is when endogenous insulin levels are not expressed in the required amount. When sugar levels decrease or a desired level of insulin is achieved, the transgene (e.g., insulin) is turned off again and turned back on until one of the three conditions occurs. In another illustrative example, if the transgene is EPO, condition A is the presence of chronic kidney disease (CKD), condition B occurs when the subject has hypoxia in the kidney, and condition C is when erythropoietin-producing cell (EPC) mobilization in the kidney is insufficient, or alternatively, when HIF-2 activation is insufficient. When oxygen levels increase or a desired level of EPO is achieved, the transgene (e.g., EPO) is turned off again and turned back on until one of the three conditions occurs.

[0224] Passcode regulatory switches are useful for fine-tuning transgene expression from ceDNA vectors. For example, passcode regulatory switches can be modular in that they include multiple switches, such as tissue-specific, inducible promoters that are turned on only in the presence of certain levels of a metabolite. In such embodiments, for transgene expression from the ceDNA vector to occur, an inducer must be present in the desired cell type (condition B) (condition A), and the metabolite must be above or below a certain threshold (condition C). In alternative embodiments, passcode regulatory switches can be designed such that transgene expression is on when conditions A and B are present, but off when condition C is present. Such embodiments are useful when condition C occurs as a direct result of an expressed transgene. That is, condition C acts as a positive feedback loop to turn off transgene expression from the ceDNA vector when the transgene has a sufficient amount of the desired therapeutic effect.

[0225] In some embodiments, a passcode regulatory switch included for use in a ceDNA vector is disclosed in WO 2017 / 059245, which describes a switch referred to as a "passcode switch," or "passcode circuit," or "passcode kill switch," which is a synthetic biological circuit that uses hybrid transcription factors (TFs) to engineer complex environmental requirements for cell survival. The passcode regulatory switch described in WO 2017 / 059245 is particularly useful for use in ceDNA vectors because it is modular and customizable, both in terms of the environmental conditions that control circuit activation and the output module that controls cell fate. Furthermore, passcode circuits are particularly useful for use in ceDNA vectors because, without the appropriate "passcode" molecule, transgene expression is only possible when the required predetermined conditions are present. If the cell encounters a problem or if further transgene expression is no longer desired for some reason, an associated kill switch (i.e., a deadman switch) can be triggered.

[0226] In some embodiments, the passcode regulatory switches or "passcode circuits" included for use in ceDNA vectors comprise hybrid transcription factors (TFs) to expand the range and complexity of environmental signals used to define biological containment conditions. Unlike deadman switches, which trigger cell death in the presence of predetermined conditions, "passcode circuits" allow cell survival or transgene expression when a particular "passcode" is present, and can be easily reprogrammed to allow transgene expression and / or cell survival only when a given environmental condition or passcode is present.

[0227] In one embodiment, a "passcode" system for restricting cell growth to the presence of a predetermined set of at least two selected drugs comprises one or more nucleic acid constructs encoding expression modules including: i) a toxin expression module encoding a toxin that is toxic to host cells, wherein the toxin-encoding sequence is operably linked to a promoter P1 that is repressed by the binding of a first hybrid repressor protein, hRP1; and ii) a first hybrid repressor protein expression module encoding a first hybrid repressor protein, hRP1, wherein expression of hRP1 is controlled by an AND gate formed by two hybrid transcription factors, hTF1 and hTF2, whose binding or activity is responsive to drugs A1 and A2, such that both drugs A1 and A2 are required for expression of hRP1; and wherein the absence of either A1 or A2 results in insufficient expression of hRP1 to repress the toxin promoter module P1 and toxin production, resulting in death of the host cell. In this system, the hybrid factors hTF1, hTF2, and hRP1 each contain an environmental sensing module from one transcription factor and a DNA recognition module from a different transcription factor, which makes the binding of their respective pathway regulatory switches sensitive to the presence of environmental substances A1 or A2, different from those to which each subunit normally binds naturally.

[0228] Thus, a ceDNA vector can contain a "passcode regulatory circuit" that requires the presence and / or absence of a specific molecule to activate the output module. In some embodiments, in which a gene encoding a cytotoxin is placed in the output module, this passcode regulatory circuit can be used not only to regulate transgene expression, but also to create a kill-switch mechanism in which the circuit kills a cell if the cell behaves in an undesirable manner (e.g., leaves a specific environment defined by the sensor domain or differentiates into another cell type). In one non-limiting example, the modularity of the hybrid transcription factors, circuit architecture, and output module allows the circuit to be reconfigured to sense and respond to other environmental signals in other ways, and to control other functions within the cell in addition to induced cell death, as understood in the art.

[0229] Any and all combinations of the regulatory switches disclosed herein, such as small molecule switches, nucleic acid-based switches, small molecule-nucleic acid hybrid switches, post-transcriptional transgene-regulated switches, post-translational regulated radiation-controlled switches, hypoxia-mediated switches, and other regulatory switches disclosed herein and known to those of skill in the art, can be used in the passcode regulatory switches disclosed herein. Regulatory switches encompassed for use are also discussed in the review article Kis et al., JR Soc Interface. 12:20141000 (2015) and summarized in Table 1 of Kis. In some embodiments, regulatory switches for use in the passcode system can be selected from any of the switches in Table 5, or combinations thereof.

[0230] D. Nucleic Acid-Based Regulatory Switches for Controlling Transgene Expression In some embodiments, the regulatory switch for controlling the transgene expressed by ceDNA is based on nucleic acid-based control mechanism.Exemplary nucleic acid control mechanism is known in the art and can be used.For example, such mechanism includes riboswitch, for example, those disclosed in US2009 / 0305253, US2008 / 0269258, US2017 / 0204477, WO2018 / 026762A1, U.S. Patent No. 9,222,093 and European Patent Application No. EP288071, and those disclosed in the review by Villa JK et al., Microbiol Spectr.2018 May;6(3).Also included are metabolite-responsive transcriptional biosensors, such as those disclosed in WO2018 / 075486 and WO2017 / 147585. Other mechanisms known in the art that may be used include silencing transgenes with siRNA or RNAi molecules (e.g., miR, shRNA). For example, a ceDNA vector may contain a regulatory switch encoding an RNAi molecule that is complementary to the transgene expressed by the ceDNA vector. If such an RNAi is expressed even when the transgene is expressed by the ceDNA vector, the transgene will be silenced by the complementary RNAi molecule; if the RNAi is not expressed when the transgene is expressed by the ceDNA vector, the transgene will not be silenced by the RNAi. Examples of such RNAi molecules that control gene expression or serve as regulatory switches are disclosed in US2017 / 0183664. In some embodiments, the regulatory switch comprises a repressor that blocks the expression of the transgene from the ceDNA vector. In some embodiments, the on / off switch is a small transcription activating RNA (STAR)-based switch, such as those disclosed in Chappell J. et al., Nat Chem Biol. 2015 Mar;11(3):214-20; and Chappell et al., Microbiol Spectr. 2018 May;6(3).In some embodiments, the adjustment switch is a toe-hold switch as disclosed in US2009 / 0191546, US2016 / 0076083, WO2017 / 087530, US2017 / 0204477, WO 2017 / 075486, and Green et al, Cell, 2014;159(4);925-939.

[0231] In some embodiments, the regulatory switch is a tissue-specific self-inactivating regulatory switch, e.g., as disclosed in US2002 / 0022018, whereby the regulatory switch purposefully switches off transgene expression in sites where transgene expression would otherwise be detrimental. In some embodiments, the regulatory switch is a recombinase reversible gene expression system, e.g., as disclosed in US2014 / 0127162 and U.S. Patent No. 8,324,436.

[0232] In some embodiments, the regulatory switch for controlling the transgene or gene of interest that is expressed by ceDNA vector is the hybrid of nucleic acid-based control mechanism and small molecule regulatory system.Such system is well known to those skilled in the art and is intended for use herein.Examples of such regulatory switch include but are not limited to LTRi system or " Lac-Tet-RNAi " system, as disclosed in, for example, US2010 / 0175141 and DEANS T.ET AL., CELL.,2007,130(2);363-372, WO2008 / 051854 and US Patent No. 9,388,425.

[0233] In some embodiments, the regulatory switch for controlling the transgene or gene of interest expressed by the ceDNA vector involves circular permutation, as disclosed in U.S. Patent No. 8,338,138. In such embodiments, the molecular switch is multistable, i.e., can switch between at least two states, or bistable, i.e., can be either "on" or "off," e.g., can emit light or not, can bind or not, can catalyze or not, can transfer electrons or not, etc. In another aspect, the molecular switch uses fusion molecules, so the switch can switch between three or more states. For example, in response to a specific threshold state exhibited by the insert sequence or acceptor sequence, each other sequence in the fusion can exhibit a range of states (e.g., a range of binding activity, a range of enzyme catalysis, etc.). Thus, rather than switching from "on" or "off," the fusion molecule can exhibit a graded response to a stimulus.

[0234] In some embodiments, the nucleic acid-based regulatory switch can be selected from any of the switches in Table 5 or a combination thereof.

[0235] E. Post-transcriptional and post-translational regulatory switches In some embodiments, the regulatory switch for controlling the transgene or gene of interest expressed by ceDNA vector is a post-transcriptional modification system.For example, such regulatory switch can be an aptazyme riboswitch that is sensitive to tetracycline or theophylline, as disclosed in US2018 / 0119156, GB2011 / 07768, WO2001 / 064956A3, EP2707487, and Beilstein et al., ACS Synth.Biol.,2015,4(5),pp 526-534, Zhong et al., Elife.2016 Nov 2;5.pii:e18858.In some embodiments, it is assumed that a person skilled in the art can code both the transgene and the inhibitory siRNA that contains a ligand-sensitive (off-switch) aptamer, and the final result is a ligand-sensitive on-switch.

[0236] In some embodiments, the regulatory switch for controlling the transgene or gene of interest expressed by ceDNA vector is a post-translational modification system.In alternative embodiments, the gene or protein of interest is expressed as a proprotein or preproprotein, or has a signal response element (SRE) or destabilization domain (DD) attached to the expressed protein, thereby preventing correct protein folding and / or activity until post-translational modification occurs.In the case of a destabilization domain (DD) or SRE, the destabilization domain is cleaved after translation in the presence of exogenous drugs or small molecules.Those skilled in the art can utilize the control method disclosed in U.S. Patent No. 8,173,792 and PCT Application No. WO2017180587. Other post-transcriptional regulatory switches contemplated for use in ceDNA vectors to control the activity of functional transgenes are disclosed in Rakhit et al., Chem Biol. 2014;21(9):1238-52 and Navarro et al., ACS Chem Biol. 2016;19;11(8):2101-2104A.

[0237] In some embodiments, the regulatory switch for controlling the transgene or gene of interest expressed by ceDNA vector is a post-translational modification system that incorporates ligand-sensitive intein into transgene coding sequence, thereby inhibiting transgene or expressed protein before splicing.For example, this has been demonstrated using both 4-hydroxytamoxifen and thyroid hormone (see, for example, U.S. Patent No. 7,541,450, U.S. Patent No. 9,200,045, U.S. Patent No. 7,192,739, Buskirk, et al., Proc Natl Acad Sci US A.2004 Jul 20;101(29):10505-10510, ACS Synth Biol.2016 Dec 16;5(12):1475-1484 and 2005 Feb;14(2):523-532 Feb;14(2):523-532). In some embodiments, the nucleic acid-based regulatory switch can be selected from any of the switches in Table 5 or a combination thereof.

[0238] F. Other Exemplary Adjustment Switches Any known regulatory switch can be used in ceDNA vector to control the gene expression of the transgene expressed by ceDNA vector, including those triggered by environmental changes. Additional examples include, but are not limited to, the BOC method of Suzuki et al., Scientific Reports 8;10051(2018), genetic code expansion and non-physiological amino acid, radiation-controlled or ultrasound-controlled on / off switch (see, for example, Scott S et al., Gene Ther.2000 July;7(13):1121-5, U.S. Patent Nos. 5,612,318, 5,571,797, 5,770,581, 5,817,636, and WO1999 / 025385A1). In some embodiments, the regulatory switch is controlled by an implantable system, e.g., as disclosed in U.S. Pat. No. 7,840,263, US2007 / 0190028A1, and gene expression is controlled by one or more forms of energy, including electromagnetic energy, that activate a promoter operably linked to a transgene in a ceDNA vector.

[0239] In some embodiments, the regulatory switch envisioned for use in the ceDNA vector is a hypoxia-mediated or stress-activated switch, such as those disclosed in WO1999 / 060142A2, U.S. Patent Nos. 5,834,306, 6,218,179, 6,709,858, US2015 / 0322410, Greco et al., (2004) Targeted Cancer Therapies 9, S368, as well as FROG, TOAD, and NRSE elements, and conditionally inducible silence elements (e.g., hypoxia response element (HRE), inflammatory response element (IRE), and shear stress activation element (SSAE) disclosed in U.S. Patent No. 9,394,526). Such embodiments are useful for turning on the expression of transgenes from ceDNA vectors after ischemia or in ischemic tissues and / or tumors.

[0240] In some embodiments, the regulatory switch contemplated for use in the ceDNA vector is an optogenetic (e.g., light-controlled) regulatory switch, such as one of the switches reviewed in Polesskaya et al., BMC Neurosci. 2018;19(Suppl 1):12, and is also contemplated for use herein. In such embodiments, the ceDNA vector may contain genetic elements that are light-sensitive and capable of regulating transgene expression in response to visible wavelengths (e.g., blue, near-infrared). ceDNA vectors containing optogenetic regulatory switches are useful for expressing transgenes in locations of the body that can receive a light source, such as the skin, eyes, and muscles, and can also be used when the ceDNA vector expresses a transgene in internal organs and tissues where a light signal can be provided by suitable means (e.g., an implantable device as disclosed herein). Such optogenetic regulatory switches include light-responsive elements, or light-induced transcriptional effectors (LITEs) (disclosed, for example, in 2014 / 0287938), the Light-On system (disclosed, for example, in Wang et al., Nat Methods. 2012 Feb 12;9(3):266-9, which has been reported to allow in vivo control of expression of the insulin transgene, the Cry2 / CIB1 system (disclosed, for example, in Kennedy et al., Nature Methods;7,973-975 (2010)), and the FKF1 / GIGANTEA system (disclosed, for example, in Yazawa et al., Nat Biotechnol. 2009 Oct;27(10):941-5).

[0241] G. Kill Switch Another embodiment of the present invention relates to a ceDNA vector comprising a kill switch. The kill switch disclosed herein can cause cells containing the ceDNA vector to be killed or undergo programmed cell death as a means of permanently removing the introduced ceDNA vector from a subject's system. Those skilled in the art will understand that the use of a kill switch in the ceDNA vector of the present invention is typically linked to targeting the ceDNA vector to a limited number of cells that a subject can tolerately lose, or to a cell type (e.g., cancer cells) for which apoptosis is desired. In all aspects, the "kill switch" disclosed herein is designed to result in rapid and robust cell killing of cells containing the ceDNA vector in the absence of an input survival signal or other specified condition. In other words, the kill switch encoded by the ceDNA vector herein can restrict cell survival of cells containing the ceDNA vector to an environment defined by a specific input signal. Such a kill switch serves as a biological containment function when it is desirable to remove the ceDNA vector from a subject or ensure that the encoded transgene is not expressed. Thus, the kill switch is a synthetic biological circuit within the ceDNA vector that links an environmental signal to the conditional survival of cells containing the ceDNA vector. In some embodiments, different ceDNA vectors can be designed with different kill switches, allowing control over which transgene-expressing cells are killed when a cocktail of ceDNA vectors is used.

[0242] In some embodiments, a ceDNA vector can include a kill switch, a modular biological containment circuit. In some embodiments, a kill switch incorporated for use in a ceDNA vector is disclosed in WO 2017 / 059245, which describes a switch called a "deadman kill switch" that includes a mutually inhibitory arrangement of at least two repressible sequences such that an environmental signal represses the activity of a second molecule in the construct (e.g., using a small molecule-binding transcription factor to create a "survival" state due to the suppression of toxin production). In cells containing a ceDNA vector containing a deadman kill switch, loss of the environmental signal permanently switches the circuit to a "dead" state, derepressing the toxin, resulting in the production of the toxin and killing the cell. In another embodiment, a synthetic biological circuit called a "passcode circuit" or "passcode kill switch" is provided that uses hybrid transcription factors (TFs) to construct complex environmental requirements for cell survival. The deadman and passcode kill switches described in WO2017 / 059245 are particularly useful for use with ceDNA vectors because they are modular and customizable, both in terms of the environmental conditions that control circuit activation and the output modules that control cell fate. By appropriate selection of toxins, including but not limited to endonucleases such as EcoRI, the passcode circuits present in the ceDNA vector can be used to not only kill host cells containing the ceDNA vector, but also to degrade their genomes and accompanying plasmids.

[0243] Other kill switches known to those of skill in the art are encompassed for use in the ceDNA vectors as disclosed herein, e.g., those disclosed in US2010 / 0175141, US2013 / 0009799, US2011 / 0172826, US2013 / 0109568, as well as the kill switches disclosed in Jusiak et al, Reviews in Cell Biology and molecular Medicine;2014;1-56, Kobayashi et al., PNAS,2004;101;8419-9, Marchisio et al., Int. Journal of Biochem and Cell Biol.,2011;43;310-319, and Reinshagen et al., Science Translational Medicine,2018,11.

[0244] Thus, in some embodiments, the ceDNA vector can include a kill-switch nucleic acid construct comprising a nucleic acid encoding an effector toxin or reporter protein, where expression of the effector toxin (e.g., death protein) or reporter protein is controlled by a predetermined condition. For example, the predetermined condition can be the presence of an environmental substance, e.g., an exogenous substance, without which the cell will by default express the effector toxin (e.g., death protein) and be killed. In an alternative embodiment, the predetermined condition is the presence of two or more environmental substances, e.g., the cell will survive only if two or more necessary exogenous substances are provided, and in the absence of either, the cell containing the ceDNA vector will be killed.

[0245] In some embodiments, the ceDNA vector is modified to incorporate a kill switch that destroys cells containing the ceDNA vector, effectively terminating the in vivo expression of the transgene expressed by the ceDNA vector (e.g., a therapeutic gene, protein, or peptide). Specifically, the ceDNA vector is further engineered to express a switch protein that does not function in mammalian cells under normal physiological conditions. Only upon administration of a drug or environmental condition that specifically targets this switch protein are cells expressing the switch protein destroyed, thereby terminating the expression of the therapeutic protein or peptide. For example, it has been reported that cells expressing HSV-thymidine kinase can be killed by administering drugs such as ganciclovir and cytosine deaminase. See, for example, Dey and Evans, "Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK)," in "Targets in Gene Therapy," edited by You (2011), and Beltinger et al., "Proc. Natl. Acad. Sci. USA 96(15):8699-8704 (1999)." In some embodiments, the ceDNA vector can include an siRNA kill switch called DISE (death by excision) (Murmann et al., Oncotarget. 2017;8:84643-84658. Induction of DISE in ovarian cancer cells in vivo).

[0246] In some embodiments, a deadman kill switch is a biological circuit or system that sensitizes a cellular response to a predetermined condition, such as the absence of an exogenous agent, in the cell growth environment. Such a circuit or system can include a nucleic acid construct that includes an expression module that forms a deadman regulatory circuit that is sensitive to the predetermined condition. The construct can include an expression module that forms a regulatory circuit, and the construct can include: i) a first repressor protein expression module, wherein the first repressor protein binds to a first repressor protein nucleic acid binding element and represses transcription from a coding sequence comprising the first repressor protein binding element, and wherein the repression activity of the first repressor protein is sensitive to inhibition by a first exogenous agent, the presence or absence of the first exogenous agent establishing a predetermined condition; ii) a second repressor protein expression module, wherein the second repressor protein binds to the second repressor protein nucleic acid binding element and represses transcription from a coding sequence that includes the second repressor protein binding element, the second repressor protein being different from the first repressor protein; and iii) an effector expression module comprising a nucleic acid sequence encoding an effector protein operably linked to a genetic element comprising a binding element for a second repressor protein, such that expression of the second repressor protein causes repression of effector expression from the effector, wherein the second expression module comprises a first repressor protein nucleic acid binding element that enables repression of transcription of the second repressor protein when the element is bound by the first repressor protein, and wherein in the absence of the first exogenous agent, the first repressor protein is produced from the first repressor protein expression module and the second repressor an effector expression module, each of which forms a regulatory circuit to repress transcription from a protein expression module, thereby relieving repression of effector expression by a second repressor protein and resulting in expression of the effector protein; however, in the presence of a first exogenous agent, activity of the first repressor protein is inhibited, allowing expression of the second repressor protein and maintaining expression of the effector protein expression in an "off" state; thereby, the first exogenous agent is required in the circuit to maintain expression of the effector protein in an "off" state; and removal or absence of the first exogenous agent does not result in expression of the effector protein.

[0247] In some embodiments, the effector is a toxin or protein that induces a cell death program. Any protein that is toxic to host cells can be used. In some embodiments, the toxin kills only those cells in which it is expressed. In other embodiments, the toxin kills other cells in the same host organism. Any of a number of products that lead to cell death can be used in a dead-man kill switch. Agents that inhibit DNA replication, protein translation, or other processes, or agents that degrade host cell nucleic acids, for example, are particularly useful. To identify an efficient mechanism for killing host cells upon activation of the circuit, several toxin genes that directly damage host cell DNA or RNA were tested. The endonuclease ecoRI21 , DNA gyrase ccdB 22 , and the ribonuclease-type toxin MazF 23 These were tested because they are well characterized, native to E. coli, and offer a range of killing mechanisms. To increase circuit robustness and provide independent methods of circuit-dependent cell death, the system can be further adapted to express, for example, targeted proteases or nucleases that further interfere with the repressor that maintains the death gene in an "off" state. Loss or withdrawal of the survival signal would more efficiently remove repression of the death gene, for example, by active degradation of the repressor protein or its message. As a non-limiting example, mf-Lon protease was used to target essential proteins for degradation in addition to degrading LacI. The mf-Lon degradation tag pdt#1 was used to identify proteins whose protein products are affected by mf-Lon degradation. 20 We were able to add a nucleotide sequence to the 3' end of five essential genes that are particularly sensitive to ATc, and measured cell viability after removal of ATc. Among the essential gene targets tested, the peptidoglycan biosynthesis gene murC provided the strongest and fastest cell death phenotype (viability <1 x 10 within 6 hours). -4 ).

[0248] As used herein, the term "predetermined input" refers to an agent or condition that affects the activity of a transcription factor polypeptide in a known manner. Generally, such agents can bind to and / or alter the conformation of a transcription factor polypeptide, thereby altering the activity of the transcription factor polypeptide. Examples of predetermined inputs include, but are not limited to, environmental input agents that are not required for the survival of a given host organism (i.e., in the absence of the synthetic biology circuit described herein). Conditions under which predetermined inputs can be provided include temperature (e.g., when the activity of one or more factors is temperature-sensitive), the presence or absence of light (including light of a given wavelength spectrum), and concentrations of gases, salts, metals, or minerals. Environmental input agents include small molecules, biological agents (such as pheromones, hormones, growth factors, metabolites, nutrients, etc.) and their analogs, chemicals, environmental by-products, concentrations of metal ions and other such molecules or agents, light levels, temperature, mechanical stress or pressure, or electrical signals (such as current and voltage).

[0249] In some embodiments, a reporter is used to quantify the strength or activity of a signal received by a module or programmable synthetic biology circuit of the invention. In some embodiments, the reporter can be fused in-frame to other protein-coding sequences to identify where the protein is located in a cell or organism. Luciferase can be used as an effector protein in various embodiments described herein, for example, to measure low levels of gene expression, since cells tend to have little or no background luminescence in the absence of luciferase. In other embodiments, enzymes that produce colored substrates can be quantified using a spectrophotometer or other instrument capable of measuring absorbance, including a plate reader. Similar to luciferase, enzymes such as β-galactosidase tend to amplify low signals and can therefore be used to measure low levels of gene expression. In some embodiments, the effector protein can be an enzyme that can degrade or otherwise destroy a given toxin. In some embodiments, the effector protein can be an odorant enzyme that converts a substrate into an odorant product. In some embodiments, the effector protein can be an enzyme that phosphorylates or dephosphorylates either a small molecule or other proteins, or an enzyme that methylates or demethylates other proteins or DNA.

[0250] In some embodiments, the effector protein can be a receptor, a ligand, or a soluble protein. Receptors tend to have three domains: an extracellular domain for binding a ligand such as a protein, peptide, or small molecule, a transmembrane domain, and an intracellular or cytoplasmic domain that can frequently be involved in certain signaling events such as phosphorylation. In some embodiments, transporter, channel, or pump gene sequences are used as effector proteins. Non-limiting examples and sequences of effector proteins for use with the kill switches described herein can be found on the World Wide Web at the Registry of Standard Biological Parts at parts.igem.org.

[0251] As used herein, a "modulator protein" is a protein that regulates expression from a target nucleic acid sequence. Modulator proteins include, for example, transcription factors, including transcription activators and repressors, among others, as well as proteins that bind to or modify transcription factors to affect their activity. In some embodiments, modulator proteins include, for example, proteases that degrade protein factors involved in regulating expression from a target nucleic acid sequence. Preferred modulator proteins include, for example, modulator proteins in which the DNA-binding and input agent-binding or response elements or domains are separable and transferable, such that, for example, fusing the DNA-binding domain of a first modulator protein to the input agent-responsive domain of a second modulator protein results in a new protein that binds the DNA sequence recognized by the first protein but is sensitive to the input agent to which the second protein normally responds. Thus, as used herein, the terms "modulator polypeptide," and more specifically, "repressor polypeptide," include, in addition to specific polypeptides, for example, "Lacl (repressor) polypeptides," mutants, or derivatives of such polypeptides that respond to different or variant input agents. Thus, in the case of LacI polypeptides, LacI mutants or variants that bind agents other than lactose or IPTG are included, and a wide variety of such agents are known in the art.

[0252] Table 5. Example Adjustment Switches b The possibility of switching ON by an effector, other than removing the effector that gives the OFF state. c Possibility of switching OFF by effector, other than removing the effector that gives ON state. d A ligand or other physical stimulus (such as temperature, electromagnetic radiation, or electricity) that stabilizes the switch in the ON or OFF state. eReference is made to the reference numbers cited in Kis et al., JR Soc Interface. 12:20141000 (2015) (both the article and the references cited therein are incorporated herein by reference). [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5]

[0253] VI. Production of ceDNA vectors A. General production Production of ceDNA vectors is described in Section IV of PCT / US18 / 49996, filed September 7, 2018, which is incorporated herein by reference in its entirety. As described herein, ceDNA vectors can be obtained by a process comprising: a) incubating a population of host cells (e.g., insect cells) harboring a polynucleotide expression construct template (e.g., a ceDNA-plasmid, a ceDNA-bacmid, and / or a ceDNA-baculovirus) lacking a viral capsid-encoding sequence in the presence of Rep proteins under conditions effective and for a sufficient time to induce production of the ceDNA vector in the host cells, wherein the host cells do not contain a viral capsid-encoding sequence; and b) harvesting and isolating the ceDNA vector from the host cells. The presence of Rep proteins induces replication of the vector polynucleotide with modified ITRs to produce the ceDNA vector in the host cells. However, viral particles (e.g., AAV virions) are not expressed. Thus, there are no size limitations such as those naturally imposed in AAV or other viral vectors.

[0254] The presence of a ceDNA vector isolated from a host cell can be confirmed by digesting the DNA isolated from the host cell with a restriction enzyme that has a single recognition site on the ceDNA vector and analyzing the digested DNA material on a non-denaturing gel to confirm the presence of a characteristic linear, continuous DNA band compared to linear, discontinuous DNA.

[0255] According to some embodiments, the present invention provides the use of host cell lines that stably integrate a DNA vector polynucleotide expression template (ceDNA template) into their own genome in the production of non-viral DNA vectors, for example, as described in Lee, L. et al. (2013) Plos One 8(8):e69879. Preferably, Rep is added to the host cells at an MOI of about 3. When the host cell line is a mammalian cell line, such as HEK293 cells, the cell line may have a stably integrated polynucleotide vector template, and a second vector, such as a herpesvirus, may be used to introduce Rep proteins into the cells, allowing for excision and amplification of ceDNA in the presence of Rep and a helper virus.

[0256] In one embodiment, the host cells used to generate the ceDNA vectors described herein are insect cells, and a baculovirus is used to deliver both the polynucleotide encoding the Rep protein and the non-viral DNA vector polynucleotide expression construct template for ceDNA, e.g., as described in Figures 4A-4C and Example 1. In some embodiments, the host cells are engineered to express the Rep protein.

[0257] The ceDNA vector is then harvested and isolated from the host cells. The time for harvesting the ceDNA vector described herein from the cells can be selected and optimized to achieve high-yield production of the ceDNA vector. For example, the harvest time can be selected taking into account cell viability, cell morphology, cell growth, etc. In one embodiment, the cells are grown under sufficient conditions and harvested after a sufficient amount of time has passed since baculovirus infection to produce the ceDNA vector, but before a portion of the cells begin to die due to the toxicity of the baculovirus. The DNA vector can be isolated using a plasmid purification kit such as the Qiagen Endo-Free Plasmid Kit. Other methods developed for plasmid isolation can also be adapted to DNA vectors. Generally, any nucleic acid purification method can be employed.

[0258] DNA vector can be purified by any means known to those skilled in the art for DNA purification.In one embodiment, ceDNA vector is purified as DNA molecule.In another embodiment, ceDNA vector is purified as exosome or microparticle.

[0259] The presence of a ceDNA vector can be confirmed by digesting vector DNA isolated from a cell with a restriction enzyme that has a single recognition site on the DNA vector, and analyzing both the digested and undigested DNA material using gel electrophoresis to confirm the presence of characteristic linear, continuous DNA compared to linear, discontinuous DNA. Figures 4C and 4D show one embodiment for identifying the presence of a closed-ended ceDNA vector produced by the processes herein.

[0260] B.ceDNA Plasmid A ceDNA-plasmid is a plasmid used for the later production of a ceDNA vector. In some embodiments, a ceDNA-plasmid can be constructed using known techniques to provide, as transcriptionally operably linked components, at least (1) a 5'ITR sequence (e.g., a wild-type or modified ITR sequence) as described herein, (2) an expression cassette containing cis-regulatory elements, such as a promoter, an inducible promoter, a regulatory switch, an enhancer, and (3) a 3'ITR sequence (e.g., a wild-type 3'ITR sequence) as described herein, where the 3'ITR sequence is symmetrical to the 5'ITR sequence. In some embodiments, the expression cassette flanked by ITRs contains a cloning site for introducing an exogenous sequence. The expression cassette replaces the rep and cap coding regions of the AAV genome.

[0261] In one aspect, the ceDNA vector is derived from a plasmid termed a "ceDNA-plasmid" that encodes, in this order, a first adeno-associated virus (AAV) inverted terminal repeat (ITR), an expression cassette comprising at least a transgene and a regulatory switch, and a mutated or modified AAV ITR, wherein the ceDNA-plasmid lacks the AAV capsid protein coding sequence. In an alternative embodiment, the ceDNA-plasmid encodes, in this order, a first (or 5') modified or mutated AAV ITR, an expression cassette comprising at least a transgene and a regulatory switch, and a second (or 3') modified AAV ITR, wherein the ceDNA-plasmid lacks the AAV capsid protein coding sequence, and the 5' and 3' ITRs are symmetrical with respect to each other. In an alternative embodiment, the ceDNA-plasmid encodes, in this order, a first (or 5') modified or mutated AAV ITR, an expression cassette comprising at least a transgene and a regulatory switch, and a second (or 3') mutated or modified AAV ITR, wherein the ceDNA-plasmid lacks an AAV capsid protein coding sequence, and the 5' and 3' modified ITRs have the same modifications (i.e., they are reverse complements or are symmetrical with respect to each other). In an alternative embodiment, the ceDNA-plasmid encodes, in this order, a first (or 5') WT AAV ITR, an expression cassette comprising at least a transgene and a regulatory switch, and a second (or 3') WT AAV ITR, wherein the ceDNA-plasmid lacks an AAV capsid protein coding sequence, and the 5' and 3' ITRs are symmetrical with respect to each other. In an alternative embodiment, the ceDNA-plasmid encodes, in that order, the first (or 5') WT AAV ITR, an expression cassette comprising at least a transgene and a regulatory switch, and the second (or 3') WT AAV ITR, wherein the ceDNA-plasmid lacks the AAV capsid protein coding sequence, and the 5' and 3' ITRs are substantially symmetrical to each other.

[0262] In further embodiments, the ceDNA-plasmid system lacks viral capsid protein coding sequences (i.e., it lacks not only the AAV capsid gene but also the capsid gene of other viruses). Additionally, in certain embodiments, the ceDNA-plasmid also lacks the AAV Rep protein coding sequence. Thus, in preferred embodiments, the ceDNA-plasmid lacks functional AAV cap and AAV rep genes (GG-3' in the case of AAV2) as well as a variable palindrome sequence that allows hairpin formation.

[0263] The ceDNA-plasmids of the present invention can be generated using the native nucleotide sequence of the genome of any AAV serotype known in the art. In one embodiment, the ceDNA-plasmid backbone is derived from the AAV1, AAV2, AAV3, AAV4, AAV5, AAV5, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genomes. See, e.g., NCBI: NC002077, NC001401, NC001729, NC001829, NC006152, NC006260, NC006261; Kotin and Smith, The Springer Index of Viruses, available at the URL maintained by Springer (www web address: oesys.springer.de / viruses / database / mkchapter.asp?virID=42.04) (Note - references to a URL or database refer to the URL or database contents as of the effective filing date of this application). In certain embodiments, the ceDNA-plasmid backbone is derived from the AAV2 genome. In another specific embodiment, the ceDNA-plasmid backbone is a synthetic backbone engineered to include 5' and 3' ITRs from one of these AAV genomes.

[0264] The ceDNA-plasmid may optionally contain a selectable or selectable marker for use in establishing a ceDNA vector-producing cell line. In one embodiment, the selectable marker may be inserted downstream (i.e., 3') of the 3' ITR sequence. In another embodiment, the selectable marker may be inserted upstream (i.e., 5') of the 5' ITR sequence. Suitable selectable markers include, for example, those that confer drug resistance. The selectable marker may be, for example, the blasticidin S resistance gene, kanamycin, geneticin, etc. In a preferred embodiment, the drug selectable marker is the blasticidin S resistance gene.

[0265] Exemplary ceDNA (e.g., rAAV0) is produced from an rAAV plasmid. A method for producing an rAAV vector can include (a) providing a host cell with an rAAV plasmid as described above, where both the host cell and the plasmid lack a capsid protein-encoding gene, (b) culturing the host cell under conditions that allow for the production of a ceDNA genome, and (c) harvesting the cells and isolating the AAV genome produced from the cells.

[0266] C. Exemplary Methods for Producing ceDNA Vectors from ceDNA Plasmids Also provided herein are methods for producing capsid-free ceDNA vectors, particularly methods with yields high enough to provide enough vector for in vivo experiments.

[0267] In some embodiments, a method for producing a ceDNA vector includes the steps of: (1) introducing a nucleic acid construct containing an expression cassette and two symmetric ITR sequences into host cells (e.g., Sf9 cells); (2) optionally, establishing a clonal cell line, for example, by using a selectable marker present on the plasmid; (3) introducing a Rep-encoding gene into the insect cells (either by transfection or infection with a baculovirus carrying the gene); and (4) harvesting the cells and purifying the ceDNA vector. The nucleic acid construct containing the expression cassette and two ITR sequences described above for producing a ceDNA vector can be in the form of a ceDNA-plasmid, or a bacmid or baculovirus generated from the ceDNA plasmid as described below. The nucleic acid construct can be introduced into host cells by transfection, viral transduction, stable integration, or other methods known in the art.

[0268] D. Cell line Host cell lines used in the production of ceDNA vectors can include insect cell lines derived from Spodoptera frugiperda (Sf9, Sf21, etc.) or Trichoplusia ni cells, or other eukaryotic cell lines, including other invertebrate, vertebrate, or mammalian cells. Other cell lines known to those skilled in the art can also be used, such as HEK293, Huh-7, HeLa, HepG2, HeplA, 911, CHO, COS, MeWo, NIH3T3, A549, HT1 180, monocytes, and mature and immature dendritic cells. Host cell lines can be transfected for stable expression of ceDNA-plasmids for high-yield ceDNA vector production.

[0269] According to some embodiments, the CeDNA-plasmid can be introduced into Sf9 cells by transient transfection using reagents known in the art (e.g., liposomes, calcium phosphate) or physical means (e.g., electroporation). Alternatively, stable Sf9 cell lines stably incorporating the ceDNA-plasmid into their genome can be established. Such stable cell lines can be established by incorporating a selection marker into the above-mentioned ceDNA-plasmid. If the ceDNA-plasmid used to transfect the cell line contains a selection marker such as an antibiotic, cells transfected with the ceDNA-plasmid and incorporating the ceDNA-plasmid DNA into their genome can be selected by adding the antibiotic to the cell growth medium. Resistant clones of cells can then be isolated and propagated by single-cell dilution or colony transfer techniques.

[0270] Isolate and purify E. ceDNA vector Examples of processes for obtaining and isolating ceDNA vectors are described in Figures 4A-4E and in the specific examples below. The ceDNA vectors disclosed herein can be obtained from producer cells expressing AAV Rep protein(s) and further transformed with ceDNA-plasmid, ceDNA-bacmid, or ceDNA-baculovirus. Plasmids useful for producing ceDNA vectors include those shown in Figure 9A (useful for Rep BIIC production) and Figure 9B (plasmids used to obtain ceDNA vectors).

[0271] According to some embodiments, the polynucleotide encodes an AAV Rep protein (Rep78 or 68) that is delivered to a producer cell in a plasmid (Rep-plasmid), bacmid (Rep-bacmid), or baculovirus (Rep-baculovirus). The Rep-plasmid, Rep-bacmid, and Rep-baculovirus can be generated by the methods described above.

[0272] A method for producing an exemplary ceDNA vector, a ceDNA vector, is described herein. The expression construct used to generate the ceDNA vector of the present invention can be a plasmid (e.g., a ceDNA-plasmid), a bacmid (e.g., a ceDNA-bacmid), and / or a baculovirus (e.g., a ceDNA-baculovirus). By way of example only, a ceDNA vector can be generated from cells co-infected with a ceDNA-baculovirus and a Rep-baculovirus. The Rep protein produced from the Rep-baculovirus replicates the ceDNA-baculovirus to generate a ceDNA vector. Alternatively, a ceDNA vector can be generated from cells stably transfected with a construct containing a sequence encoding the AAV Rep protein (Rep78 / 52) delivered in a Rep-plasmid, Rep-bacmid, or Rep-baculovirus. The ceDNA-baculovirus can be transiently transfected into cells and replicated by the Rep protein to produce a ceDNA vector.

[0273] The bacmid (e.g., ceDNA-bacmid) can be transfected into permissive insect cells, such as Sf9, Sf21, Tni (Trichoplusia ni) cells, or High Five cells, to generate a ceDNA-baculovirus, a recombinant baculovirus containing sequences including symmetric ITRs and an expression cassette. The ceDNA-baculovirus can be reinfected into insect cells to obtain the next generation of recombinant baculovirus. Optionally, this step can be repeated one or more times to produce larger quantities of recombinant baculovirus.

[0274] The time for harvesting the ceDNA vector described herein from cells can be selected and optimized to achieve high-yield production of the ceDNA vector. For example, the harvest time can be selected taking into account cell viability, cell morphology, cell growth, etc. Typically, cells can be harvested after sufficient time has passed since baculovirus infection to produce the ceDNA vector (e.g., the ceDNA vector), but before a portion of the cells begin to die due to viral toxicity. The ceDNA vector can be isolated from Sf9 cells using a plasmid purification kit, such as the Qiagen ENDO-FREE PLASMID® kit. Other methods developed for plasmid isolation can also be adapted for ceDNA vectors. Generally, any nucleic acid purification method known in the art, as well as commercially available DNA extraction kits, can be employed.

[0275] Alternatively, purification can be achieved by subjecting the cell pellet to an alkaline lysis process, centrifuging the resulting lysate, and performing chromatographic separation. As a non-limiting example, this process can be carried out by loading the supernatant onto an ion exchange column (e.g., SARTOBIND Q®) that retains nucleic acids, then eluting (e.g., with a 1.2 M NaCl solution), and performing further chromatographic purification on a gel filtration column (e.g., 6 Fast Flow GE). The capsid-free AAV vector is then recovered, for example, by precipitation.

[0276] In some embodiments, ceDNA vectors can also be purified in the form of exosomes or microparticles. It is known in the art that many cell types release not only soluble proteins but also complex protein / nucleic acid cargoes through the shedding of membrane microvesicles (Cocucci et al., 2009, EP10306226.1). Such vesicles include microvesicles (also called microparticles) and exosomes (also called nanovesicles), both of which contain proteins and RNA as cargo. Microvesicles are generated by direct budding of the plasma membrane, and exosomes are released into the extracellular environment upon fusion of multivesicular endosomes with the plasma membrane. Therefore, microvesicles and / or exosomes containing ceDNA vectors can be isolated from cells transduced with ceDNA plasmids or bacmids or baculoviruses produced with ceDNA plasmids.

[0277] Microvesicles can be isolated by filtration or ultracentrifugation of the culture medium at 20,000 x g and exosomes at 100,000 x g. The optimal duration of ultracentrifugation can be determined experimentally and will depend on the specific cell type from which vesicles are isolated. Preferably, the culture medium is first cleared by low-speed centrifugation (e.g., 2000 x g for 5-20 minutes) and then subjected to spin concentration, for example, using an AMICON® spin column (Millipore, Watford, UK). Microvesicles and exosomes can be further purified via FACS or MACS by using specific antibodies that recognize specific surface antigens present on microvesicles and exosomes. Other microvesicle and exosome purification methods include, but are not limited to, immunoprecipitation, affinity chromatography, filtration, and magnetic beads coated with specific antibodies or aptamers. During purification, vesicles are washed, for example, with phosphate-buffered saline. One advantage of using microvesicles or exosomes to deliver ceDNA-containing vesicles is that these vesicles can be targeted to various cell types by containing on them membrane proteins that are recognized by specific receptors on each cell type (see also EP10306226).

[0278] Another aspect of the present invention relates to a method for purifying ceDNA vectors from host cell lines that have stably integrated ceDNA constructs into their genomes. In one embodiment, the ceDNA vectors are purified as DNA molecules. In another embodiment, the ceDNA vectors are purified as exosomes or microparticles.

[0279] Figure 5 of PCT / US18 / 49996 shows a gel confirming the production of ceDNA from several ceDNA plasmid constructs using the methods described in the Examples. The ceDNA is confirmed by a characteristic band pattern in the gel, as discussed herein.

[0280] VII. Pharmaceutical Compositions In another aspect, a pharmaceutical composition is provided. Typically, the pharmaceutical composition comprises a ceDNA vector disclosed herein and a pharmaceutically acceptable carrier or diluent.

[0281] The ceDNA vectors disclosed herein can be incorporated into pharmaceutical compositions suitable for administration to a subject for in vivo delivery to the subject's cells, tissues, or organs. Typically, the pharmaceutical composition comprises the ceDNA vectors disclosed herein and a pharmaceutically acceptable carrier. For example, the ceDNA vectors described herein can be incorporated into pharmaceutical compositions suitable for the desired route of therapeutic administration (e.g., parenteral administration). Passive tissue transduction via high-pressure intravenous or intraarterial injection, as well as intracellular injection, such as intranuclear microinjection or intracytoplasmic injection, are also contemplated. Pharmaceutical compositions for therapeutic purposes can be formulated as solutions, microemulsions, dispersions, liposomes, or other ordered structures suitable for high ceDNA vector concentrations. A sterile injectable solution can be prepared by combining the required amount of ceDNA vector compound in an appropriate buffer with one or a combination of the above-listed components and sterilizing by filtration.

[0282] The ceDNA vector-containing pharmaceutically active composition can be formulated to deliver the transgene in the nucleic acid to the recipient's cells, resulting in therapeutic expression of the transgene therein. The composition can also include a pharmaceutically acceptable carrier.

[0283] The ceDNA vectors disclosed herein can be incorporated into pharmaceutical compositions suitable for local, systemic, intra-amniotic, intrathecal, intracranial, intra-arterial, intravenous, intralymphatic, intraperitoneal, subcutaneous, tracheal, intratissue (e.g., intramuscular, intracardiac, intrahepatic, intrarenal, intracerebral), intrathecal, intravesical, conjunctival (e.g., extraorbital, intraorbital, retroorbital, intraretinal, subretinal, choroidal, subchoroidal, intrainterstitial, intracameral, and intravitreal), intracochlear, and mucosal (e.g., oral, rectal, nasal) administration. Passive tissue transduction via high-pressure intravenous or intra-arterial injection, as well as intracellular injection, e.g., intranuclear microinjection or intracytoplasmic injection, are also contemplated.

[0284] Pharmaceutical compositions for therapeutic purposes must typically be sterile and stable under the conditions of manufacture and storage.Compositions can be formulated as solutions, microemulsions, dispersions, liposomes, or other ordered structures suitable for high ceDNA vector concentrations.Sterile injectable solutions can be prepared by incorporating the required amount of ceDNA vector compounds in a suitable buffer with one or a combination of the above-listed components, and then filtering and sterilizing.

[0285] Various techniques and methods for delivering nucleic acid to cells are known in the art.For example, nucleic acid such as ceDNA can be formulated in lipid nanoparticle (LNP), lipidoid, liposome, lipid nanoparticle, lipoplex or core-shell nanoparticle.Typically, LNP is composed of nucleic acid (for example, ceDNA) molecule, one or more ionized or cationic lipid (or their salt), one or more non-ionic or neutral lipid (for example, phospholipid), aggregation prevention molecule (for example, PEG or PEG-lipid complex), and optionally sterol (for example, cholesterol).

[0286] Another method for delivering nucleic acid such as ceDNA into cells is by complexing nucleic acid with a ligand that can be internalized by cells.For example, the ligand can bind to a receptor on the cell surface and be internalized through endocytosis.The ligand can be covalently bound to the nucleotide in nucleic acid.Exemplary complexes for delivering nucleic acid into cells are described in, for example, WO2015 / 006740, WO2014 / 025805, WO2012 / 037254, WO2009 / 082606, WO2009 / 073809, WO2009 / 018332, WO2006 / 112872, WO2004 / 090108, WO2004 / 091515 and WO2017 / 177326.

[0287] Nucleic acids such as ceDNA can also be delivered to cells by transfection. Useful transfection methods include, but are not limited to, lipid-mediated transfection, cationic polymer-mediated transfection, or calcium phosphate precipitation. Transfection reagents are well known in the art and include TurboFect transfection reagent (Thermo Fisher Scientific), Pro-Ject reagent (Thermo Fisher Scientific), TRANSPASS™ P protein transfection reagent (New England Biolabs), CHARIOT™ protein delivery reagent (Active Motif), PROTEOJUICE™ protein transfection reagent (EMD Millipore), 293fectin, LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ 3000 (Thermo Fisher Scientific), LIPOFECTAMINE™ (Thermo Fisher Scientific), LIPOFECTIN™ (Thermo Fisher Scientific), DMRIE-C, CELLFECTIN™ (Thermo Fisher Scientific), OLIGOFECTAMINE™ (Thermo Fisher Scientific), and LIPOFECTAMINE™ (Thermo Fisher Scientific). Scientific), LIPOFECTACE(TM), FUGENE(TM)(Roche, Basel, Switzerland), FUGENE(TM) HD(Roche), TRANSFECTAM(TM)(Transfectam, Promega, Madison, Wis.), TFX-10(TM)(Pr omega), TFX-20(TM)(Promega), TFX-50(TM)(Promega), TRANSFECTIN(TM)(BioRad, Hercules, Calif.), SILENTFECT(TM)(Bio-Rad), Effectene(TM)(Qiagen, Valencia, Calif.).), DC-chol (Avanti Polar Lipids), GENEPORTER™ (Gene Therapy Systems, San Diego, Calif.), DHARMAFECT 1™ (Dharmacon, Lafayette, Colo.), DHARMAFECT 2™ (Dharmacon), DHARMAFECT 3™ (Dharmacon), DHARMAFECT 4™ (Dharmacon), ESCORT™ III (Sigma, St. Louis, Mo.), and ESCORT™ IV (Sigma Chemical Co.). Nucleic acids, such as cDNA, can also be delivered to cells via microfluidics methods known to those skilled in the art.

[0288] Non-viral methods for in vivo or ex vivo delivery of nucleic acids include electroporation, lipofection (U.S. Pat. Nos. 5,049,386, 4,946,787, and commercially available reagents such as Transfectam™ and Lipofectin™), microinjection, biolistics, virosomes, liposomes (e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992), U.S. Patent Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787), immunoliposomes, microbubbles (Frenkel et al., Ultrasound Med. Biol. (2002) 28(6):817-22; Tsutsui et al., Cardiovasc. Ultrasound (2004) 2:23), polycation or lipid:nucleic acid complexes, naked DNA, and drug-enhanced uptake of DNA. Sonoporation, using, for example, the Sonitron 2000 system (Rich-Mar), can also be used for delivery of nucleic acids.

[0289] The ceDNA vector described herein can also be directly administered to organism for in vivo cell transduction.Administered by any of the routes that are usually used to finally bring molecules into contact with blood or tissue cells, including but not limited to infusion, injection, topical application and electroporation.Suitable methods for administering such nucleic acid are available and well known to those skilled in the art, and two or more routes can be used to administer certain compositions, although certain routes can often bring about more immediate and effective responses than other routes.

[0290] Methods for Introduction of Nucleic Acid Vectors The ceDNA vectors disclosed herein can be delivered into, for example, hematopoietic stem cells by the methods described in, for example, US Pat. No. 5,928,638.

[0291] ceDNA vector can be delivered in vitro or in vivo using various delivery methods known in the art or their modifications.For example, in some embodiments, ceDNA vector is delivered by creating temporary punctures in cell membrane by mechanical, electrical, ultrasonic, hydrodynamic or laser-based energy, thereby facilitating DNA entry into target cells.For example, ceDNA vector can be delivered by squeezing cells through size-restricted channels or by other means known in the art to temporarily disrupt cell membrane.In some cases, ceDNA vector is directly injected into skin, thyroid, cardiac muscle, skeletal muscle or liver cells as naked DNA alone.

[0292] In some cases, cDNA vectors are delivered by gene gun: gold or tungsten spherical particles (1–3 μm diameter) coated with capsid-free AAV vectors are accelerated to high velocities by pressurized gas and can penetrate into target tissue cells.

[0293] In some embodiments, electroporation is used to deliver ceDNA vector.Electroporation causes the temporary destabilization of cell membrane target cell tissue by inserting electrode pair into tissue, so that the DNA molecules in the surrounding medium of destabilized membrane can penetrate into the cytoplasm and nucleoplasm of cell.Electroporation has been used in many tissue types in vivo, such as skin, lung and muscle.

[0294] In some cases, ceDNA vectors are delivered by hydrodynamic injection, a simple and highly efficient method for the direct intracellular delivery of any water-soluble compound and particle into skeletal muscles throughout the viscera and limbs.

[0295] In some cases, ceDNA vectors are delivered by ultrasound, creating nanoscopic pores in the membrane to facilitate intracellular delivery of DNA particles to organ or tumor cells, so the size and concentration of the plasmid DNA play a major role in the efficiency of this system. In some cases, ceDNA vectors are delivered by magnetofection, using a magnetic field to concentrate nucleic acid-containing particles in target cells.

[0296] In some cases, chemical delivery systems can be used, for example, by using nanomer complexes, including the compression of negatively charged nucleic acids with cationic liposomes / micelles or polycationic nanomer particles belonging to cationic polymers.Cationic lipids used in delivery methods include, but are not limited to, monovalent cationic lipids, polyvalent cationic lipids, guanidine-containing compounds, cholesterol-derivative compounds, cationic polymers (e.g., poly(ethyleneimine), poly-L-lysine, protamine, other cationic polymers), and lipid-polymer hybrids.

[0297] A. Exosomes In some embodiments, the ceDNA vectors disclosed herein are delivered by packaging them into exosomes. Exosomes are small membrane vesicles of endocytic origin that are released into the extracellular environment following fusion of multivesicular bodies with the plasma membrane. Their surface consists of a lipid bilayer from the plasma membrane of the donor cell; they contain cytosol from the cell that produced the exosome and exhibit membrane proteins from the parent cell on their surface. Exosomes are produced by various cell types, including epithelial cel...

Claims

1. A non-viral capsid-free DNA vector (ceDNA vector) having covalently closed ends, said ceDNA vector comprising at least one heterologous nucleic acid sequence operably disposed between two adjacent symmetric inverted terminal repeats (symmetric ITRs), said symmetric ITRs being different from wild-type ITRs, each of said adjacent symmetric ITRs being modified by a deletion, insertion and / or substitution in the A' and / or A regions, A non-viral capsid-free DNA vector with covalently closed ends (ceDNA vector), wherein one of the adjacent symmetric ITRs comprises a sequence having at least 95% identity to SEQ ID NO: 497 (ITR-46 left) and the other of the adjacent symmetric ITRs comprises a sequence having at least 95% identity to SEQ ID NO: 481 (ITR-30 right), and each adjacent ITR has the same symmetric modification.

2. The ceDNA vector of claim 1, wherein the two adjacent symmetric ITRs comprise a pair of ITRs consisting of SEQ ID NO:497 (ITR-46 left) and SEQ ID NO:481 (ITR-30 right).

3. The ceDNA vector of claim 1 , wherein the flanking symmetric ITRs are synthetic.

4. A ceDNA vector according to any one of claims 1 to 3, comprising an aptamer.

5. A ceDNA vector according to any one of claims 1 to 4, comprising at least one regulatory switch.

6. The ceDNA vector of any one of claims 1 to 5, wherein the symmetric ITRs are derived from a virus selected from the group consisting of parvovirus, dependovirus and adeno-associated virus (AAV).

7. 7. The ceDNA vector of claim 6, wherein the symmetric ITRs are derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 and AAV12.

8. The ceDNA vector of any one of claims 1 to 7, wherein the vector is within a lipid nanoparticle (LNP).

9. 9. The ceDNA vector according to any one of claims 1 to 8, wherein the ceDNA vector is obtained from a process comprising the steps of: (a) incubating a population of insect cells harboring a ceDNA expression construct in the presence of at least one Rep protein under conditions effective and for a time sufficient to induce production of the ceDNA vector in the insect cells, the ceDNA expression construct encoding the ceDNA vector; and (b) isolating the ceDNA vector from the insect cells.

10. The ceDNA vector of claim 9 , wherein the insect cell expresses at least one Rep protein.

11. A ceDNA expression construct encoding the ceDNA vector of any one of claims 1 to 10.

12. A host cell comprising the ceDNA expression construct of claim 11.

13. 13. The host cell of claim 12, which expresses at least one Rep protein.

14. 14. The host cell of claim 13, wherein the at least one Rep protein is derived from a virus selected from the group consisting of a parvovirus, a dependovirus and an adeno-associated virus (AAV).

15. 15. The host cell of claim 14, wherein the at least one Rep protein is derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 and AAV12.

16. The host cell according to any one of claims 12 to 15, which is an insect cell.

17. 17. The host cell of claim 16, wherein the insect cell is an Sf9 cell.

18. 18. A method for producing a ceDNA vector, comprising: (a) incubating a host cell according to any one of claims 12 to 17 under conditions effective and for a time sufficient to induce production of said ceDNA vector; and (b) isolating said ceDNA from said host cell.

19. A pharmaceutical composition comprising the ceDNA vector of any one of claims 1 to 10 for use in a method for treating, preventing, ameliorating, monitoring or diagnosing a disease or disorder in a subject.

20. 20. The pharmaceutical composition of claim 19, wherein said at least one heterologous nucleic acid sequence, when transcribed or translated, modulates the abnormal amount, function or activity of an endogenous protein in said subject.

21. said at least one heterologous nucleic acid sequence encodes or comprises a nucleotide molecule selected from the group consisting of RNAi, siRNA, miRNA, lncRNA, aptamer and antisense oligonucleotide or polynucleotide; the at least one heterologous nucleic acid sequence encodes a protein; the at least one heterologous nucleic acid sequence encodes an agonist or antagonist of an endogenous protein or pathway associated with the disease or disorder; or the at least one heterologous nucleic acid sequence encodes an antibody; 20. The pharmaceutical composition of claim 19.

22. The disease or disorder is A metabolic disease or disorder selected from the group consisting of diabetes, lysosomal storage disorders, mucopolysaccharidosis, urea cycle disorders, and glycogen storage disorders; said lysosomal storage disorders are selected from the group consisting of Gaucher disease, Pompe disease, metachromatic leukodystrophy (MLD), phenylketonuria (PKU), and Fabry disease; said urea cycle disorder is ornithine transcarbamylase (OTC) deficiency; and said mucopolysaccharidosis disorder is selected from the group consisting of Sly syndrome, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome, Morquio syndrome, and Maroteaux-Lamy syndrome; a CNS disease or disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Canavan disease, Leigh's disease, Refsum's disease, Tourette's syndrome, primary lateral sclerosis, amyotrophic lateral sclerosis, progressive muscular atrophy, Pick's disease, muscular dystrophy, multiple sclerosis, myasthenia gravis, Binswanger's disease, trauma from spinal cord or head injury, Tay-Sachs disease, Leschnyan's disease, epilepsy, cerebral infarction, psychiatric disorders, schizophrenia, drug addiction, neurosis, psychosis, dementia, paranoia, attention deficit disorder, sleep disorder, pain disorder, eating or weight disorder, and cancers and tumors of the CNS; an ophthalmic disease or disorder selected from the group consisting of ophthalmic disorders involving the retina, the posterior thalamic tract, and / or the optic nerve; wherein the ophthalmic disorder involving the retina, the posterior thalamic tract, and / or the optic nerve is selected from the group consisting of diabetic retinopathy, macular degeneration including age-related macular degeneration, geographic atrophy and vascular or "wet" macular degeneration, glaucoma, uveitis, retinitis pigmentosa, Stargardt's disease, Leber's congenital amaurosis (LCA), Usher syndrome, pseudoxanthoma elasticum (PXE), X-linked retinitis pigmentosa (XLRP), X-linked retinoschisis (XLRS), total choroidal atrophy, Leber's hereditary optic neuropathy (LHON), color blindness, cone-rod degeneration, Fuchs' endothelial corneal dystrophy, diabetic macular edema, and eye cancers and tumors; A blood disease or disorder selected from the group consisting of hemophilia A, hemophilia B, thalassemia, anemia and blood cancer; A liver disease or disorder, the liver disease or disorder being selected from the group consisting of progressive familial intrahepatic cholestasis (PFIC) and liver cancer, and tumors; Cystic fibrosis; and The pharmaceutical composition according to any one of claims 19 to 21, which is selected from the group consisting of immune diseases or disorders, infectious diseases, muscular diseases or disorders, cancer, and diseases or disorders based on abnormal levels and / or function of gene products.

23. The pharmaceutical composition of any one of claims 19 to 22, wherein the ceDNA vector further comprises an aptamer.

24. A pharmaceutical composition comprising a ceDNA vector according to any one of claims 1 to 10 for use in a method for delivering a therapeutic protein to a subject, wherein said at least one heterologous nucleic acid sequence encodes a therapeutic protein.

25. A kit comprising a ceDNA vector described in any one of claims 1 to 10 and a nanocarrier packaged in a container comprising instructions for use.

Citation Information

Patent Citations

  • Capsid-free AAV vector, composition, and method for vector production and gene delivery.

    JP2014513928A

  • Modified closed-terminal DNA (CEDNA)

    JP2020532981A

  • Gene editing using modified closed-end DNA (CEDNA)

    JP2021505159A

  • Process for obtaining closed-end DNA vectors and ceDNA vectors obtainable from cell-free synthesis

    JP2021511047A

  • Controlled expression of transgenes using closed-end DNA (CEDNA) vectors

    JP2021513999A